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Abstract
Heart attacks are a leading cause of mortality in the United States, responsible for over 500,000 deaths
annually. Despite advancing treatments for acute heart attack, 5-year mortality exceeds 50% as the organ
fails to heal the resulting scar.
Recent studies revealed modest cardiac regeneration occurring throughout life and accelerating (albeit
insufficiently) post-injury. However, the magnitude is contested with some studies indicating low
cardiomyocyte formation and others indicating rapid formation of increasingly inferior cardiomyocytes.
Resolving this question determines the needed strategy for repair augmentation. Chapter 3 scrutinizes
current apparently-paradoxical studies and offers a unified estimate of cardiomyocyte turnover via a
hybrid-model software platform.
As limited engraftment (<2%) was cited as a primary impediment in bone marrow cell (BMC) infusion
clinical trials, Chapter 4 recapitulates these trials in an intact-organ murine model--the isolated perfused
heart. Flow cytometry enables objective, sensitive identification of strongly-retained BMC phenotypes.
Results show that endothelial P-selectin surfaces at 30 minutes post ischemia-reperfusion injury, leading
to preferential engraftment of c-kit+ BMCs (which exhibit superior P-selectin adherence in vitro).
Chapter 5 adapts the flow cytometry technique to measurement of absolute cell retention (nonratiometric) to evaluate chemotactic properties of Stromal Derived Factor (SDF)-eluting implants of
polymerized hyaluronic acid. Stem cells home to chemokine concentration gradients and thus SDF-eluting
hydrogels can draw infused stem cells to the implant site. The hydrogel increases cardiac BMC homing by
5-fold, confirming that local chemokine milieu alteration can augment BMC therapy.
Leveraging Chapter 4 results, Chapter 6 artificially stimulates P-selectin endothelialization in quiescent
endothelium to improve BMC engraftment rates even after endogenous activation subsides. Low-dose
peroxide, a reactive oxygen species known to induce brief inflammation, when delivered prior to BMC
infusion, enhances retention by 3-fold. Interestingly, peroxide-induced c-kit+ BMC retention rates are
equivalent to true ischemic injury rates, while c-kit-negative BMCs also experience enhanced engraftment.
This work spans the scientific process, conducting basic research of natural physiology and leveraging
results to propose and test two promising therapeutic strategies--alteration of local chemokine
concentrations and endothelial adhesion molecule display. Additionally, new techniques, including
computational methods and flow cytometry-based engraftment assays enable future work in cardiac
regeneration.
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ABSTRACT
DYNAMICS OF ENDOGENOUS CARDIAC REPAIR AND METHODS FOR ENHANCED
POST-INJURY CELL THERAPY
Jeremy Alan Elser
Kenneth Margulies, MD

Heart attacks are a leading cause of mortality in the United States, responsible for over
500,000 deaths annually. Despite advancing treatments for acute heart attack, 5-year
mortality exceeds 50% as the organ fails to heal the resulting scar.

Recent studies revealed modest cardiac regeneration occurring throughout life and
accelerating (albeit insufficiently) post-injury. However, the magnitude is contested with
some studies indicating low cardiomyocyte formation and others indicating rapid
formation of increasingly inferior cardiomyocytes. Resolving this question determines
the needed strategy for repair augmentation. Chapter 3 scrutinizes current apparentlyparadoxical studies and offers a unified estimate of cardiomyocyte turnover via a hybridmodel software platform.

As limited engraftment (<2%) was cited as a primary impediment in bone marrow cell
(BMC) infusion clinical trials, Chapter 4 recapitulates these trials in an intact-organ
murine model--the isolated perfused heart. Flow cytometry enables objective, sensitive
identification of strongly-retained BMC phenotypes. Results show that endothelial Pselectin surfaces at 30 minutes post ischemia-reperfusion injury, leading to preferential
engraftment of c-kit+ BMCs (which exhibit superior P-selectin adherence in vitro).

v

Chapter 5 adapts the flow cytometry technique to measurement of absolute cell retention
(non-ratiometric) to evaluate chemotactic properties of Stromal Derived Factor (SDF)eluting implants of polymerized hyaluronic acid. Stem cells home to chemokine
concentration gradients and thus SDF-eluting hydrogels can draw infused stem cells to
the implant site. The hydrogel increases cardiac BMC homing by 5-fold, confirming that
local chemokine milieu alteration can augment BMC therapy.

Leveraging Chapter 4 results, Chapter 6 artificially stimulates P-selectin
endothelialization in quiescent endothelium to improve BMC engraftment rates even
after endogenous activation subsides. Low-dose peroxide, a reactive oxygen species
known to induce brief inflammation, when delivered prior to BMC infusion, enhances
retention by 3-fold. Interestingly, peroxide-induced c-kit+ BMC retention rates are
equivalent to true ischemic injury rates, while c-kit-negative BMCs also experience
enhanced engraftment.

This work spans the scientific process, conducting basic research of natural physiology
and leveraging results to propose and test two promising therapeutic strategies—
alteration of local chemokine concentrations and endothelial adhesion molecule display.
Additionally, new techniques, including computational methods and flow cytometrybased engraftment assays enable future work in cardiac regeneration.
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CHAPTER 1
1. Overview of Cardiac Stem Cell Therapy
1.1 Cardiac Injury
Heart failure (HF) is a leading cause of disability and death which accounts for
approximately one million hospitalizations, over 50,000 deaths, and almost $35 billion in
health care costs in the United States each year [1]. Despite therapeutic advances in
the treatment of myocardial infarction, hypertension, valvular heart disease and
cardiomyopathies, the prevalence of HF continues to grow. Mortality rates remain high
with 50% of HF patients dying within five years of initial diagnosis [2].

Progressive loss of cardiomyocytes (CM), due to myocardial infarction (MI) and/or
programmed cell death (apoptosis), is a feature of most causes of HF. Therefore,
therapies to increase the number of functional CMs are expected to improve the course
of this syndrome.

The human heart was long believed to have virtually no capacity for new CM formation
after childhood. This conclusion was drawn largely from the heart’s inability to repair
tissue damaged after myocardial infarction [3]. However, increasing evidence supports
the existence of endogenous cardiac renewal and repair mechanisms that contribute to
normal homeostasis and responses to pathological insults, which could be augmented to
prevent heart failure.

1.2 Cardiomyogenesis in Physiological Homeostasis
Overturning the dogma of the adult human heart as a terminally differentiated organ,
Bergmann et al used a fate-mapping approach to demonstrate and quantify the rate
1

cardiomyocyte renewal [4]. Recognizing that an era of nuclear bomb tests between
1955 and 1963 (when the nuclear Test Ban Treaty was signed) produced a spike in
atmospheric carbon14 (C14), these investigators used cardiac specific markers to
identify and isolate CMs from hearts obtained at the time of autopsy. Because the C14
content of CM DNA should reflect the atmospheric the ambient C14 level at the time of
cell formation, differences between the actual C14 content of DNA and the predicted
level based on atmospheric C14 levels provided a means of identifying net cell
replacement. In fact, higher than expected C14 CM DNA levels observed among those
born before 1955 and the lower than expected C14 CM DNA levels observed those born
after 1963 supported the replacement of some CMs during adult life. Even after
accounting for previously described CM nuclear division (poly-ploidization), these
investigators estimated that about 1% of CMs are replaced annually at the age of 25 and
that this rate gradually decreases to about 0.45% annually by age 75.

In 2010, Kajstura et al performed extensive histological analyses of 74 non-diseased
hearts of various ages to evaluate the presence of a proposed class of cardiomyocyte
stem cells (CSCs) and the fraction of these cells undergoing mitosis at time of patient
death. Supported by in vitro cycling and apoptosis kinetics parameters, mathematical
modeling was used to compute the annual turnover rate as a function of patient age.
Kajstura reported a turnover rate approximately 7% in young adult males that increases
to 32% with advanced age, with even higher rates of cardiac myocyte turnover
calculated among females [5].

While these two studies both confirm that new CM formation exists in the healthy, adult
human heart, the discrepancy in magnitude is perplexingly large. As abundant
2

endogenous cardiac regeneration influences potential therapies, clarification of the true
reconstructive ability of the heart is critical.

1.3 Cardiomyogenesis in Pathophysiologic Response
Several lines of evidence suggest that cardiomyogenesis can occur in adult hearts
following injury or trauma. In humans, some of the strongest data comes from sexmismatched transplanted hearts (male recipient, female donor) in which Y-chromosome
positive cardiac myocytes (as well as endothelial cells and smooth muscle cells) have
been found within the cardiac allografts obtained from a female donor. Though the rates
of this phenomenon vary considerably in different reports [6,7], higher rates of allograft
chimerism were observed when the donor hearts suffered acute ischemic events [7],
suggesting that host-derived progenitor cell recruitment may be injury-responsive. In
addition, Urbanek et al reported increases in endogenous cardiac stem/progenitor cells
(S/PCs) in hearts from patients who died from acute MI and, to a lesser extent, in
patients with end-stage chronic post-MI cardiomyopathy [8].

In animal models, recent reviews highlight studies demonstrating activation of
endogenous cardiac repair processes in response to experimental cardiac injury [9, 10].
Some studies have employed bone-marrow ablation and reconstitution with GFPlabeled cells, and then reported GFP-labeled cardiac myocytes, vascular cells and
fibroblasts within and around the infarcted myocardium [11]. Other studies have
employed direct myocardial injection of enriched and labeled S/PCs derived from
autologous sources [12] or from allogeneic donors, including humans [13]. Most studies
indicate that local myocardial injury augments cell engraftment into the recipient
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myocardium, but other studies suggest a high rate of attrition for these newly engrafted
cells [14].

The degree to which endogenous S/PCs contribute to the native response to
myocardial injury and failure in the adult mammalian heart remains a key unresolved
question. Studies in mice by Fazel et al indicate that MI triggers homing of bone
marrow-derived progenitors expressing the c-kit surface marker to the murine heart and
that these cells contribute to angiogenesis and reduced post-infarct dilation [15].
Because very few new cardiac myocytes or blood vessels appeared to be derived from
the GFP-labeled bone marrow cells, this report concluded that secretion of angiogenic
cytokines by bone marrow-derived c-kit+ cells accounts for their beneficial impact
independent of any direct myocardial incorporation as new cardiac myocytes or
vascular structures [15]. Additionally, subsequent studies by Hsieh et al used a fatemapping approach in mice to demonstrate that early increases in myocardial c-kit+ cells
precede new cardiac myocyte formation following experimental MI or pressure overload
[16]. Together, these studies in animal models indicate that myocardial injury and
failure induce a demonstrable, but relatively minor, endogenous repair response.

1.4 Augmentation of the Repair Response
A series of randomized, controlled clinical trials (RCTs) have attempted to augment the
repair response through the manipulation of endogenous or delivered S/PCs.

4

1.4.1 Mobilization of Bone Marrow Progenitors
The first BMPC (Bone Marrow Progenitor Cell) trials delivered Granulocyte Colony
Stimulating Factor (G-CSF) to the bloodstream post-infarction in an effort to stimulate
progenitor cell release from the bone marrow, but did not involve administration of S/PCs
directly. This strategy has been shown to temporarily increase circulating progenitor
concentration, as defined by concentration of CD34+ cells [17]. However, placebo
controlled, double blind clinical trials such as STEMMI [18] found no improvement for GCSF treatment over controls. In fact, a meta-analysis of four blinded and six nonblinded
trials found no statistically significant improvement in ejection fraction (EF) or decrease
in infarct size when using G-CSF [19]. For this meta-analysis, G-CSF doses ranged
from 2.5-10 ug/kg per day for delivery periods of 4-10 days. Delay between coronary
angioplasty and treatment ranged from 90 +/- 35 minutes in the FIRSTLINE-AMI trial to 5
days for the MAGIC-Cell and REVIVAL-2 trials. Based on these findings, direct cell
administration to the heart has emerged as the dominant therapeutic approach in recent
clinical trials, though G-CSF may be used in conjunction with other interventions.

1.4.2 Direct Delivery of Unfractionated Bone Marrow Cells.
Following a series of small interventional trials, several larger RCTs have been
performed using the direct injection of bone marrow cells into the coronary arteries or
myocardium. Several studies have shown modest but consistent improvements in
cardiac performance and overall mortality, although the mechanism for their benefit
remains uncertain. REPAIR-AMI, the largest RCT to date, included 204 patients and
found that delivering bone-marrow S/PCs 4 days post-MI increased left ventricular
ejection fraction (by 3.2±1.3 %) at 4 months. Although the difference compared with
placebo was lost by 12 months, a subanalysis focusing on patients with a baseline EF
5

below the median of 48.9% had statistically significant increases in EF compared to
placebo throughout the experiment [20]. These results mirrored the BOOST trial in
which bone marrow cells administered 5 days post-PCI was associated with a 6.7%
absolute increase in EF in the bone marrow treated group compared with a 0.7% in the
control group (p=0.0026) [21]. Here again, intergroup differences were no longer
significant during later follow up (18 months), suggesting that the benefit of infused
BMCs may be in speeding recovery but not in long-term benefit. A meta-analysis of 13
randomized controlled trials (811 patients) determined that intracoronary injection of
BMCs improves EF by 2.99 points (p=0.0007) over 3-6 months, though not all trials have
been positive [22, 23]. Supplementing these findings are several other recent trials
including the unblinded BALANCE study which reported that delivery of BMCs 7 days
following AMI decreased 5-year mortality (2.35 vs. 0.35% annual mortality rates, p=0.03)
and increased EF (4.6% differential EF improvement over baseline for BMC delivery vs.
a decrease of 5.8% differential EF for controls [24]. In patients with an EF less than
45%, the MYSTAR (n=60) study found no difference in the improvement in EF and
reduction in infarct size when a dual cell introduction method (intramyocardial and
intracoronary injection) was utilized at 3-6 weeks vs. 3-4 months post MI, though MI size
was smaller in treated hearts than in controls [25].

1.4.3 Direct Delivery of Purified Stem Cells
Lackluster results from the bone marrow cell trials prompted investigation of alternative
and sub-population cell sources with higher regenerative potential. Chen et al evaluated
mesenchymal stem cells (MSCs) in a placebo-controlled trial of 69 patients and reported
the largest increases in EF for trial groups over controls when delivering 8-10 billion
MSCs via intracoronary injection at about 18 days after Percutaneous Intervention (PCI).
6

At three and six months, the study reported an average EF of 67±11% and 67±3% in
MSC-treated patients, compared with 53±18 and 54±5 in placebo-treated controls.
Several other cardiac performance measurements supported these results [26].

Two additional reports describing the effects of enriched bone marrow cell subsets
reported rather modest benefits. In a blinded study of 22 patients reported by Katritsis,
1-2 million BMCs enriched for MSCs (about 33%) and endothelial progenitor cells
(EPCs, about 66%) improved wall-score indices and tissue viability were observed
without significant improvement in EF [27]. A clinical trial utilizing intracoronary delivery
of AC133+ enriched bone marrow cells 2 weeks after MI reported significant
improvements in EF and perfusion defects when compared with control patients
receiving no cell therapy [28].

Two ongoing clinical trials are also evaluating the therapeutic potential of MSCs. The
Prospective Randomized assessment Of MEsenchymal stem cell THErapy in patients
Undergoing Surgery (PROMETHEUS, clinicaltrials.gov ID: NCT00587990) is a placebocontrolled study that of intracardiac injection of expanded autologous MSCs in patients
who require coronary artery bypass surgery and who have an EF between 20 and 50%.
The Transendocardial Autologous Cells in Heart Failure Trial (TAC-HFT,
clinicaltrials.gov ID: NCT00768066) is a similar study in which autologous MSCs or
autologous whole bone marrow are delivered percutaneously by means of the
BioCardia® delivery system.

Additionally, therapeutic cells derived from autologous heart biopsy tissue are being
evaluated. Cardiac Stem Cells in Patients with Ischemic CardiOmyopathy (SCIPIO), an
7

open-label trial in which harvested resident c-kit+ cardiac cells are expanded and redelivered intracoronarily, has yielded encouraging interim results including increased
Left Ventricular Ejection Fraction (LVEF) and decreased infarct size at 1 year [29].
Similarly, phase 1 results from the CArdiosphere-Derived aUtologous stem Cells to
reverse ventricular dysfunction (CADUCEUS) trial, in which CD105+/CD45- cardiac
biopsy cells were re-implanted in injured hearts, show reductions in scar mass and
improvements in cardiac contractility at 6 months [30].
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CHAPTER 2
2. Specific Aims
Each year over 500,000 Americans suffer myocardial infarctions. While many of these
patients survive the acute phase of the injury, the resulting tissue death and scar
formation initiate a remodeling process that ultimately destroys the organ. Thus, the 5year mortality rate for victims of myocardial infarction exceeds 50%. Over the past
decade, there has been an increasing appreciation that augmenting native repair
mechanisms via administration of exogenous stem or progenitor cells (S/PCs) might
provide fruitful approaches for reducing morbidity and mortality following myocardial
infarction. While cell therapy, using infused bone marrow-derived progenitors to
stimulate endogenous cardiac repair, has yielded modest improvements in cardiac
performance, the magnitude of this repair has been insufficient to improve clinical
outcomes. Despite many interventional studies of cell therapy, the underlying
physiology of endogenous repair is poorly understood. The magnitude of adult
cardiomyocyte formation rates is highly controversial and therefore the baseline context
of myocardial injury and repair efforts are unknown. Furthermore, though low
engraftment rates are cited as a primary limitation of current cell therapies, mechanisms
of infused cell engraftment are also unknown. Accordingly, this dissertation describes a
series of inquiries that examine three timely questions: what is the baseline
cardiomyocyte turnover rate in the nondiseased heart, what mechanisms are involved in
S/PC cell homing/engraftment to the heart, and can these insights into engraftment
mechanisms be exploited to increase the retention rates of infused cells and improve
future cardiac cell therapeutic techniques.
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Global Hypothesis: We hypothesize that endogenous cardiac repair can be understood
and augmented via manipulation of the extant repair phenomena and mechanisms.
Specifically, this work will test the four hypotheses that are described below. The overall
goal of this study is to identify and manipulate mechanisms of cell-based cardiac repair
to increase cardiac retention of infused cells thereby enhancing the effectiveness of
cardiac repair strategies.

Specific Aim 1: To quantify baseline cardiac repair levels in normal adult human
hearts by critically evaluating and synthesizing prominent studies of maintenance
cardiomyocyte formation rates. A computerized, agent-based model will be
programmed to incorporate data and modeling techniques used in the primary literature
describing adult cardiomyocyte turnover rates, which currently offer conflicting
estimations. Using this hybrid model, the mathematical models and underlying
assumptions present in existing literature will be probed for validity, self-consistency,
thoroughness, robustness, and sensitivity to parameter variance. A composite estimate
of cardiomyocyte turnover in normal adult human hearts will be formulated, thus
illuminating the baseline level of cardiomyogenesis and providing biological context for
cell therapy in injured hearts.
Specific Hypothesis 1: Scrutiny of the methodology and mathematical
constructions in existing relevant literature will help clarify alternative theories of adult
cardiomyocyte formation rates in normal human hearts.

Specific Aim 2: To identify bone marrow cell subtypes with strong engraftment
capability and subsequently identify primary mechanisms responsible for the
observed engraftment superiority. Freshly-harvested bone marrow cells will be
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labeled and infused into a murine intact organ model of ischemia-reperfusion injury (the
Isolated Perfused Mouse Heart). The phenotypic distribution of labeled cells retained in
the heart after infusion will be analyzed via flow cytometry and compared to the
distribution of the infused cell source to identify subtypes with superior relative
engraftment rates. Biomarker co-expression analysis, functional antagonists, and flow
chamber molecular interaction studies will be used to identify the adherence
mechanisms used by these preferentially-engrafting cells.
Specific Hypothesis 2: Upon infusion to the injured heart, phenotypic subsets
within heterogeneous bone marrow will engraft preferentially relative to other subsets
using mechanisms that, once identified, can inform future improvements to cell therapy.

Specific Aim 3: To increase bone marrow cell homing from the systemic
circulation to the injured heart using a chemokine-eluting hydrogel implanted
upon the epicardial surface. Chemotactic factors will be encapsulated in a
methacrylated macromer solution. In an in vivo murine model, a cryoinjury will be
surgically performed to simulate myocardial infarction. In some trials, the chemokinelaced polymer will be photo-polymerized into a hydrogel patch deployed on the
epicardial surface of the injury site. At three hours post-injury, labeled syngenic bone
marrow cells will be injected into the cryoinjured mouse via the femoral vein. Blood will
be harvested and the presence of labeled cells will be quantified at 1 and 7 days postinjury. At 7 days post-injury, hearts will be excised and digested for quantification of
labeled cell content via flow cytometry. Histology on non-digested hearts will determine
the spatial distribution of labeled cells within the heart relative to the injury site.
Specific Hypothesis 3: Site-specific, extended-release delivery of chemotactic
factors will encourage homing of infused bone marrow cells to the injured heart.
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Specific Aim 4: To increase bone marrow cell engraftment from the coronary
circulation to the injured heart using an adjuvant endothelial stimulant prior to cell
infusion. A chemical adjuvant will be selected based on the results of Specific Aim 2.
Isolated-Perfused Mouse Hearts will be prepared and treated with the chemical adjuvant
(contained in the perfusate solution) prior to infusion of labeled bone marrow cells. The
absolute number of retained cells will be quantified using flow cytometry and compared
to untreated hearts to determine impact of the adjuvant on total retention. Additionally,
flow cytometry will be used to identify the impact of the adjuvant on phenotypic subset
relative retention rates.
Specific Hypothesis 4: Intracoronary infusion of adjuvant chemicals prior to bone
marrow cell delivery will increase the absolute overall engraftment rate of bone marrow
cells and/or specific subsets of bone marrow cells.
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CHAPTER 3
3. Modeling Myocyte Turnover in the Adult Human Heart
3.1 Introduction
The human heart was long believed to have virtually no capacity for new cardiomyocyte
(CM) formation occurring after childhood. This conclusion was drawn largely from the
heart’s inability to repair tissue damaged after myocardial infarction [1]. However,
studies of sex-mismatched heart transplant recipients and reports of myogenic
progenitors within human hearts raised doubts about the absence of new CM formation
within adult human hearts [2-5]. A landmark study by Bergmann et al [6] utilized a pulsechase approach to identify and quantify the rate of new CM formation in normal human
hearts based on the average percentage of Carbon14 (C14) in the DNA of CMs in 12
autopsied human hearts (demographics reproduced in Table 3.1). Bergmann and
colleagues compared the C14 content in cardiac myocyte DNA at the time of death to
the known atmospheric concentrations of C14 at the time of the subject’s birth
(reproduced in Figure 3.1) [7,8], with differences reflecting cell cycle activity as would
occur during CM formation. Subjects born before the spike in atmospheric C14 were
found to have more C14 in their CM nuclei than was present at time of birth while
subjects born after the C14 spike had less C14 in their CM nuclei, suggesting new CMs
had been created and incorporated new C14 into their DNA. Based on mathematical
modeling that considered atmospheric C14, CM DNA C14 content, and DNA
polyploidization estimates, Bergmann et al reported a CM turnover rate of approximately
1% per annum during youth, decreasing to 0.5% during advancing age.

In 2010, Kajstura et al [9] performed extensive histological analyses of 74 non-diseased
hearts of various ages to evaluate the presence of a proposed class of cardiomyocyte
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stem cells (CSCs) and the fraction of these cells undergoing mitosis at time of subject
death. Supported by in vitro cycling and apoptosis kinetics parameters, mathematical
modeling was used to compute the annual turnover rate as a function of subject age.
Kajstura reported a turnover rate approximately 7% in young adult males that increases
to 32% with advanced age of 100 years, with even higher rates of CM turnover
calculated for females.

While these two studies both confirm that new CM formation exists in the healthy, adult
human heart, the discrepancy in magnitude and age progression is perplexingly large.
Accordingly, we developed a hybrid mathematical model designed to evaluate the two
models simultaneously. The hybrid model automaton algorithm is described in Figure
3.2 and is programmed to accept turnover rate (CM formation, apoptosis rate, and
polyploidization) parameters that vary with subject age and sex, such as those found in
the Kajstura paper (Figure 3.2 Mode A); however, these variables may be substituted for
time-varying CM formation and destruction rates as employed by Bergmann (Figure 3.2
Mode B). By applying this model to the two data sets, we have identified explanations
for their discrepancies and defined whether differences can be reconciled, while
providing a tool for modeling data derived from subsequent inquiries.

We first examine the Kajstura model in isolation. This section is divided into 3 main
subsections: (3.3.1) confirming the hybrid model’s fidelity in reproducing identical
conclusions (outputs) to the Kajstura manuscript when the Kajstura measurements
(inputs) are used, (3.3.2) evaluating the sensitivity of the Kajstura model to variations in
input parameters and assumptions, and (3.3.3) addressing important factors that were
not considered in the Kajstura document. We then provide a similar three-subsection
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analysis of the Bergmann manuscript in isolation with (3.3.4) confirmation of hybrid
model fidelity to the Bergmann methodology, (3.3.5) sensitivity analysis of the Bergmann
model to its parameters and assumptions, and (3.3.6) model modification based on
heretofore unconsidered factors. Finally in subsection 3.3.7, we seek turnover scenarios
that are consistent with both datasets when reasonable estimates of input variable
uncertainty are included and unproven assumptions are challenged and modified.
Code
ND60
ND67
ND73
ND61
ND51
ND56
ND68
ND50
ND69
ND71
ND54
ND74

Table 3.1 Bergmann Subject Dataset
Gender Birth Year
Lifespan (Yrs)
M
1933
73
M
1939
68
M
1944
63
M
1948
58
M
1955
51
M
1964
43
M
1967
40
F
1967
39
M
1973
34
M
1983
24
F
1983
23
F
1987
20

Table 3.1. Modeled Subject Genders, Birth Years, and Lifespans. Modeled subject input
parameters were extracted from the Bergmann study.

Figure 3.1. Input Atmospheric C14 Levels from 1930-2007. In accordance with the Bergmann
approach, C14 measurements were extracted from the Levin datasets (Europe from 1959-2003,
and 2003-2007) and scaled to the Bergmann unit system. Years prior to 1955 were estimated as
null as no human nuclear activity occurred during this time. For modeling purposes, a 1 year
smoothing function was applied, consistent with the Bergmann approach.
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Figure 3.2. Hybrid Model Automaton Algorithm. Subject hearts are modeled by initiating a
“Starting CM Count” for the subject at the “Start Age” of the simulation (typically birth) and a
“Subject Lifespan” that determines the number of year-repetitions. An age distribution of CM at
the time of subject autopsy is produced either via Mode A or Mode B. Mode A uses variables and
formulas from the Kajstura methodology to perform iterations of CM creation and destruction
throughout each year-iteration according to the duration and frequency of these cycles. In this
formulation, NCSC = Number of Cardiac Stem Cells, %Cyc = Fraction of CSCs cycling, and E =
Number of CSC divisions occurring before loss of pluripotency. Alternatively, Mode B uses input
annual creation and destruction values directly and these values may be dependent on either the
subject age (at time of CM formation or at current iteration of production/destruction) or on the
age of the CM undergoing destruction. There are two main outputs: (1) a distribution of surviving
CM by CM age and (2) an end average C14 measurement, modeling the Bergmann methodology
applied to model hearts, which is produced by incorporation of the CM age distribution with
atmospheric C14 timecourse data and human polyploidization magnitudes/rates.

3.2 Methods
3.2.1 Modeling Approach
A JAVA-based mathematical model heart was developed in which a modeled subject’s
end-of-life CM age distributions, defined by the modeled subject’s lifespan and CM
turnover dynamics, could be computed. These age distributions were produced by
initializing the model with a starting number of CMs and then iteratively forming new
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CMs and destroying existing CMs in accordance with formation/destruction parameters
either specified with direct numeric rates or computed from component parameters, as
those shown in Figure 3.2. In some model simulations, apoptotic elimination was
formulated to selectively target CMs based on subject age or CM age (iteration of CM
formation within the progression of iterations) whereas other model regimes assumed
random CM elimination.

When a timeline of atmospheric C14 was included as a reference input and the model
heart was assigned a finite birth (start) year on that timeline, each CM formed in the
simulation was assigned a DNA C14 value roughly equal to the appropriate atmospheric
C14 level at the time of CM formation but adjusted for polyploidization. Polyploidization
adjustment was computed by, for each CM age group in the simulation, beginning with
the atmospheric C14 level at time of CM age group formation and iteratively (for each
year between from formation until subject death) replacing that C14 number with a
weighted average of the number (weighted by 100%) and the atmospheric C14 level
contemporary to the next iteration’s polyploidization event (weighted by the percentage
of CM undergoing polyploidization at that stage in the subject’s life, as specified by the
Adler/Bergmann sigmoidal polyploidization curve).

Under these conditions, each CM surviving to the end of the simulation contributed DNA
C14 to an average CM DNA C14 value for the modeled subject. Subtracting the initial
atmospheric C14 level (at the start of simulation) from this final C14 weighted average
yielded a ΔC14 value associated with the modeled subject.
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In some analyses, the inverse operation was performed—converting an experimentally
measured ΔC14 value (or a simulated ΔC14 value) attributed to a subject, into a best fit
turnover solution—the turnover dynamics that best produce the observed or target ΔC14
value. For this task, a numerical solver evaluated a wide range of turnover solutions
(constant or time-varying depending on specified restrictions) by generating a time-ofdeath CM age distribution resulting from each potential turnover solution in the testable
range. Then, for each CM age group in each hypothetical distribution, the C14
contributed by a CM in the age group was computed (with polyploidization correction as
aforementioned). Multiplying the fractional representation of each CM age group by the
polyploidization-adjusted C14 contribution of that age group yields a net ΔC14 value for
the potential turnover solution. The turnover dynamics yielding the closest fit to the
measured or target ΔC14 is selected as the best fit solution.

3.2.2 Sources of Input Parameters
Age-dependent, gender-dependent parameter values for the number of CSCs, fraction
of such CSCs cycling at any given moment, number of CSC divisions prior to
senescence, and fraction of CM undergoing apoptosis at any given moment were
extracted from the Kajstura manuscript. Thus for any modeled subject of any age or
gender, a single value for each of these parameters (derived from regression models of
74 subjects computed in the Kajstura document) could be referenced and incorporated
into a dynamic model heart. The formula for single-iteration CM count change (Figure
3.2, Mode A) was also obtained from the Kajstura manuscript.

Similarly, raw data regarding subject-specific year of birth, year of death, and CM DNA
C14 levels for each of 12 subjects studied in the Bergmann manuscript were extracted.
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These CM DNA C14 levels were reported by Bergmann as differential C14
measurements (measured C14 relative to 1955, prior to the rise in atmospheric C14.
These differential measurements were converted to ΔC14 values by subtraction from the
initial C14 levels (also differentials from 1955 values) for use in the hybrid model. The
polyploidization age progression formula was obtained from the Bergmann manuscript.

3.2.3 Examination of Kajstura Manuscript in Isolation Using Hybrid Model
The Kajstura manuscript proposes two complementary modeling methods—a
hierarchically-structured cell kinetics model (controlled by CSC cycling rates and CM
apoptosis rates) and an age-structured cell kinetics model (controlled by CM half-life and
apoptosis rates). In the hierchically-structured model, an initial cell population of 500
Million CM/10 g tissue was used to start the simulation. Then, for each year in the
simulation, CM were iteratively created or destroyed based on the assumed modeling
parameters (enumerated in Figure 3.2, Mode A). For the age-structured model, CM age
distributions at time of subject death were produced for simulated subjects (defined by
age at time of death and gender) according to the formula utilized by Kajstura et al, a
modified version of the McKendrick von Foerster population dynamics formula:
where n(a) is the number of CM of a given age present at

time of autopsy (for 10 g tissue), N is the initial number of CM present in 10 g tissue, a is
the age of the CM, h is the halflife of a CM, and µ(a,t) is a mortality function dependent
on a and the subject age t. In the hybrid model, µ(a,t) is realized by iteratively computing
for all t (0 to lifespan) the number of CM destroyed (given as “per million” values by
Kajstura measurements) and deducting the destroyed CM from the then-current total.
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3.2.4 Examination of the Bergmann Manuscript in Isolation Using Hybrid Model
The ability of the hybrid model to faithfully emulate the Bergmann methodology for
computation of turnover levels from ΔC14 data was measured by substituting the hybrid
model inputs with the single turnover value (or age-progression series of values)
concluded by Bergmann in the Bergmann document for each of the 12 Bergmann
subjects (modeled hearts with birth date and lifespan equivalent to that of a Bergmann
subject). After integrating atmospheric C14, polyploidization data, and turnover
derivation methodology from the Bergmann document, closeness of hybrid model output
turnover to input turnover was observed, allowing quantification of distortion caused by
the hybrid modeling procedure.

To determine inherent sensitivity of the Bergmann algorithm, a wide range of input
turnovers was supplied to the hybrid model (as substitution for CM formation/destruction
parameters) and output turnover for each input was reported. The impact of
polyploidization correction on turnover estimations for the 12 Bergmann subjects was
performed by conducting simulations with scaled fractions of subject-specific
polyploidization correction factors measured in the Bergmann document and reporting
the outputted turnover estimation. The impact of a delay in incorporation of atmospheric
C14 into human tissue was performed by running the hybrid model with the bomb curve
moved forward in time by the proposed delay. Effect of initial C14 values on the hybrid
model was performed by running the hybrid model with initial C14 levels (generally
obtained from 1-year smoothing of atmospheric C14 readings obtained by Levin [7, 8])
with the minimal or maximal readings obtained during that 1-year period.
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3.2.5 Turnover Models Simultaneously Compatible with Bergmann and Kajstura Data
A global fit solver was produced to identify turnover parameter combinations most
consistent with the ΔC14 measurements made by Bergmann. To test the global fit
solver’s equivalence to the Bergmann global fit solver, model regimes utilized by
Bergmann were subjected to the hybrid model global fit solver and optimum parameter
selection and mean squared error were compared to those reported by Bergmann.

In one of the Bergmann models (denoted Scenario E2 by Bergmann), the best-fit
parameters γ0 and γ1 were disregarded by Bergmann in favor of artificially restricted
values to minimize the value of γ1, thus achieving maximal differentiation from the
Bergmann constant turnover scenario (denoted Scenario A by Bergmann). In our
analysis, comparisons of the new models to the Bergmann E2 model utilize the
parameters chosen by Bergman. However, we find the best fit parameters for this model
to be γ0 =0.45, γ1 =0.4, with a SSE of 29,793 (AIC=3.57) when ranges are γ0:{0, 0.5} at
increments of 0.01 and γ1:{0,2} at increments of 0.05.

An alternative model (denoted Time-Varying Birth Rate, Time Varying-Death Rate or
“TVB-TVDR”), inspired by the Kajstura conclusion of subject age (time)-increasing
turnover with subject age (time)-increasing vulnerability of newly formed CMs to
apoptosis, was evaluated for quality of fit with the Bergmann ΔC14 measurements in the
12 subject dataset from the Bergmann document. The TVB-TVDR model was
constructed of four independent parameters with CM formation dependent on Bs and Bi
(forming a linear curve dependent on subject age) and Ds and Di determining an annual
death rate experienced by CM formed in a given subject year:
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Ranges of values for the TVB-TVDR (with fully independent variables) were as follows:
Bs:{-1.0%/year2, +1.0%/year2}, Bi:{0%/year, 10%/year}, Ds:{-1.0%/year2, +1.0%/year2},
Di:{0%/year, 10% /year} with slopes (Bs, Ds) tested at increments of 0.05%/year2 and
intercepts (Bi, Di) tested at increments of 0.1%/year). Notably, the parameter sweep
included negative, constant, and positive temporal dependence. Though the concept of
subject age-dependent inferiority of newly-created CMs is conceptually derived from the
Kajstura findings, single age-dependent CM formation/death rates were used in this
model and thus no formulas, parameters, values, or assumptions from the Kajstura
manuscript were used in this exercise.

Parameterized model fits to the Bergmann end C14 measurements were compared by
computing the Sum of Squared Error (SSE)--for each of the 12 Bergmann subjects,
squaring the subtraction difference between the measured end C14 value and the
model’s predicted value, then summing over all 12 subjects. To compare models with
differing numbers of parameters, the Akaike Information Criteria (AIC) score was
computed according to the formula in the Bergmann manuscript—specifically,
AIC=log2(SSE/104)+N, where N is the number of parameters. Similarly to SSE, a lower
AIC score indicates superior model fit.

3.2.6 Hybrid Model Integration of Kajstura and Bergmann Models
The 12 Bergmann subjects were modeled (i.e. models were created using birth date and
lifespans equivalent to the Bergmann subject set) with input turnover dynamics as
prescribed by Kajstura, Bergmann, or with turnover dynamics using best global
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parameter fits to the Bergmann data (as identified by the global solver) to produce CM
age histograms at time of modeled subject death. Expected ΔC14 levels corresponding
to each of these CM age histograms were then produced for comparison to the ΔC14
observations made by Bergmann for these subjects.

3.3 Results
3.3.1 Hybrid Model Demonstrates Fidelity to Kajstura Model
The Kajstura manuscript proposes two complementary modeling methods—a
hierarchically-structured cell kinetics model (controlled by CSC cycling rates and CM
apoptosis rates) and an age-structured cell kinetics model controlled by CM half-life and
apoptosis rates). We first verified that our hybrid model successfully reproduces the
Kajstura hierarchically-structured model’s age-dependent rates of CM apoptosis,
formation, and turnover results when the primary input parameters (enumerated
schematically in Figure 3.2, Mode A), extracted from the Kajstura measurements, are
incorporated (Figure 3.3). We then validated the hybrid model’s ability to recapitulate
the age-structured cell kinetics model, which is responsible for generating CM age
distributions for modeled subjects in the Kajstura manuscript. For any simulated subject
(defined by turnover rates and a selected subject lifespan), the model generates an age
distribution of CMs present in the heart at the end of the simulation (time of subject
death). These age distributions are also in excellent agreement with the Kajstura results
for both genders (Figure 3.4). Thus, the hybrid model outputs the Kajstura cell dynamics
results when the Kajstura inputs are used, confirming that the model is a faithful means
of probing the Kajstura analysis.
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Figure 3.3. The Hybrid Model Successfully Reproduces Kajstura Cell Dynamics Results
from Kajstura Input Parameters. A) If cardiomyogenesis is removed from the model, the
Kajstura CM count trajectories for male and female subjects decay identically with the trajectories
reported in the Kajstura manuscript. B) Hybrid model myocyte formation for both male and
females is identical to the temporal trend reported in the Kajstura manuscript. C) Hybrid model
CM turnover for both male and females is identical to the temporal trend reported in the Kajstura
manuscript. Collectively, these results indicate that the hybrid model captures the Kajstura model
dynamics and is functioning as intended.
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Figure 3.4. The Hybrid Model Successfully Reproduces Kajstura CM Age Distribution.
Male and female distributions for young, middle-aged, and old subjects were extracted from the
Kajstura manuscript via a pixel-counting method. The hybrid model produced age distributions
for these age groups for both genders. The hybrid models are highly overlapping with the
reported Kajstura results and are nearly identical in average CM age for the various age groups
for both genders. The trend towards sharper, younger distributions with advancing age is
captured by the hybrid model for both genders. These results indicate that the hybrid model is a
reliable mechanism for modeling subjects using the Kajstura parameters.

3.3.2 Parameter and Assumption Sensitivity in the Kajstura Model
Manipulating this hybrid model in hierarchical-structure mode demonstrates the
sensitivity of modeling conclusions to variation in input parameters. Turnover estimates
in the Kajstura model are exquisitely sensitive to estimates of the expansion exponent
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(the number of cell divisions a CSC is expected to undergo before losing regenerative
capability), with a 20% variance in this parameter causing a 200% variance in estimated
turnover (Figure 3.5). The Kajstura manuscript determined this expansion exponent by
comparison of the relative abundances of CSCs to transit amplifying cells (classified by
phenotypic markers) found in autopsy tissue. Such phenotypic categorization into
discrete progenitor cell populations likely oversimplifies a more complex lineage
progression. Further justification for investigation of this exponent comes from analyzing
total CM counts over the course of a lifespan (accounting for proliferation and
apoptosis). For example, under the reported Kajstura parameters, modeled female CM
count increases with age, peaks in middle age, and then decreases but does not fall to
levels of youth. Such a net increase in cardiomyocyte count is not consistent with the
net decreases reported elsewhere [10]. Notably, applying a 20% decrease in the
expansion exponent produces model hearts with a monotonically decreasing trajectory
(Figure 3.6).

Figure 3.5. Sensitivity of the Kajstura Analysis Estimate of CM Turnover to the Expansion
Exponent Variable. The Expansion Exponent is the number of divisions that a Cardiac Stem
Cell is expected to undergo before becoming senescent (non-replicative). The hybrid model was
tested with the value of the exponent (which changes with subject age and is gender-specific)
decreased by 20% (E=80%) or increased by 20% (E=120%). Acute sensitivity to the exponent is
shown as a 20% variation in E results in a 2-fold change in turnover for A) Male and B) Female.
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Figure 3.6. Kajstura CM Count Trajectories and Sensitivity to Input Variables. The number
of CM in the heart is assumed to be 500 Million/10 gram tissue at age 20 (reported in the Kajstura
manuscript). The hybrid model is applied for male and female hearts while one variable is either
at 80%, 100%, or 120% of the value reported in the Kajstura manuscript. A) The duration of
apoptosis is varied (100% = 4 hours, based on literature maximum values for other cell types). B)
The duration of mitosis is varied (100% = 26 hours, in vitro cycling of CSCs observed by
Kajstura). C) The expansion exponent—number of CSC divisions prior to loss of replicative
ability—is varied. CM count change with age (a function of CM formation and apoptotic
destruction) is most sensitive to the Expansion Exponent. Under parameters reported by
Kajstura (E = 100%), modeled female hearts contain more CM per 10 grams in middle-age than
at youth. Reduction of the Expansion Exponent by 20% produces a monotonically decreasing
CM count trajectory for females.
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While the Kajstura turnover estimates are computed via the hierarchical-structured
model using the expansion exponent and as a primary variable, the Kajstura CM age
distributions are generated via the age-structured model using a CM half-life parameter
that indirectly incorporates, though is separate from, the apoptosis duration parameter.
This half-life is computed using a phenotyping technique similar to that used for the
expansion exponent. The effect of variation in this parameter on the CM age
distributions is shown for young, middle-aged, and older modeled hearts in Figure 3.7. A
20% variation in this parameter will cause as much as a 45% variation in average
cardiomyocyte age at time of subject death.

Together, these analyses demonstrate that the CM turnover estimates in the Kajstura
models are particularly sensitive to the magnitude of the expansion exponent (in the
hierarchical model of CM turnover) and the CM half-life parameter (in the age-structed
model of end-of-life CM age distributions).
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Figure 3.7. Sensitivity of CM Age Histograms for Young, Middle-Aged, and Old Subjects to
Input Variables. The hybrid model was run with either A) apoptosis cycle duration at 80%,
100% (4 hours), or 120% of the value used in the Kajstura manuscript or B) CM half life at 80%,
100%, or 120% (function of subject age) of the value used in the Kajstura manuscript. 80%
values are indicated in red. 100% values are indicated in black. 120% values are indicated in
green. For both male and female modeled hearts, and for all age groups, decreasing apoptosis
duration resulted in slightly younger CM age distributions, while increasing apoptosis resulted in
slightly older CM age distributions. Age distributions were more sensitive to half life (which
indirectly incorporates apoptosis) and, for all age groups and both genders, decreasing half life
resulted in younger distributions while increasing half life resulted in older distributions. The
effect of half life was most noticeable on younger model hearts.
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3.3.3 New Considerations Applied to the Kajstura Model
Turnover estimates in the Kajstura model are also affected by assumptions about
changes in total CM number that are derived from average CM volume and apoptosis
rates as a function of age. When only changes in average CM volume are considered,
estimates of turnover closely parallel rates of formation. In fact, in the Kajstura plot of
“annual turnover of myocytes” vs. subject age, dividing the regression line of the
turnover plot by the regression line of the preceding CM formation plot indicates that a
value of approximately 500 million CM per 10 g of tissue was employed by Kajstura et al.
However, the Kajstura primary input parameters do not concur with an assumption of
constant CM presence and instead lead to fluctuations with age (Figure 3.6, blue traces).
When the number of CM present is allowed to fluctuate as dictated by the Kajstura
model and measured parameters, and when turnover is defined as the number of new
CM formed in a given year divided by the number of CM present at that year in the
subject’s lifespan, turnover plots are as shown in Figure 3.8. Interestingly, the agedependent decline in total CMs in male hearts amplifies the annual turnover in males
while a net gain of CM suppresses the turnover rate in females.
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Figure 3.8. Apoptosis-Dependent Definition of CM Turnover in the Kajstura Model. The
hybrid model was parameterized in accordance with the Kajstura published values for Cardiac
Stem Cell number, cycling frequency, mitosis duration, and expansion exponenent. Turnover
was computed as newly formed CM divided by either a constant CM density (5,000,000 CM per
10 g tissue, as in the Kajstura publication) or a variable CM density determined by iterative
production and destruction of CM using the aforementioned Kajstura CM formation parameters in
conjunction with the Kajstura CM apoptosis parameters. The simulation is performed for A)
Males and B) Females
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In turn, a time-varying CM count allows examination of the impact of CM apoptosis on
turnover rate. Although the Kajstura manuscript empirically measures apoptotic rate
using TUNEL staining, alternative estimations of apoptosis using similar techniques have
reported discordant results. One such study of human healthy human hearts by Mallet,
et al found similar magnitudes of apoptosis but no age-dependency (although apoptosis
was higher in males than females, in agreement with the Kajstura paper) [11]. A version
of the model using Kajstura parameters with the apoptosis rate substituted by Mallet is
shown in Figure 3.9; such parameterization generates relatively low annual CM turnover
for males and females (below 5%) declining with age to 2%--a finding larger but
substantially more concordant with the Bergmann conclusions though primarily driven by
large net gains in CM count.
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Figure 3.9. Kajstura Turnover with Alternative Apoptosis Parameters. The hybrid model
was parameterized in accordance with the Kajstura published values for Cardiac Stem Cell
number, cycling frequency, mitosis duration, and expansion exponenent, as well as either the
Kajstura apoptosis parameters (red) or from an alternative estimation by Mallet (blue). To include
apoptosis (and thus, non-constant CM heart content) in the computation of CM turnover, turnover
for a given year was computed as “newly formed CM in that year divided the CM density at that
year as determined by preceding iterative production and destruction of CM,” rather than as
“newly formed CM in year divided by a constant 5,000,000 CM/10 g tissue” as was done in the
Kajstura manuscript. The simulation is performed for A) Males and B) Females
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The impact of varying the magnitude of apoptosis also merits consideration. Perimortem increases in tissue TUNEL staining becomes significant around 24 hours postmortem and can double the apparent apoptotic fractions (highly tissue dependent) [12].
Alternatively, TUNEL staining has been shown to underestimate apoptosis (particularly
when high levels of necrosis occur) with sensitivities ranging from 60-90% [13].
Therefore, Figure 3.10 illustrates the impact of potential apoptosis variation in the
Kajstura model. The absolute rate of apoptosis has a roughly linear impact on turnover
estimation. Notably, at extremely small multiples of apoptosis fractions found by
Kajstura (but with the same age-increasing trajectory), reported turnover in the Kajstura
model becomes low and age-decreasing, albeit primarily dominated by a net gain in CM
content that serves as the denominator in this formulation of the turnover definition.

Figure 3.10. Kajstura Model Turnover Conclusions under Various Apoptotic CM Fractions.
The hybrid model was parameterized in accordance with the Kajstura published values for
Cardiac Stem Cell number, cycling frequency, mitosis duration, and expansion exponent, as well
as either the Kajstura apoptotic CM fraction as a function of time (A=1X) or some multiple of that
parameter (A=0X, 0.25X, 0.5X, 1.5X, 2X). To include apoptosis (and thus, non-constant CM
heart content) in the computation of CM turnover, turnover for a given year was computed as
“newly formed CM in that year divided the CM density at that year as determined by preceding
iterative production and destruction of CM.” The simulation is performed for A) Males and B)
Females
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3.3.4 Hybrid Model Demonstrates Fidelity to Bergmann Dataset
The hybrid model, generally parameterized with CM formation/destruction parameters,
produces CM age distributions for simulated subjects as described above. If a subject
birth date is also supplied, the hybrid model can cross-reference the birth years of all
CMs remaining at the end of the simulation with atmospheric C14 levels at various
points in history (reproduced in Figure 3.1), to calculate an associated ΔC14 for the
simulation. An age-dependent polyploidization compensation factor must also be
supplied; this polyploidization compensation is a function of both the Bergmann/Adler
data [14] for human poly-ploidization rate age-dependency and also the simulated CM
formation/destruction rates (unique to each simulation). A numerical solver then
translates simulated ΔC14 values into annual turnover levels for any simulated subject
under various model assumptions (such as constant or fluctuating turnover, independent
or dependent formation/destruction rates, etc).

The hybrid model fidelity to the Bergmann analytical system can be shown in a 3-part
process outlined schematically in Figure 3.11. Briefly, the subject-specific constant
annual CM turnover rate and polyploidization rate measurements obtained by Bergmann
were substituted as input for the cellular formation/destruction parameters. Subjectspecific CM age distributions were built from this parameterization scheme, and
subsequently, simulated end C14 levels were produced from these age distributions by
cross-referencing historical atmospheric C14 levels. Under these conditions, the hybrid
model produced faithful estimates of end C14 (within 10% of the Bergmann measured
raw values from autopsy, Figure 3.12A). Furthermore, the hybrid model polyploidization
compensator module, parameterized using the sigmoidal formula applied by Bergmann
(derived from the Bergmann/Adler composite polyploidization measurements), performs
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identical compensation to that applied by Bergmann (Figure 3.12B). Finally, the
numerical solver constructed for the hybrid model that converts subject-specific ΔC14
values (obtained by subtracting initial C14 values, equivalent to atmospheric C14 at time
of birth, from the end C14 modeled values) into estimates of annual CM turnover also
functioned identically to the Bergmann system with no distortions, as shown by the
solver’s ability to convert the simulated ΔC14 values into the original input turnovers
(Figure 3.12C). Thus the hybrid model application to C14 data provides an excellent
representation of the Bergmann analytical system without distortion.

Figure 3.11. Hybrid Model Validation Strategy. To demonstrate hybrid model fidelity to the
Bergmann system, the hybrid model CM formation/destruction inputs were substituted with the
constant turnover levels concluded by Bergmann. When the hybrid model’s polyploidization
function is disabled, the hybrid model computed ΔC14 levels expected to be produced by such
stipulated turnover (these values may be compared to the non-polyploidization-corrected values,
i.e. raw measured values obtained by Bergmann [Bergmann Fig 3A/3B] for closeness). Similarly,
when the hybrid model’s polyploidization function was enabled, the hybrid model computed ΔC14
levels expected to be produced by such stipulated turnover (these may be compared for
closeness to Bergmann’s post-ploidy corrected ΔC14 values [Bergmann Fig 3D]). If both tests
report similar C14 values to those reported by Bergmann, than the model introduces no unwanted
distortions in the development of CM age histograms or in computing C14 values from them.
Also, if both tests conform to Bergmann, than the hybrid model compensates for polyploidization
identically to Bergmann. Furthermore, non-polyploidization-corrected C14 values can be fed into
the hybrid model’s numerical solver (which has a polyploidization correction module equivalent to
that used to test the aforementioned points), and the resulting turnover conclusions can be
compared with the Bergmann concluded turnover results to validate that no distortions are
caused by the numerical solver.
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Figure 3.12. Hybrid Model Validation Results. The validation strategy described in Figure
3.11 is applied. When the Bergmann final concluded turnover levels were used as the hybrid
model input, the hybrid model created simulated hearts for each subject (displayed individually
from oldest on the left to youngest on the right) and estimated final average C14 content based
on the age histograms produced for each subject under these turnover conditions. A) The raw
C14 measurement produced matched those in the Bergmann manuscript. B) The hybrid model
then computed C14 attributable to poly-ploidization, which again matched the Bergmann
conclusions. C) After compensating for poly-ploidization, the Hybrid Model’s numerical solver
converted C14 values into annual turnovers which matched the initial parameterization values.
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3.3.5 Parameter and Assumption Sensitivity in the Bergmann Model
Because the polyploidization correction factor is used to directly minimize the concluded
annual turnover level, precision in this estimate might be important. In fact, other studies
provide diverse, generally reduced values for poly-ploidization in healthy adults [15-18].
In one representative study by Takamatsu et al, human age-dependent polyploidization
was found to follow a sigmoidal time course with poly-ploidization essentially completed
during adolescence and ultimately resulting in an average cardiomyocyte DNA content
of approximately 3.0n (with diploid counted as 2n) [19]. In comparison to Takamatsu,
the Bergmann/Adler dataset shows a similar temporal sequence but an ultimate average
cardiomyocyte DNA content of approximately 3.8n. Substituting the a poly-ploidization
correction based on the Takamatsu data (about 20% less than the Bergmann correction
factor), rather than using the more severe Bergmann correction, would results in a
modest 25% increase in the Bergmann turnover estimates for younger subjects from
1.3%±0.2% annually under the Bergmann estimate to 1.6%±0.1% under the Takamatsu
estimate, p<0.15), while estimates of turnover for the 4 oldest subjects, born such that
polyploidization occurred prior to the atmospheric C14 spike, are largely unaltered
(Figure 3.13A). As true poly-ploidization magnitude is disputed, a more complete
analysis of the impact of polyploidization magnitude is provided in Figure 3.13B, which
plots the subject-specific concluded turnover resulting from a range of polyploidization
scaling (from 0%, ie no polyploidization, to 200% of the Bergmann/Adler values). In
general, increases in assumed polyploidization levels result in lower estimates of
turnover and the effect is linear for most subjects, but does depend on the unique timing
of the subject’s life within the atmospheric C14 level trace.
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Figure 3.13. Cardiomyocyte Turnover Estimates using Bergmann Approach and Dataset
with Bergmann Various Poly-ploidization Correction Factors. A) Takamatsu et al concluded
a poly-ploidization level approximately equal to 78% of the level concluded by Bergmann with
nearly identical age progression. Substituting a poly-ploidization correction factor based on the
Takamatsu conclusion to the Bergmann ΔC14 dataset yields modestly higher estimates of
turnover that concluded by Bergmann for subjects born after the rise in atmospheric C14
(1.3%±0.2% by Takamatsu versus 1.6%±0.1% by Bergmann, p<0.15). The substitution of
Takamatsu correction factor has no impact on the 4 modeled subjects born prior to 1950 because
poly-ploidization largely completes prior to C14 atmospheric rise for these subjects
(0.18%±0.08% by Takamatsu versus 0.15%±0.09%). B) A wide range of poly-ploidization
magnitudes (with unchanged age relationship) are applied to the hybrid modeled subjects. A
scaling of 100% is equivalent to the Bergmann values used by Bergmann, whereas 200% is
equivalent to twice the level of ploidization and 0% indicates an assumption that poly-ploidization
does not exist. In general, there is a negative linear relationship between concluded turnover and
poly-ploidization correction. The turnover estimates for the 3 oldest subjects, having completed
adolescence prior to the rise in atmospheric C14, are not dependent on poly-ploidization
correction (not shown).
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3.3.6 New Considerations Applied to the Bergmann Model
The Bergmann manuscript makes the simplifying assumption that C14 incorporated into
DNA corresponds instantaneously to the atmospheric concentration at the time of cell
formation. However, this assumption is questionable in light of a study by Broecker et al
that analyzed C14 incorporation into the food supply and human tissue. Broecker
concluded a delay, dependent on diet, of up to 2 years [20]. Such a delay substantially
affects turnover levels in subjects meeting both of two criteria: (1) true turnover is low
(~1% annually) such that hearts at time of subject death are substantially composed of
original CMs and (2) subjects are born in a time of rapidly changing atmospheric C14
such that a small delay results in substantially different initial C14 values. Thus, while
the older (pre-bomb subjects) are largely unaffected by delays of atmospheric C14
incorporation into CM DNA, younger subjects are highly susceptible; a 2-year delay can
result in a nearly 5-fold change in turnover for some subjects. Among the 5 youngest
subjects in the Bergmann dataset, a 2-year delay causes average turnover conclusion to
increase from 1.4%±0.1% to 5.7%±0.8%, p<0.001 (Figure 3.14A).

Similarly, the atmospheric C14 measurements from the Levin dataset [7, 8] show wide
monthly variations that indicate the variability of the metric. As a further illustration of the
sensitivity of C14 tracer studies to initial conditions, the hybrid model was seeded with
initial C14 values for each subject taking on either the highest or lowest atmospheric
C14 measurement obtained within 12 months of subject birth and results are shown as
error bars upon the concluded turnover obtained when the 1 year smoothing function is
applied (Figure 3.14B); extreme fluctuation is observed ranging in nearly all subjects
from 0% annual turnover to several multiples of the smoothed-C14 conclusions.
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Figure 3.14. Hybrid Model Simulations for the Bergmann Subject Dataset under Various
Initial C14 Incorporation Assumptions. A) The hybrid model was parameterized with turnover
levels as concluded by Bergmann to generate an assumed CM age histogram at time of autopsy.
The hybrid model then determined an associated ΔC14 for each surviving CM in each modeled
subject under the assumption that atmospheric C14 is either instantly incorporated into newly
formed CM DNA or that there is a 2-year delay (such that CM DNA C14 concentrations are equal
to the atmospheric concentration 2 years prior to CM formation). The numerical solver was used
to derive corresponding turnover levels (assuming constant turnover) from computed ΔC14
values. B) The hybrid model was parameterized with turnover levels as concluded by Bergmann
to generate an assumed CM age histogram at time of autopsy. The hybrid model then
determined an associated ΔC14 for each surviving CM in each modeled subject under the
assumption that atmospheric C14 is instantly incorporated into newly formed CM DNA. However,
initial C14 levels (specifying the C14 content of initial CMs, which comprise the bulk of CMs
present at time of autopsy in low turnover models), were assigned C14 levels equal to either (1)
the 1-year smoothed atmospheric C14 level at time of subject birth, or (2) the lowest C14 level
measured by Levin within 1 year of subject birth, or (3) the highest C14 level measured by Levin
within 1 year of subject birth. Subject ΔC14 levels were then computed and the numerical solver
was used to derive corresponding turnover levels (assuming constant turnover). The turnover
levels derived from smoothed C14 measurements are shown as blue bars, with the turnover
levels produced by using minimal and maximal atmospheric C14 levels as initial C14 levels are
shown as error bars.
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The 3 oldest subjects (ND60, ND67, and ND73) in the Bergman dataset are interesting
for several reasons. The analysis of these subjects, born in 1933, 1939, and 1944
respectively, are independent of complications from polyploidization and initial C14
levels as the increase in atmospheric C14 takes place after their adolescence.
Bergmann deduced, based on the fact that the measured end C14 values for these
subjects is lower than contemporary atmospheric conditions, that a large fraction of CMs
produced either at birth or shortly after (prior to the atmospheric C14 spike), must persist
until death. Accordingly, these subjects were computed to have undergone very low
annual turnover rates of 0.10%, 0.09%, and 0%, respectively, by Bergmann (under the
Bergmann “Scenario A” constant turnover scenario). For example, the meaning of this
metric suggests that for the oldest subject, during each year from birth to death, 0.10%
of CMs were replaced at random by newly-formed CMs; at the end of the subject’s 73
year lifespan, 90% of original CMs would remain and the 10% of CMs that were created
post-birth contain the necessary C14 to raise the measured average level to 21.30.

However, the younger subjects (aged 19-43 at time of death) all report average annual
turnover values ranging from 1-2%. In contrast to the Scenario A assumptions, a true
model of turnover ought to require that older subjects go through a phase in youth that is
similar to that of the youthful subjects, i.e. that subjects ND60, ND67, and ND73 each
experienced phases of their lives (at least from age 0-40) where turnover was on the
order of 1-2% annually. Such turnover levels, even allowing turnover to cease entirely at
age 40, would have reduced the final contribution of initial CMs in these 3 subjects to
65% of the total CM count, substantially less than the claimed approximately 90% under
Scenario A. Indeed, such turnover would lead to ΔC14 values of 62, 77, and 84 per mil
(final average C14 less initial at birth), far greater than the measured 21.3, 18.84, and
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3.65. Allowing turnover to continue beyond year 40 actually serves to partially reconcile
the simulated ΔC14 values with the paradox by allowing for elimination of the high-C14
CMs generated during the atmospheric C14 spike, with increasing turnover providing
better agreement (although, as contemporary C14 levels never fall below the observed
ΔC14 results, no amount of turnover can fully resolve this paradox).

Bergmann also highlights a modified version of Scenario A in which total cell count is
again constant (full CM replacement) but turnover can change with subject age. The
global solution (derived from C14 measurements in all 12 subjects) was:

However, for all 3 of the eldest study subjects, ΔC14 measurements should have
exceeded 100 per mil (101, 110, and 116 for ND60, ND67, and ND73, respectively)
according to this model, several multiples above the observed. This model also
demonstrates the inherent incompatibility of C14 measurements in the oldest subjects
with C14 measurements in the younger subjects.

Another notable phenomenon occurs for subjects born before the atmospheric C14
spike; at a certain patient-specific value of measured ΔC14, the numerical solution
bifurcates creating a satisfactory low and high solution. Beyond the bifurcation point, the
low solution reports a turnover estimate of 0.75%, whereas the high solution remains
approximately truthful to the ideal at all turnover levels. This effect is illustrated in Figure
3.15 where annual CM turnovers ranging from 0-40% are used as the sole input to the
hybrid model. The hybrid model then computes estimated ΔC14 for each subject under
each turnover input scenario and then solves for a best-fit constant turnover solution
using either using either the low or high solution. While the measured ΔC14 for subjects
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born before the C14 spike is below the threshold needed to make a high solution viable,
the high solution becomes viable at surprisingly low ΔC14 measurements (approximately
60 per mil), lower than the ΔC14 measurement that could have been expected in these
subjects from the global Scenario A best-fit data (by which Bergmann concluded 1%
annual turnover). These facts exist independent of complications from polyploidization
as the simulation was conducted using input parameter turnover assumed to be true (i.e.
with polyploidization appropriately compensated for, regardless of its true value).

Figure 3.15. Simulations Derived from Applying Pre-specified Annual CM Turnover Rates
to Bergmann Model Analysis Method. A model was produced for each of the 12 Bergmann
subjects (defined by their lifespans and birth years). Instead of cycling dynamics parameters
from the Kajstura manuscript, true constant annual turnover was specified as input (Figure 3.2
Mode B). The category “Older Subjects” includes ND60, ND67, ND73, ND61, and ND51 from the
Bergmann study, while the category “Young Subjects” includes ND56, ND68, ND50, ND69,
ND71, ND54, and ND74. When true turnover input is high (beginning at 4%/year and fully
apparent by 10%/year), the resulting ΔC14 has two numerical solutions—a low solution (plotted in
A) and a high solution (plotted in B). The high solution tracks the true (ideal) input whereas the
low solution asymptotes at 0.75%/year. Although the ΔC14 levels obtained by Bergmann for
older subjects (~20 per mil) are too low for the high solution to be enabled (~60 per mil, not
shown), this graph illustrates that, for measured ΔC14 exceeding a certain discrete threshold, a
bifurcation point exists such that adoption of the low solution leads to insensitivity.
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Alternatively, the scenario ultimately favored by Bergmann, denoted “Scenario E2,”
allowed CM destruction rates to be inversely proportional to CM age while time-varying
CM formation rates balanced destruction to keep a constant total CM count.
Formulaically, the model is represented below (where t represents the subject age and a
represents the age of a given CM:
Time Dependent CM Formation Rate:

Age Dependent CM Destruction Rate:

In this model, younger CM (when the CM’s a is low regardless of the subject year t in
which it was formed) are destroyed more frequently than CM that have persisted to an
older age a.

This model, when fitted with γ0 = 0.123 and γ1 = 1.42 as dictated by Bergmann, yields
turnover values with magnitude and age-dependency similar to Scenario A. The
expected end C14 values for ND60, ND67, and ND73 under this scenario are 58, 68,
and 82, respectively, which mitigates the inconsistency but still drastically exceeds the
measured values.

Combining (1) the fact that the low measured C14 values observed in the 3 oldest
subjects (used by Bergmann to eliminate the high solution) are incompatible with
measured C14 values from the younger subjects with (2) the fact that a high turnover
solution becomes viable with unexpectedly low C14 measurements—not substantially
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higher than was actually observed, a high-turnover scenario for elderly subjects
becomes reasonable.

3.3.7 Models Simultaneously Compatible with Bergmann and Kajstura Datasets
The prior results demonstrate that both models have reasonable uncertainty in
concluded turnover estimates. In the Kajstura manuscript, these uncertainties stem
primarily from strong sensitivity to primary input variables (particularly ones that can only
be measured indirectly). In the Bergmann manuscript, uncertainty arises both from a
conspicuous inconsistency in data from old versus young subjects and also from
assumptions regarding the incorporation of atmospheric C14 into CM DNA. In section
3.3.7, we attempt to vary key input parameters and modify tenuous model assumptions
to find scenarios that are simultaneously compatible with both datasets.

The Bergmann manuscript applied 8 separate scenarios (defined by the way in which
parameters are assumed to fluctuate relative to each other, to subject age, and to CM
age in various combinations) to the dataset of 12 subjects. Bergmann performed a
global regression analysis to determine which turnover parameters best fit the measured
ΔC14 data for each scenario. Reported turnover levels were obtained from the
optimized parameters for the scenario that best fit the observed ΔC14 of the 12 subjects.

To test new models beyond the original 8 evaluated by Bergmann, we constructed a
global numerical solver that allows all linear turnover solutions to be evaluated.

The 4-

parameter generic model, denoted as the Time-Varying Birth Rate/Time Varying-Death
Rate (TVB-TVDR) model, assumed a linear dependence of CM formation rate and CM
annual destruction rate on subject age (where death rate controls not the fractional
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destruction of CM at Subject Age, but the rate at which CM produced at that Subject Age
will be destructed annually such that CM formed at different times may be destroyed at
different rates), thus generating the parameters Bs, Bi, Ds, and Di as shown:

In this construction, the annual CM formation rate at birth is given by Bi, and is increased
or decreased to a new value in each subsequent year as dictated by the value of Bs.
Thus, in a linear model, Bi is the “Intercept” and Bs is the “Slope with respect to subject
age.” Each CM, once formed, is assigned an annual death rate dependent on the year
of the subject’s life in which it was formed such that a cohort of CM formed during a
certain year of a subject’s life will be fractionally depleted (as determined by that cohort’s
computed Annual Death Rate, which has a slope Ds and intercept Di) in each
subsequent year of subject life. Notably, this model differs conceptually from the
Bergmann’s E2 model, which allowed each CM (regardless of when it was formed in the
subject’s life) to experience a death rate dependent on the age of the CM. To clarify, the
Bergmann E2 model assumes that every CM experiences an identical “death likelihood
trajectory” regardless of how old the subject was at the time of formation whereas the
TVB-TVDR model assumes that CM formed at different times in the subject’s life are
fundamentally different (experience different annual death rates).

To verify the fidelity of the numerical solver and thus justify its ability to compare the best
fit of models from the Bergmann manuscript to new, less-restrictive TVB-TVDR models,
we recapitulate various Bergmann models and demonstrate that our solver produces
identical best-fit results. For example, in the constant turnover scenario (Scenario A,
Bergmann Supplement), where Myocyte Formation Rate(%) = Annual Death Rate(%) by
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assumption, the solver computed a best-fit annual turnover rate of 0.99% (Bs = Ds = 0, Bi
= Di = 0.99%) with a sum of squares error (SSE) of 45,168—highly comparable to the
Bergmann solver’s result of 1.0% with an SSE of 27,770. As another example, the
solver also computed a best-fit CM formation rate of 1.3% with best-fit destruction rate of
0.0%, SSE = 43,376, for Bergmann’s Scenario B—the regime where CM birth and
destruction rates are constant but not necessarily equal— in which Bergmann concluded
identical rates of 1.3% and 0.0% with SSE = 27000).

Of the 8 scenarios tested by Bergmann, no model allowed CM formation rate to change
with subject age while simultaneously allowing new CMs to experience destruction rates
dependent on subject age at time of formation. Because the Kajstura data suggests that
CM formation increases with age, but that CMs formed in advanced age are shorterlived, we evaluated such a model using the global solver by allowing all 4 parameters of
the TVB-TVDR to vary independently (notably, TVB-TVDR parameter sweeps allowed
for positive, constant, and negative age-dependency and used no data, methods, or
influences from Kajstura aside from this conceptual rationale). To compare the fit quality
of models with different numbers of parameters, we compute the Akaike Information
Criteria (AIC) value for the Sum of Squared Error (SSE) associated with each model
using the formula employed by Bergmann; this formula essentially penalizes models with
many parameters to give an adjusted fit values (with low AIC scores suggesting better
fit).

The global best fit for the TVB-TVDR model was Bs = 0.10%, Bi = 2.5%, Ds = 0.5%, Di =
1.0% and SSE = 5589 (AIC=3.16)—a scenario of age-increasing turnover but where CM
created at late subject age are destroyed more quickly than predecessor CM. This and
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other scenarios (not shown) report superior AIC scores than the constant turnover
scenario (Scenario A) of (Bs = Ds = 0, Bi = Di = 0.99%), which yielded AIC=3.18 in the
Hybrid Model. Similarly, the TVB-TVDR model achieves better fit than Bergmann’s
preferred model of Cumulative Survival with Cell Replacement Inversely Proportional to
Cell Age (denoted as “E2” in the Bergmann supplementary information), which yielded a
SSE of 29,578 (AIC=3.56). The end C14 values produced by the best-fit TVB-TVDR
model are greatly superior for each subject (including the critically important most elderly
3 subjects) than either the Bergmann or Kajstura models (Figure 3.16).
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Figure 3.16. Performance of Various Model Scenarios. A) Representative CM age histogram
for oldest Bergmann subject (ND70) under Kajstura, Bergmann Scenario E2, Bergmann Scenario
A, and TVB-TVDR best-fit models. Age distribution is bimodal in the Best Global Fit TVB-TVDR
model with a cohort of original CMs persisting until death, bolstered by low death rate and high
initial representation, and young CMs produced due to high rates and having undergone few
annual death cycles. B) Representative CM age histogram for youngest subject (ND74). C)
Expected end C14 (time of autopsy) measurements for the various scenarios (Bergmann
measured values supplied for reference). The TVB-TVDR model, by selective depletion of
intermediate CMs, fits both older and younger subjects well despite having a comparatively high
(with regards to the Bergmann conclusions) turnover of 4.5% increasing to 15% by age 70. The
Bergmann models (E2 and A) capture the general temporal pattern but shows substantial
deviations numerically; particularly for the oldest 3 subjects which are the lynchpin of the low
turnover solution hypothesis. The Kajstura turnover actually fits older subjects better than the
constant turnover scenario due to the elimination of CM produced during the highest atmospheric
C14 concentrations, but fails to match younger subjects as the high turnover drives all Kajstura
predicted C14 levels to peri-mortem levels. Error bars represent the simulated end C14
concentrations for each subject when either the lowest or highest initial atmospheric C14 (within 1
year of time of subject birth) levels are used (except for the Kajstura model, which has no
sensitivity to initial C14 concentration due to obliteration of nearly all initial CMs; for this model
set, the primary variable “CM Half Life” is varied to 80% or 120% of values concluded by
Kajstura). *Of interest, the best fit TVB-TVDR model (age-increasing CM formation) would
increase total CM in adolescence to a peak of 130% of initial count (birth) by age 20, which would
then decrease to 87% of count at birth by year 70 (not shown).
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Figure 3.17 describes the relationship between CM turnover and subject age. The TVBTVDR best fit model is parameterized as described and polyploidization correction is
performed as according to the Bergmann estimates. Notably, no Kajstura turnover
dynamics are incorporated in the creation of the TVB-TVDR dataset. The best fit model
(with age-increasing turnover) is displayed as a solid blue line. The zone of best-fit TVBTVDR parameter solution sets compatible with Bergmann datasets is determined by
repeating the computation while substituting the initial C14 values for each subject with
either the higher or lower of initial C14 values found within 1 year of the subject’s birth,
thus roughly illustrating precision. Turnover is defined as the number of new CM formed
in a given year divided by the number present in the heart at that year (though the exact
initial count is numerically irrelevant and can be scaled without affecting the
computation).

For comparison, the Kajstura turnover estimation using the adjusting turnover definition
is also shown in Figure 3.17 with variations to its key parameters. Variation in apoptosis
frequency rate affects turnover conclusions primarily in aged subjects with little influence
in youth (Figure 3.18). Alternatively, variation in expansion exponent affects turnover
conclusions primarily in youthful subjects and does not influence turnover conclusions at
old age (Figure 3.19); while the expansion exponent drastically affects CM formation at
all ages, particularly in old age (Figure 3.5), this effect is roughly offset by cumulative CM
count changes (Figure 3.6) yielding little impact on turnover. While Figures 3.18 and
3.19 explore the variable sensitivity in a gender-specific manner, Figure 3.17 displays a
gender-composite computation for comparison to the Bergmann simulations. As the
original Bergmann manuscript amalgamated data from 9 males and 3 females, the
Kajstura best estimate trajectory shown in Figure 3.17 is also computed as the weighted
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composite of the male (75% weight) and female (25% weight) turnover trajectories (red
solid line) with variations in parameters also plotted.

When both models incorporate reasonable estimates for variations in their primary
parameters (CM Apoptosis Rate and Expansion Exponent for Kajstura, Initial C14
parameter for Bergmann), a region of agreement emerges. Figure 3.17 suggests that
initial turnover levels of 4-6%, increasing with age to 15-22%, are compatible with both
datasets.
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Figure 3.17. Impact of Assumptions and Parameter Measurement Uncertainty on Two
Independent Models of CM Turnover. Turnover rates derived from Kajstura data plotted (red
solid) with a range of reasonable uncertainty created by varying the primary model variables (CM
Apoptosis Frequency “A” and Expansion Exponent, “E”) simultaneously by ±20% (red dashed)
under the adjusting CM count scenario (wherein the number of CM cells varies in time according
to the computed CM formation/destruction rates) with gender weighting as equivalent to the
gender-weighting of the Bergmann dataset (75% male, 25% female). Turnover rates derived
from Bergmann data, when conclusions from the TVB-TVDR model, parameterized by optimum
fit to the 12 Bergmann subjects ΔC14 data, are shown (blue solid) with a range of reasonable
uncertainty created by performing the TVB-TVDR global fit function with initial C14 levels either
set to the lowest or highest within 1 year of each subject’s birth (blue dashed). A region of
overlap, indicating turnover levels consistent with both the Bergmann and Kajstura datasets, is
indicated in purple.
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Figure 3.18. Sensitivity of the Kajstura Analysis Estimate of CM Turnover to the Apoptosis
Fraction Variable. The Apoptosis Fraction is the measured percent of CM observed to be
undergoing apoptosis at any given point in time. The hybrid model, under the adjusting turnover
definition, was tested with the value of the fraction (which changes with subject age and is
gender-specific) decreased by 20% (A=80%) or increased by 20% (A=120%). Sensitivity to the
parameter A seems to be greatest when considering subjects of advanced age. Simulations
were run for A) Male and B) Female.
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Figure 3.19. Sensitivity of the Kajstura Analysis Estimate of CM Turnover to the
Expansion Exponent Variable. The Expansion Exponent is the number of divisions that a
Cardiac Stem Cell is expected to undergo before becoming senescent (non-replicative). The
hybrid model, under the adjusting turnover definition, was tested with the value of the fraction
(which changes with subject age and is gender-specific) decreased by 20% (E=80%) or
increased by 20% (E=120%). Sensitivity to the parameter E seems to be greatest when
considering subjects of youthful age whereas in advanced age, changes in CM formation are
roughly compensated for by changes in cumulative cell count. Simulations were run for A) Male
and B) Female.
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3.4 Discussion
Kajstura et al concluded that younger subjects experience turnover of approximately 58% (with no statement about turnover during childhood up to 20 years of age).
Bergmann et al concluded a turnover rate of 1-2% for these younger subjects, a result
not far removed from Kajstura when consideration of axioms, methods, and parameter
sensitivity are included (Figures 3.5-3.10, 3.13, 3.14).

Discrepancy arises primarily in the older subjects, where Kajstura concludes ageincreasing turnover (approximately 20% in aged males, higher in females), Bergmann
concludes age-decreasing turnover (approximately 0.5%). The definition of the turnover
formula itself is open to interpretation. In the Kajstura paper, a constant baseline value
of CM content (which becomes the denominator in the formula “Turnover = CM
Formation/CM Content)” is used for subjects of all ages thus allowing turnover plots to
be wholly dictated by CM formation rates. However this constant value is inconsistent
with the measured CM formation and destruction parameters obtained by the Kajstura
experiments. When the heart CM content is allowed to fluctuate as dictated by the
Kajstura parameter measurements, apoptosis enters into the turnover computation
(Figures 3.9, 3.10). Moreover, though the Kajstura age-increasing CM apoptosis rates
are supported by their empirical data, alternative datasets from other laboratories have
found similar CM apoptotic rate magnitudes with no evidence of age correlation. When
such alternative apoptosis rate data sources are substituted into the Kajstura model,
age-dependent CM depletion does not occur and thus a fluctuating-denominator
interpretation of turnover indicates age-decreasing turnover down to levels of
approximately 2%. Notably this circumstance only arises in scenarios where net CM
count increases dramatically with age, a circumstance uncorroborated in existing
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literature. Similarly, peri-mortem increases in apoptosis and imperfect sensitivity of the
TUNEL staining assay may further have confounded estimations of apoptosis; extreme
apoptosis over-estimation by Kajstura could potentially have masked lower levels of
turnover particularly in older subjects. While the question of proper apoptosis valuation
persists, this examination demonstrates the strong impact that subtle and often overlooked differences in definitions of terms and in parameter selection has on iterative
mathematical models.

Similarly in the Bergmann model, the assumption of instantaneous incorporation of
atmospheric C14 into human tissue, which is not supported by prior studies [20], may
have caused an underestimation of turnover in young subjects. Regarding aged
subjects, Bergmann makes the logical deduction that end C14 measurements for the 3
oldest subjects, which are below atmospheric C14 levels at all points after the rise in
atmospheric C14, implies that a large number of initial CM (created peri-natal) must
persist to the end of subject life. Bergmann goes on to deduce that a large number of
initial CM surviving to death implies low turnover rates throughout life; however a linear
model that allows high and age-increasing turnover can also preserve peri-natal CMs by
allowing newly-formed CMs to experience a higher rate of destruction than older CMs.
Indeed, such a model provides superior fit both globally and for each individual subject in
the Bergmann dataset than is achieved by constant turnover scenarios, while also
producing reasonable associated trajectories for total CM count.

An additional insensitivity effect may have contributed to the conclusion of low-turnover
in advanced age. The ability of high-turnover scenarios to fit low ΔC14 observations for
subjects born before the spike in atmospheric C14 may appear paradoxical, but high
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turnover solutions in general can decrease expected ΔC14 measurements by eliminating
CMs containing copious amounts of C14 absorbed during the atmospheric C14 peak.
Such an effect is manifested in Figure 3.15, which shows that annual turnover beginning
at 4% would generate ΔC14 values that would support two solutions—a low solution and
a high solution. Thus, at surprisingly low ΔC14 measurements, the appropriate level of
turnover to conclude from such measurements exhibits a bifurcation—a radically higher
solution can be appropriate for a modestly higher ΔC14 measurement. If the Bergmann
measurements for the 3 eldest subjects are accurate representations of true CM DNA
content at time of death, then this high solution is irrelevant as C14 levels never decline
below the measured ΔC14 values during the lifetimes of these subjects. However, the
credibility of these low measurements is made suspect by the fact that ΔC14
measurements from the younger subjects imply turnover levels that ought to (under a
low turnover scenario), have produced drastically higher ΔC14 values than were
observed in these older subjects.

Any statistical variance in either the Bergmann analysis (possibly resulting from the
widely fluctuating atmospheric C14 levels) or from the Kajstura modeling process (which
invokes in vitro estimations of cellular proliferation, differentiation, and apoptosis as well
as a discrete hierarchical progression of CM differentiation, could blur the conclusions of
turnover magnitude and age-dependence. Furthermore, inherent model assumptions,
such as the age at which turnover is assumed to begin, variance of turnover with subject
age, variance of CM apoptosis likelihood as a function of CM age, and many others can
dramatically alter model results without being directly testable.
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Several scenarios achieve similar fit to the Bergmann C14 measurements; however the
TVB-TVDR model emerges as the best-fitting scenario with global best fit parameters
fitting the end C14 values of each subject better than either the Bergmann or Kajstura
models without invoking unreasonable total CM count trajectories (Figure 3.16).
Notably, the TVB-TVDR model, in many best-fit and near-best-fit parameter solution
sets, also concurs with the conclusion reported by Kajstura that CMs formed later in life
experience diminished longevity compared to predecessor CMs, despite the fact that no
Kajstura data was used to obtain these solutions.

When attempts are made to incorporate reasonable measurement and assumption
uncertainty into the Bergmann and Kajstura models, a range of turnover parameters
emerges that are compatible with both datasets—specifically, that turnover in the healthy
human heart is approximately 4-6% in youth increasing to 15-22% with advancing age.

While the primary objective of the present study is to rigorously investigate the intricacies
of the mathematical models used in both studies, additional complications regarding the
biological methodologies have been proposed both by authors affiliated with the
Bergmann and Kajstura manuscripts [21-23] and also by independent investigators [24,
25]. These additional factors may further obscure conclusions derived from these
mathematical models.

Potential underestimation notwithstanding, the exploitation of atmospheric C14 flux to
permit a novel C14 tracer analysis of the human heart represents a seminal contribution
to the growing acceptance that some level of effective cardiomyogenesis contributes to
the homeostasis the nondiseased human heart. At the same time, studies
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characterizing the varied progenitor and CM phenotypes within a large number of
nondiseased of adult human hearts confirm, extend, and refine the evolving conclusions
about human CM turnover as a function of age. Both studies rely heavily on
mathematical models with inherent assumptions in both the model structure and the
parameter precision. Our analysis highlights the need to explore these assumptions
under various axiomatic regimes to evaluate their impact on the final results. When such
considerations are applied to these two estimates of cardiomyogenesis, we find a
reasonable mechanism (“subject-age-at-time-of-formation”-dependent CM death rates)
capable of reconciling the apparent discrepancies of the turnover estimates.
Recognizing the ongoing need to investigate assumptions in mathematical models of
turnover, especially as we examine datasets derived from diseased-hearts, we have
provided our full Java program in the supplement to facilitate such exploration, with
coding options present to test various inherent premises.
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CHAPTER 4
4. Injury-Dependent Progenitor Cell Engraftment Mediated by P-selectin
4.1 Introduction
Prior dogma asserted that the heart is a terminally differentiated organ with no capacity
for generating new cardiomyocytes. However, recent evidence indicates that
cardiomyocyte formation occurs throughout life [1, 2]. Furthermore, fate-mapping
studies in mice likewise suggest low level cardiac myogenesis at baseline that is
enhanced following myocardial infarction or sustained pressure overload [3]. In failing
human hearts, Kubo et al showed that myogenic c-kit+ progenitor cells are enriched
compared to nonfailing hearts. Most of these c-kit+ progenitors coexpressed the panleukocyte marker CD45, suggesting a bone marrow origin [4]. However, the typical scar
formation following MI suggests that this native repair response is largely inadequate.

The realization that myocyte repopulation is possible has prompted a series of clinical
trials aimed at augmenting the natural repair response in patients with myocardial
infarction (MI). Systemic administration of chemokines such as GM-CSF induces
increases in circulating bone marrow cells (BMCs) that are believed to be a source of
angiogenic and cardiomyogenic progenitors. However, GM-CSF alone has not
improved clinical outcomes following MI. In some studies, direct delivery of filtered,
autologous bone marrow cells (BMCs) into the coronary arteries or myocardial wall
resulted in statistically-significant increases in cardiac performance, but these
improvements were also inadequate to improve survival. Low engraftment rates were
cited as a primary limitation in some of these studies [5]. Indeed, follow-up studies
determined that 93–98% of bone marrow cells delivered via coronary artery fail to
engraft and cannot be detected in the heart within 1 h [6, 7].
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Although these trials provide encouragement for pursuing progenitor-based therapies,
full understanding of the engraftment process and the nature of the engrafted progenitor
cells remain underdeveloped. In particular, little is understood about the mechanisms
regulating progenitor cell engraftment immediately after myocardial injury or stress.
Accordingly, we adapted an isolated-perfused mouse heart (IPMH) model to study BMC
engraftment dynamics following ischemia–reperfusion injury (IR-injury). In particular, we
employed a heterogenous population of unfractionated BMCs so that ischemiaresponsive engraftment would provide unbiased insights into factors affecting this
process. Using this model, we identified a subset of BMCs with injury-dependent
selective engraftment into the heart and also a necessary adhesion molecule that
facilitates this selectivity. The mechanism for this preferential engraftment was
confirmed using an established in vitro model of cell rolling dynamics. These studies
provide new insights into endogenous myocardial repair processes and suggest
potential improvements to future therapies for myocardial infarction.

4.2 Methods
4.2.1 Isolation of Mouse BMCs
Adult C57BL/6 mice (18–22 g, 10–12 weeks old) were anesthetized with 100mg/kg
ketamine and xylazine, and 1000 units/kg of heparin was administered IP. Bone marrow
was obtained by removing the femurs, and flushing them with sterile PBS over a 40 μm
filter. The cells were pelleted by centrifugation and resuspended in lysis buffer (BD
Biosciences) for 1 min to lyse red blood cells. Cells were again pelleted and
resuspended in 1 mL PBS to remove remaining lysis buffer. Cells were counted using a
hemocytometer on an aliquotted sample, and 12±3 million viable (trypan blue exclusion)
BMCs were obtained to perform infusions.
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4.2.2 Isolated Perfused Mouse Heart for Ischemia–Reperfusion Studies
Following anesthesia and heparization, the heart was rapidly excised, the ascending
aorta was cannulated and perfusion was initiated with a modified Krebs bicarbonate
buffer, as previously described [8]. Perfusion was restored within 1 min of excision and
maintained at 37 °C and 2 mL/min. The perfusion solution was aerated with 95% O2, 5%
CO2 in order to maintain a pH of 7.4. A side arm in the perfusion line proximal to the
heart inflow cannula allowed for entrainment of labeled BMCs along with the oxygenated
perfusate.

In all experiments, the perfused hearts underwent 10 min of equilibration time at a flow
rate of 2 mL/min at 37 °C. After equilibration, the trial cohort underwent no-flow
ischemia for 15min (i.e. buffer pump flow was entirely halted), whereas a control group
(sham ischemia) received normal flow of buffer for 15 min. For all experiments, the
ischemia or sham ischemia was followed by reperfusion of plain buffer for 0, 15, 30, 45,
or 60 min. Effects of this injury model (among others) are reviewed by Murphy and
Steenbergen [9]. After this reperfusion with plain buffer, 15 min of reperfusion with
freshly-harvested, PKH26GL-labeled (Sigma Aldrich, MO) BMCs occurred. At the
completion of cell infusion, plain buffer was administered for 15 min to clear the
circulation of non-engrafted BMCs. Most hearts were then perfusion digested with
collagenase (180 unit/mL for 15 min) followed by filtration for flow cytometry. A subset of
hearts evaluated by histology was not perfused with collagenase.

4.2.3 Flow Cytometry for IPMH Ischemia–Reperfusion Studies
The heart digest was pelleted by centrifugation and resuspended in 1 mL PBS. A
representative sample (0.1 mL) of the heart tissue digest and the infused BMC aliquot
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were stained with the viability dye DAPI (4′,6-diamidino-2-phenylindole dihydrochloride,
Invitrogen, CA), an anti-CD117 (c-kit) antibody conjugated to AF-488 (Biolegend, CA)
and an anti-CD45 antibody conjugated to PE-Texas Red (Abcam Inc., MA).

After excluding dead cells (DAPI+) along with cell fragments and aggregates, gating
based on PKH26GL fluorescence was employed to identify the infused BMCs.
DAPI−/PKH26GL+, size/granularity-gated cells from both the perfusate aliquot and heart
digests were evaluated for c-kit and CD45 expression. Demarcation intensities for each
fluorochrome were determined using the Fluorescence Minus One (FMO) technique
(Figure 4.1). For each immunophenotypic subtype, the percent representation in the
retained cells was divided by original percent representation in the perfusate aliquot to
determine a ‘selectivity ratio’ of engraftment: a ratio of 1 reflects non-selective
engraftment while a ratio significantly greater than 1 indicates preferential engraftment.

Figure 4.1. c-kit FMO on Filtered, RBC-Depleted Bone Marrow Cells. The fluorescence
intensity cutoff between negative and positive cells is determined by comparison of fully-stained
sample to a sample missing only 1 fluorophore. A) BMCs stained with all fluorophores except AF488 c-kit, the chosen delineation intensity is the intensity at which false positives are 0.05%,
which is in good agreement with visual assessment. B) The fully stained BMC sample with the
gate from FMO c-kit sample drawn. This cutoff point is used for all samples (perfusate and heart
digest) to which the AF-488 c-kit antibody has been applied.
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4.2.4 Selectin Neutralization Studies in Isolated–Perfused Hearts
IPMHs were prepared as described above with the exception that, prior to BMC infusion,
PKHGL26-labeled BMCs were incubated for 15 min with 30 μg neutralizing antibody for
either P-selectin (BD Pharmingen CD62P) or L-selectin (BD Pharmingen CD62L)
immediately prior to infusion. Additionally, during the final 5 min of the 30 min
reperfusion, buffer flow to the heart was supplemented with 80 μg neutralizing antibody
for either P-selectin or L-selectin. Hearts were then rinsed with plain buffer for 15 min
and prepared for histology or flow cytometry as described above.

4.2.5 Histologic Analysis for IPMH Ischemia–Reperfusion Studies
Cryosectioning was used to visualize infused (PKH26GL or PKH67GL-labeled) cells
retained in the heart. Following the cell infusion protocol and rinse protocol, hearts were
embedded in Tissue-Tek O.C.T compound and snap frozen in liquid nitrogen. Frozen
samples were stored at −20°C before sectioning. In various preparations, sections were
analyzed following exposure to antibodies for c-kit (PE conjugated CD117, Abcam, or
FITC conjugated, Biolegend), CD45 (PE-Texas Red conjugated, Abcam), and/or Pselectin (FITC conjugated, BD Pharmingen). Sections were stained with
DAPI-containing ProLong Gold (Invitrogen, CA) and visualized with a Nikon light
microscope with DAPI, FITC, and TRITC filters.

4.2.6 Sorting of c-kit+ Cells from Mouse BMCs for Parallel Plate Flow Chamber Studies
Once isolated, mouse BMCs were stained with DAPI and an anti-CD117 (c-kit) antibody
conjugated to PE (Abcam). DAPI-/c-kit+ and DAPI-/c-kit- populations were isolated by
FACS. Sorted c-kit− cells were always >95% purity, and c-kit+ cells were >85% purity.
Based on the c-kit+ cell recovery rate, equal concentrations of c-kit− and c-kit+ cell
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suspensions of approximately 50,000 cells/mL were used in the flow chamber
experiment.

4.2.7 Parallel Plate Flow Chamber Studies
Recombinant P- and L-selectin-IgG chimeras were purchased from R&D Systems.
Modified flexiPERM wells (Sigma Aldrich, MO) were attached to 35 mm Corning nontreated culture dishes. To immobilize adhesion molecules, the surface was first
incubated with recombinant protein A/G (Thermo Scientific, MA) at 4 °C on a rocker
overnight.

The surface was then washed with a blocking solution (1% BSA in sterile PBS) 3 times
and the surface was coated with 0.5 μg/mL of P-selectin and incubated at 4 °C on a
rocker for 5 h. The surface was again washed 3 times with blocking solution and
incubated in flowing buffer (HBSS, 2mM Ca2+, 2mM Mg2+, 10 mM HEPES+ 0.5%
BSA), until used for the flow chamber experiment. For L-selectin, which has a histidine
tag on the C-terminus, the protocol was changed to include an overnight incubation with
an anti-polyhistidine antibody (R&D Systems, MN), between the protein A/G and selectin
coating steps. The apparatus was set up as previously described [10].

4.2.8 Data Analysis for Parallel Plate Flow Chamber Studies
A video of rolling and adhered cells was recorded over the same area for both c-kit− and
c-kit+ cell populations, and later processed using ImageJ software with the MTrack2
plug-in for calculating rolling velocity and a cell counter for tracking the number of
adhered cells. Rolling velocity (μm/s) was calculated by marking the change in position
of the cell at every frame. Rolling flux (rolling cells/mm2/min) indicates the number of
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rolling cells, and rolling concentration (rolling flux/rolling velocity) measures rolling
efficiency (slow and steady rolling indicates higher efficiency). The number of adhered
cells was counted by scanning the same area for both c-kit+ and c-kit− cells and is
expressed as a percent of the total cells that entered the flow chamber. A cell was
considered firmly attached if it did not move for more than 30 s. Each experiment was
done in triplicate (n=3).

4.3 Results
4.3.1 Histological Evidence Infused Cell Engraftment
Frozen IPMH tissue sections subjected to the ischemia–reperfusion protocol (15 min
ischemia or sham ischemia, 30 min cell-free reperfusion, 15-min cell infusion with
PKH26GL-labeled BMCs, and 15 min buffer-only wash) revealed that retained BMCs
(PKH26GL+) were distributed uniformly within the tissue, with most in the left ventricular
free wall. Cell clumping and occlusion of coronary vasculature was rarely observed
(Figure 4.2). Costaining for the myocardial marker α-actinin is shown in Figure 4.3.
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Figure 4.2. Transverse Cryosection of Ischemia-Reperfused Mouse Heart (IPMH ) Infused
with PKH26GL+ BMCs. Histological visualization of hearts having undergone either 15 min
sham ischemia (left) or ischemia (right) followed by 30 min reperfusion, 15 min PKH26GL-labeled
BMC infusion, 15 min buffer-only rinse, and preparation for histology. 10 μm slices are shown as
merged images of TRITC filter (infused PKH26GL-labeled BMCs appear orange) and DAPI
(blue), which represents nuclei. A) 10x of sham ischemic lateral free wall. B) 10x of ischemic
lateral free wall. C) 40x of sham ischemic lateral free wall. D) 40x of ischemic lateral free wall.
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Figure 4.3. Transverse Cryosection of Ischemia-Reperfused Mouse Heart (IPMH ) Infused
with PKH67GL+ BMCs and Co-staining for α-actinin and DAPI. Histological visualization of
heart having undergone 15 min ischemia followed by 30 min reperfusion, 15 min PKH67GLlabeled BMC infusion, 15 min buffer-only rinse, and preparation for histology. A representative 10
µm section stained and filtered for DAPI, PKH67GL (green), α-actinin (red) shown at 40X.
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4.3.2 Identification of Engrafted Cells in Non-ischemia Control Experiments
The goal of these experiments was to demonstrate the ability to identify infused BMCs in
the IPMH and distinguish them from native heart cells. After serial gating is used to
exclude dead cells and cell fragments or aggregates, flow cytometric analysis
demonstrates high efficiency PKH26GL labeling of the infused BMCs, as shown in
Figure 4.4 (A-D). After identical gating, the smaller proportion of cells identified as
PKH26GL+ in the heart digest represents infused BMCs that have been engrafted while
the PKH26GL− cells represent nonengrafted heart-derived cells (Figure 4.4, E-H).

When identically-gated BMCs from the perfusate and heart digest are characterized
based on biomarker expression (c-kit and CD45), the selectivity of retention, or lack
thereof, is demonstrated. One such comparison derived from a sham ischemia
experiment reveals that the four possible biomarker combinations (c-kit+/CD45+, ckit+/CD45−, c-kit−/CD45+, c-kit−/CD45−) are similarly represented in both the sham
ischemic heart and the bone marrow perfusate aliquot, suggesting that perfusate cell
retention in the heart is essentially random (nonselective) in the absence of antecedent
ischemia–reperfusion injury (Figure 4.4 D&H).
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Figure 4.4. Serial Gating to Identify Retained BMCs in Heart Digest. Perfusate aliquots (A-D)
and heart samples (E-H) were serially gated to isolate the population of viable BMCs. DAPI+
cells were excluded as dead (A & E). Gating on forward scatter (FSC, size), side scatter (SSC,
cellular granularity), and removed non-cellular material (B & F). PKH26GL positivity was used to
isolate retained BMCs in heart digests (C & G) for further analysis with biomarker antibodies (D &
H). Data from a representative sham-ischemic heart is shown in this figure.
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4.3.3 Injury-Dependent Engraftment Selectivity for c-kit+/CD45+ Autologous BMCs
In contrast to sham ischemia, stop-flow ischemia for 15 min followed by cell-free
reperfusion and then BMC infusion significantly altered the pattern of retained cells
compared with the infused cells. As the representative sample in Figure 4.5 shows, ckit+/CD45+ and c-kit+/CD45− cells comprise a far greater fraction of the retained cells in
IR-injured hearts than in the sham ischemic hearts at a reperfusion duration of 30 min.
Based on a series of experiments of this type, the observed proportion of ckit+/CD45+
cells increased from 3±1% in sham ischemia heart to 25±7% in the stop-flow ischemia
heart after reperfusion duration of 30 min (Figure 4.6, n=3). These results confirm that ckit expression by BMCs is associated with selective retention irrespective of CD45
expression. We also examined the preferential retention of c-kit+ BMCs as a function of
the duration of cell-free reperfusion prior to initiation of BMC administration.
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Figure 4.5. Biomarker Expression of Retained BMCs Following Sham-Ischemic and
Ischemic Protocol. Bone marrow perfusate aliquots and heart digests were serially gated as
described in Figure 4.4 (FSC: Forward Scatter, SSC: Side Scatter). A) Aliquot from BMCs infused
into a sham ischemic heart (results of corresponding heart digest displayed in graph C below). B)
Aliquot from BMCs infused into an ischemic heart (results of corresponding heart digest displayed
in graph D below). C-kit+ BMCs made up a greater percentage of retained BMCs in ischemiareperfusion injured hearts than in sham-ischemic hearts despite similar c-kit+ representation in
infused BMCs.
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Figure 4.6. Cell Subtype Distribution in Bone Marrow, Sham-Ischemic Hearts, and Ischemic
Hearts. For each cell subtype, the percent composition of viable, infused cells (DAPI-,
FSC&SSC-gated, PKH26GL+) isolated from bone marrow, sham-ischemic hearts, and ischemic
hearts are displayed as histograms. A histogram set for each possible reperfusion duration (0,
15, 30, 45, 60 min) was computed; the histogram set for reperfusion time of 30 min (n=3) is
shown as an example. The c-kit+/CD45+ subpopulation is more strongly represented in heart
than in bone marrow and is considered to be preferentially recruited.

As shown in Table 4.1, c-kit+ cells were found at significantly higher concentrations in
ischemic hearts than in sham-ischemic hearts at reperfusion durations of 30, 45, and 60
min of reperfusion but not at reperfusion durations of 0 and 15 min. Control experiments
performed without PKH26GL labeling determined that the contribution of native heart
cells to the PKH26GL+ recorded event count was less than 11% (see Inset 4.1).
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Inset 4.1 Derivation of False PKH26GL Contribution to Engrafted Cell Counts
Negative controls (Infused BMCs were not labeled with PKH26GL) experiments were used to
analyze the contribution of native heart cells to the PKH26GL+ recorded events. Antibody
staining of heart and aliquot occurred identically to trials that used PKH26GL. Of 2.5 million
recorded events, native heart was capable of producing only 140 ± 60 false PKH26GL+ events
and only 16 ± 1 PKH26GL+/c-kit+ events (n=4). Of 2.5 million recorded events for each trial
(PKH26GL-labeled BMCs infused) heart, 2000 ± 300 PKH26GL+ events were recorded (n=30),
suggesting that only 7% of PKH26GL+ events can be attributed to native heart false positives.
The average number of PKH26GL+/c-kit+ cells in 2.5 million heart digest events was 200 ± 50
for ischemic hearts and 140 ± 40 for sham-ischemic hearts, suggesting that only 8% of
PKH26GL+/c-kit+ cells in ischemic hearts, and 11% of PKH26GL+/c-kit+ cells in shamischemic hearts can be explained as false positives from the native heart. Thus, native heart
PKH26GL false positives are insufficient to explain the observed selectivity.

Table 4.1 Selective Retention of c-kit+ Subsets at Various Reperfusion Durations
Cell Type
Reperfusion Fraction of
Fraction of
P-value
Duration
Retained BMCs in
Retained BMCs in
(min)
Sham-Ischemic
Ischemic Heart (%)
Heart (%)
c-kit+*
0
9±2
11 ± 7
0.73
15
4±2
10 ± 1
0.22
30
3±1
26 ± 7
0.036
45
3±1
25 ± 5
0.013
60
6.9 ± 0.6
10.8 ± 0.3
0.005†
c-kit+/CD45+
0
8±2
11 ± 7
0.67
15
4±2
9±1
0.053
30
3±1
25 ± 7
0.036
45
3±1
24 ± 5
0.012
60
6.6 ± 0.5
10.5 ± 0.3
0.004†
c-kit+/CD45- ‡ 0
0.9 ± 0.1
0.2 ± 0.1
0.018
15
0.2 ± 0.1
0.3 ± 0.1
0.54
30
0.29 ± 0.03
1.0 ± 0.4
0.15
45
0.27 ± 0.07
0.8± 0.5
0.30
60
0.3 ± 0.1
0.4 ± 0.2
0.90
Table 4.1. Preferential Retention of c-kit+ BMCs as a Function of Reperfusion Duration.
Table 4.1 shows a compiled sample BMC subtype compositions for all tested reperfusion
timepoints of 0-60 min (n=3 for each data point). *C-kit data is aggregated from the c-kit+/CD45+
and c-kit+/CD45- entries in the lower 2 rows. †Standard deviation for sham-ischemic and
ischemic hearts was very low for reperfusion time of 60 min. The p-value comparing c-kit+ at
reperfusion time of 60 min to c-kit+ at reperfusion time of 15 min = 0.4. ‡This population is difficult
to study due to its rarity, comprising only 0.14%±0.4% of the bone marrow and is variably
discernible among experiments.
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Direct comparison for selective retention between c-kit+/CD45+ and c-kit+/CD45−
populations requires the comparison of selectivity ratios (defined as the fraction in
engrafted BMCs divided by the fraction in the BMC perfusate for each
immunophenotypic subclass). Using this approach, the selectivity ratios for each
phenotypic subtype are shown as a function of reperfusion time in Figure 4.7. These
data reveal that the presence of c-kit positivity alone results in average selectivity ratios
that peak above 15 after 30 min of reperfusion and remain above 10 when cells are
infused after 60 min of reperfusion. When the analysis focuses on both c-kit and CD45
immunophenotypes, the selectivity ratios are even higher for the subset of c-kit+ cells
that are also CD45+ (Figure 4.7).
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Figure 4.7. Engraftment Ratios for Various BMC Subtypes at Reperfusion Durations of 0,
15, 30, 45, and 60 min. The ordinate plots the percent composition of the retained BMCs found
in the heart (DAPI-, FSC&SSC-gated, PKH26GL+) divided by the percent composition of that
BMC subtype in the perfusate (i.e. the BMC subtype’s Selectivity Ratio). Thus comparisons
between selective engraftment of different BMC subtypes can be drawn even when the absolute
percent representation of these subtypes in the bone marrow are highly disparate. (n=3 for each
data point)

In order to visualize the expression of CD45 and c-kit biomarkers on infused cells, a
subset of hearts underwent 15 min of ischemia (or sham ischemia) followed by 30 min of
reperfusion and then infusion with labeled BMCs (PKH67GL, a green dye), was
substituted for PKH26GL, an orange dye, to further minimize spectral overlap with the
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other fluorophores and improve image clarity. As expected from the flow cytometric
analyses, nearly all PKH67GL-labeled cells in heart sections stained positively for CD45
in ischemic and sham ischemic hearts, while approximately 25% stained positively for ckit in the ischemic hearts and very little c-kit staining was observed in sham ischemic
hearts (representative cell images shown in Figure 4.8 and Figure 4.9). Representative
cell images co-stained with CD45 and c-kit in combination are shown in Figure 4.10.
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Figure 4.8. Transverse Cryosection of Ischemia-Reperfused Mouse Heart (IPMH) Infused
with PKH67GL+ BMCs and Co-staining for CD45. Histological visualization of heart having
undergone 15 min ischemia followed by 30 min reperfusion, 15 min PKH67GL-labeled BMC
infusion, 15 min buffer-only rinse, and preparation for histology. Representative 10 µm sections
are shown at 40X (A-D) and 20X (E-H) stained and filtered for DAPI (A&E), PKH67GL (B&F),
CD45 (C&G), and merged (D&H) are shown.
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Figure 4.9. Transverse Cryosection of Ischemia-Reperfused Mouse Heart (IPMH) Infused
with PKH67GL+ BMCs and Co-staining for c-kit. Histological visualization of heart having
undergone 15 min ischemia followed by 30 min reperfusion, 15 min PKH67GL-labeled BMC
infusion, 15 min buffer-only rinse, and preparation for histology. Representative 10 µm sections
are shown at 40X (A-D) and 20X (E-H) stained and filtered for DAPI (A&E), PKH67GL (B&F), c-kit
(C&G), and merged (D&H) are shown.
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Figure 4.10. Transverse Cryosection of Ischemia-Reperfused Mouse Heart (IPMH) Infused
with unlabeled BMCs and Co-stained for c-kit and CD45. Histological visualization of heart
having undergone 15 min ischemia followed by 30 min reperfusion, 15 min unlabeled BMC
infusion, 15 min buffer-only rinse, and preparation for histology. Representative 10 µm sections
are shown at 40X (A-D) and 20X (E-H) stained and filtered for DAPI (A&E), CD45 (B&F), c-kit
(C&G), and merged (D&H) are shown.
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4.3.4 Inhibition of P-selectin or L-selectin in Ischemic Conditions
In several hearts undergoing 15 min ischemia and 30 min reperfusion, the final 5 min of
reperfusion were supplemented with soluble P-selectin or L-selectin neutralizing
antibodies (80 μg). Additionally, PKH26GL-labeled BMCs were incubated with the same
blocking antibody (5×106 BMCs with 30 μg antibody in 0.5 mL) for 15 min prior to being
infused to IPMHs. As shown in Figure 4.11A, P-selectin inhibition reduced the selectivity
ratio for c-kit+/CD45+ BMCs in ischemic hearts to 2±1 (compared to 18±2without
neutralization, p=0.002), a result equivalent to unblocked sham ischemia trials. Lselectin inhibition in ischemic hearts produced a c-kit+/CD45+ selectivity ratio of 10±4,
which was significantly greater than observed in unblocked sham ischemic trials
(selectivity ratio of 2±1, p=0.03) and not significantly below unblocked ischemic trials,
though a downward trend is observed. For BMC subtypes besides c-kit+/CD45+, no
significant differences were found between any of the 4 protocols (unblocked sham
ischemia, unblocked ischemia, or ischemia with either L-selectin or P-selectin blockage).
To further confirm the interaction of c-kit+ BMCs with endothelial P-selectin, histological
sections of a representative ischemic IPMH (15 min ischemia followed by 30 min
reperfusion and then BMC infusion) were produced with co-staining for c-kit and
endothelial P-selectin. P-selectin is observed only in ischemic, but not sham ischemic,
hearts and c-kit+ BMCs are frequently found adjacent to regions of P-selectin (Figures
4.11B, 4.11C, and 4.12).
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Figure 4.11. Neutralizing Antibodies and Co-localization Implicate P-selectin in c-kit
Selective Cell Engraftment. A) Ischemia induces strong selective retention of c-kit+/CD45+
BMCs compared to sham ischemic trials. Concomitant incubation of infused BMCs with and
infusion of neutralizing antibodies for P-selectin eliminates ischemia-induced selective
engraftment. Identical treatment with L-selectin neutralizing antibodies in ischemic hearts fails to
significantly eliminate selectivity (although a trend towards reduction is observed). (n=3 for each
data point). (* p<0.05, ** p<0.01). B&C) Histological visualization of heart having undergone 15
min sham ischemia (B) or ischemia (C) followed by 30 min reperfusion with out neutralizing
antibodies, 15 min PKH67GL-labeled BMC infusion, 15 min buffer-only rinse, and preparation for
histology. P-selectin (green) is not observed in sham ischemic hearts but is co-localized with c-kit
(orange) cells in ischemic hearts.
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Figure 4.12. Transverse Cryosection of Ischemia-Reperfused Mouse Heart (IPMH) Infused
with PKH67GL+ BMCs and Co-staining for P-selectin and c-kit. Histological visualization of
heart having undergone 15 min sham ischemia (A-D) or ischemia (E-H) followed by 30 min
reperfusion, 15 min PKH67GL-labeled BMC infusion, 15 min buffer-only rinse, and preparation for
histology. Sections are 10 µm thick, visualized at 40X, and stained/filtered for DAPI (A&E), Pselectin (B&F), c-kit (C&G), and merged (D&H).
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To assess potential coexpression of c-kit and the primary P-selectin ligand (PSGL-1) on
BMCs, BMCs were stained with anti-c-kit (AF700-conjugated) and anti-PSGL-1 (PEconjugated) fluorochromes. The odds ratio of PSGL-1 positivity among c-kit+ BMCs was
computed as the fraction of c-kit+/PSGL-1+ BMCs divided by the fraction of c-kit+/PSGL1− BMCs. The odds ratio of PSGL-1 positivity among c-kit− BMCs was computed as the
fraction of c-kit−/PSGL-1+ BMCs divided by the fraction of c-kit-/PSGL-1− BMCs. The
relative quotient of these ratios was 16±4, indicating that c-kit+ BMCs are 16±4 times
more likely to be PSGL-1+ than are c-kit− BMCs (Figure 4.13).
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Figure 4.13. Coexpression of PSGL-1 and c-kit in Bone Marrow Cells. Mouse BMCs were
harvested as described in Methods 4.2.1 and stained with anti-c-kit (AF700-conjugated) and antiPSGL-1 (PE-conjugated) fluorescent antibodies. The FMO technique (see Figure 4.1) was used
to delineate positive versus negative expression levels. A representative trial is shown here. The
odds ratio of PSGL-1 positivity among c-kit+ BMCs for this sample was computed as (ckit+/PSGL-1+)/(c-kit+/PSGL-1-) and equals 17.3 in this trial. The odds ratio of PSGL-1 positivity
among c-kit- BMCs for this sample was computed as (c-kit-/PSGL-1+)/(c-kit-/PSGL-1-) and
equaled 1.05 in this sample. The relative quotient for this sample is 16.3, meaning that c-kit+
BMCs are 16.3X more likely to be PSGL-1+ than are c-kit- BMCs. A) Fully stained BMC sample.
B) Fully stained BMC sample with PSGL-1 shown against SSC. C) Fully stained BMC sample
with c-kit shown against SSC. D) FMO for PSGL-1. E) FMO for c-kit. (n=3)
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4.3.5 Rolling and Adhesion of c-kit+ Versus c-kit- BMCs on Selectins
To further define the interaction between c-kit+ cells and cell adhesion molecules, fresh
BMCs were FACS sorted to obtain purified samples of c-kit+ and c-kit− (50,000 cells/mL
in 3 mL each). Using the parallel-plate flow chamber, cells were flowed over substrates
coated with 0.5 μg/mL of either P-selectin or L-selectin with a shear stress of 1 dyn/cm2
in the flow chamber. After a known volume of the cell suspension had run through the
flow chamber, a fixed region was scanned for firmly adhered cells. A cell was
considered firmly attached if it remained stationary for more than 30 s. The adherence
of c-kit- BMCs was minimally affected by the substrate (0.18±0.04% adhered on Lselectin versus 0.17±0.04% adhered on P-selectin). In contrast, c-kit+ BMCs adhered
poorly to L-selectin and showed an approximately 9-fold increase in percentage adhered
on P-selectin (0.03±0.01% adhered on L-selectin versus 0.28±0.04% adhered on Pselectin). Rolling velocities were similar for all combinations of substrate and BMC type
with velocities on P-selectin (23±7 μm/s for c-kit−, 19±1 μm/s for c-kit+) and tended to be
lower than velocities on L-selectin (39±14 μm/s for c-kit−, 64±11 μm/s for c-kit+). The
percentage of adhered cells and rolling velocity results are summarized in Figure 4.14.
Rolling flux, a manual count of the number of rolling cells observed over a fixed area for
a known period of time, was similar between all substrate/cell type combinations.
Rolling concentration (rolling flux divided by rolling velocity) was also similar between all
substrate/cell type combinations. Rolling flux and rolling concentration data are
available as Figure 4.15.

92

Figure 4.14. Rolling and Adhesion Dynamics of c-kit- and c-kit+ cells on P-Selectin and LSelectin. A) The number of cells found to be adhered to a substrate coated with either Lselectin or P-selectin is graphed for a perfusate sample containing either c-kit- or c-kit+ BMCs.
While the adherence percentage for c-kit- cells does not vary with substrate, c-kit+ BMC
demonstrate significantly stronger adherence to P-selectin than to L-selectin. B) Rolling velocities
are graphed for c-kit- and c-kit+ BMCs over L-selectin or P-selectin. Rolling velocities for both
cell types trend lower for L-selectin than P-selectin and c-kit+ BMCs show a stronger sensitivity to
choice of selectin (* p < 0.05 between marked groups, one-way ANOVA, student’s t-test). (n=3 for
each data point)

Figure 4.15. Rolling Flux and Rolling Concentration for c-kit- and c-kit+ BMCs over Lselectin and P-selectin Substrates. A) Rolling flux was computed as the manual count of the
number of rolling cells observed over a fixed area for a known period of time. B) Rolling
concentration was computed as rolling flux divided by rolling velocity. No statistically significant
variations were found between cell type (c-kit- versus c-kit+) or between selectin molecules (Lselectin versus P-selectin). (n=3)
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4.4 Discussion
These studies demonstrate, for the first time, that BMCs expressing the c-kit are
preferably retained in the heart following ischemia–reperfusion injury. This selectivity
varies in time following the ischemic insult with a delay in the onset of selectivity and
greatest selectivity seen after 30 min of reperfusion. The optimum engraftment time of
30 min reperfusion also corresponds with the post-ischemia time required for type 1
activation of the endothelium, during which P-selectin molecules surface from
intracellular Weibel-Palade bodies [11]. In contrast, type II activation, which requires
transcription, generally requires hours [12] and is likely not responsible for the results we
report. Our results are also in excellent temporal agreement with in vivo P-selectin
dependent increases in overall leukocyte rolling following activation of cremaster
endothelium conducted by Ley et al [13]. P-selectin is further implicated as the
mediating mechanism for this selective retention by our antibody neutralization
experiments, which found that P-selectin, but not L-selectin, was required to produce
selective engraftment of c-kit+ BMCs. P-selectin is additionally implicated by histological
demonstration that engrafted c-kit+ cells are usually found adjacent to cells expressing
P-selectin. Our analysis of the BMCs further demonstrated that c-kit+ BMCs are
generally positive for PSGL-1, the primary P-selectin ligand in leukocytes, while only
about half of c-kit- BMCs express this adhesion molecule. Together, these results
indicate that P-selectin/PSGL-1 mediate selective engraftment of c-kit+ cells to the heart
early after ischemia–reperfusion stress.

Complementing the ex-vivo studies, in vitro exploration of P and L-selectins, which have
been shown to play a part in the inflammatory cell adhesion process [14], showed a
strong selective interaction of c-kit+ BMCs with P-selectin. While c-kit+ cells
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demonstrated a statistically-significant decrease in rolling velocity along with a 9-fold
increase in firm adhesion from L- to P-selectin, c-kit− BMCs showed nearly identical
dynamics regardless of the selectin substrate.

As P-selectin is not highly expressed on resting endothelium but is known to surface
when the endothelium is activated [15,16], the enhanced P-selectin interaction for c-kit+
BMCs supports the mechanistic hypothesis that ischemia-induced activation of the
coronary endothelium results in P-selectin-mediated selective retention of c-kit+ BMCs.

Although the in vivo regenerative capacity of c-kit+ BMCs remains controversial, these
cells have been shown to differentiate into cardiomyocytes in vivo [17,18]. Additional
angiogenic paracrine signaling effects have been identified for c-kit+ BMCs in the injured
heart [19].

Thus, the strong retention for these cells in response to injury (selectivity ratio of 18±2)
may indicate initiation of a repair response. Together, these findings provide new
insights into the dynamics of cell recruitment to the injured heart while highlighting the
utility and versatility of the IPMH model for mechanistic studies focusing on endogenous
repair and translational studies aimed at developing or refining new therapeutic
strategies.

The features of preferential engraftment of c-kit+ BMCs to the heart following ischemia–
reperfusion stress in these studies provide clues to the mechanisms of this dynamic
process. Most importantly, the preferential recruitment in an IPMH model obviates a
requirement for systemic hemodynamic, neural, or biochemical triggers for preferential
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engraftment. However, an auxillary role for such extracardiac factors is not excluded by
these studies. Additional factors may be causally related to the selective retention we
have described. For example, because ischemia durations of 10 and 30 min release a
burst of reactive oxygen species (ROS) in isolated-perfused rabbit hearts upon
reperfusion, the 15 min ischemia duration utilized in these studies is expected to
produce a significant ROS burst that could activate the coronary endothelium [20].
These factors may be causally related to cell engraftment and should be further
elucidated to complete our understanding of the mechanistic pathway.
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CHAPTER 5
5. Local Chemokine Environment Modification Enhances Progenitor Cell Homing
5.1 Introduction
5.1.1 Rationale for Modification of the Injury-Site Chemokine Concentrations
Low retention rates diminish the effectiveness of progenitor cell therapy, as the majority
of infused cells are immediately lost to the systemic circulation [1, 2]. Many progenitor
cells types such as Mesenchymal Stem Cells (MSCs), Hematopoietic Stem Cells
(HSCs), and Endothelial Progenitor Cells (EPCs) are motile and can navigate the blood
stream using concentration gradients of chemotactic proteins such as Stromal Derived
Factor 1 (SDF-1) and Vascular Endothelial Growth Factor (VEGF) [3-5]. Chemokines
such as SDF-1 and Monocyte Chemotactic Protein-3 (MCP-3) are released from
infarcted myocardium and encourage stem cell homing to the injured tissue; however
this release is temporary and insufficient to repair the damaged heart [6, 7].

Chemokines such as Granulocyte-Colony Stimulating Factor (G-CSF) have been
intraveneously delivered to the systemic circulation to encourage migration of stem cells
from the bone marrow to the circulation, but a series of clinical trials demonstrated that
this technique was ultimately ineffective at improving myocardial repair [8, 9]. One
limitation of systemic chemokine application is a lack of site specificity and an inability to
encourage migration from the blood stream to the injured heart.

Direct myocardial injection of pro-angiogenic chemoattractant cytokines to the
chronically ischemic hearts (which, like infarcted hearts, exhibit compromised ejection
fraction, exercise tolerance, and coronary perfusion), have been attempted clinically in
randomized, placebo-controlled trials. The VIVA trial delivered recombinant Vascular
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Endothelial Growth Factor (VEGF) as a single intramyocardial dose (followed by 3
intravenous doses over the following 9 days), but equivalent functional improvement in
both treatment and placebo group resulted in premature study termination [10].
Similarly, the FIRST trial employed a single dose of Fibroblast Growth Factor 2 (FGF2)
but failed to demonstrate functional benefit at 180 days [11]. Given that an alternative
trial delivering FGF2 encapsulated in extended release heparin-alginate microspheres,
performed by the same group, maintained perfusion quality (while placebo-receiving
patients exhibited worsening perfusion) [12], evidence exists for the importance of longterm, site-specific chemokine release rather than short-term or systemic chemokine
delivery.

5.1.2 Hydrogel Delivery Systems for Extended Release of Chemokines:
Hydrogels are biocompatible materials that, once implanted, are naturally degraded over
an extended period of time. Typical hydrogels may be delivered to a specified location
in liquid phase and then solidified in situ. Pharmaceutical agents, including chemokines,
can be mixed with the liquid phase hydrogel solution prior to gelation and released in a
controlled manner over extended time. Thus, hydrogels offer a mechanism for sustained
chemokine delivery to encourage site-specific homing of progenitor cells (either
delivered or endogenous) from the circulation directly to the site of injury [13].

5.1.3 Stromal Derived Factor 1α and Progenitor Cell Chemotaxis:
Many chemotactic factors are known. Specifically, SDF-1a is a well-studied chemokine
with a known ability to attract bone marrow-derived progenitor cells, including
mesenchymal stem cells (MSCs), in vitro and in vivo. In particular, SDF-1α expression is
upregulated in the myocardium during ischemia and occurs concomitantly with increase
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in circulating bone marrow cells displaying the SDF-1α receptor CXCR4, suggesting that
myocardial SDF-1α mobilizes these cells [14, 15]. However, despite evidence that the
mobilized BMCs home to the myocardium via SDF-1 and contribute to tissue repair
[16-19], the extent of this brief endogenous response is insufficient to prevent the
eventual onset of heart failure following MI.

Theoretically, longer-term delivery of SDF-1a could increase the extent of myocardial
repair. However, SDF-1a, due to its strong positive charge, low molecular weight, and
proteolytic susceptibility, is difficult to sequester in a hydrogel. Inspiration for SDF-1α
manipulation can be found in other components of the bone marrow niche (a repository
of CXCR4+ cells), such as interactions with glycosaminoglycans (GAGs). Cationic SDF1 binds to GAGs through ionic interactions between basic amino acid residues and
acidic groups along the disaccharide backbone [20-23]. The affinity between SDF-1
and GAGs plays an important role in localizing SDF-1 on the endothelium to direct cell
homing [24, 25] and sustaining SDF-1 activity in the presence of proteases [26]. In
addition to their roles in chemokine presentation, some GAGs play a more direct role in
BMC homing through receptor interactions. For example, hyaluronic acid (HA) is
abundant in the bone marrow, where it serves as an anchoring molecule for BMC
homing through binding to the CD44 receptor [27-29]. Interestingly, HA is localized to
regions of SDF-1α expression in the bone marrow and HA via CD44 mediate cell
responsiveness to SDF-1α during cell migration in vitro and cell homing in vivo [28].
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5.1.4 Summary of Work
The degradation rates and chemotactic properties (regarding BMCs and MSCs) of this
hydrogel formulation composed of SDF-1a stabilized by polymerized HA monomers
have been studied in vitro [30], but the present work is the first in vivo evaluation.
Results show that both the SDF-1a and hyaluronic acid have chemotactic abilities
towards unfractionated bone marrow cells (BMCs) in vivo, but that combination of these
into a single hydrogel provides synergistic chemotactic abilities. Furthermore, flow
cytometry is leveraged to quantitatively evaluate the effects of this hydrogel on stem cell
retention in the circulation and heart over a 7-day period in an in vivo model of
myocardial infarction.

5.2. Materials and Methods
5.2.1 Animals
Adult BALB/CAnNHsd mice (Charles River, Production) were housed in a dedicated
vivarium under conventional conditions. Mice received a standard diet (LabDiet 5010)
and water ad libitum. All experimental procedure were performed according to the NIH
Guide for Care and Use of Laboratory Animals and approved by the Institutional Animal
Care and Use Committee (IACUC) at the University of Pennsylvania.

5.2.2 Macromer Synthesis
A degradable HA macromer with methacrylate functionality was synthesized through
hydroxyethyl methacrylate (HEMA) modification of the HA backbone in a three step
process. (1) Sodium hyaluronate (74 kDa, Lifecore) was converted to a
tetrabutylammonium (TBA) salt by acidic ion exchange with Dowex resin (50W×8–200,
Sigma), followed by neutralization with TBA-OH, and lyophilization. (2) 2-hydroxyethyl
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methacrylate was reacted with succinic anhydride in dichloroethane (DCE) via a ring
opening polymerization (65C, 16hrs) in the presence of N-methylimidazole to obtain
HEMA-COOH. HEMA-COOH was purified via hydrochloric acid wash, DI H2O wash,
and DCE evaporation with a rotary evaporator. (3) HEMA-COOH was coupled to HATBA in anhydrous dimethyl sulfoxide through an esterification reaction in the presence of
4-dimethylaminopyridine (DMAP) and di-tert-butyl dicarbonate (BOC2O) activating
agents (45C, 20hrs). The following molar ratios of reactants were used: HA-TBA (1),
HEMA-COOH (1.4), BOC2O (1.2), DMAP (0.1). The modified HEMA-HA macromer was
purified via overnight dialysis in DI H2O at 4°C, acetone precipitation, another 5 days of
dialysis in DI H2O at 4°C, followed by lyophilization. 1H NMR was used to determine the
degree of modification and purity of the HEMA-HA.

5.2.3 Hydrogel Formation
Hydrogels were formed upon visible light exposure using a previously established
initiator system consisting of eosin Y, triethanolamine (TEOA), 1-vinyl-2-pyrrolidinone
(VP), and a halogen curing light (Elipar 2500, 3M, MN) [31]. 50 μL hydrogel precursor
solutions were prepared by mixing HEMA-HA and initiators in PBS at final
concentrations of: 6 wt% HEMA-HA, 0.02 wt% eosin Y, 225 mM TEOA, and 37 mM VP.
200 ng rSDF-1α was mixed into the 50 μL hydrogel precursor solution for HA Gel/rSDF1α groups. Hydrogels were formed in cylindrical molds upon light exposure for 90
seconds.
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5.2.4 BMC Isolation
Adult BALB/CAnNHsd mice (10–12 weeks old, 22-26 g) were anesthetized with 100
mg/kg ketamine and 20 mg/kg xylazine. Unfractionated BMCs were obtained by
removing the femurs, and flushing the marrow cavity with sterile PBS over a 40 μm filter.
The cells were pelleted by centrifugation and resuspended in lysis buffer (BD
Biosciences, NJ) for 1 min to lyse red blood cells. Cells were again pelleted and
resuspended in 1 mL PBS to remove remaining lysis buffer. To visualize the cells in
vitro and in vivo, PKH fluorescent linker kits were employed (Sigma, MO).

5.2.5 Experimental MyocardiaI Infarction (MI)
A cryoinjury model of MI was used to initiate MI remodeling [32, 33]. Adult
BALB/CAnNHsd mice (10–12 weeks old, 22-26 g) were anesthetized with 20 mg/kg
ketamine and 4 mg/kg xylazine, shaved and disinfected with alcohol. The mice were
kept under anesthesia (1.5% isoflurane), incubated and ventilated with 95% O2 using a
mechanical ventilator (MiniVent, Harvard Apparatus, MA). The heart was exposed
through a left lateral thoracotomy and cryoinjury was introduced by applying a round 2
mm diameter stainless steel probe frozen with liquid nitrogen to the epicardial surface of
the ventricle for 10 sec. After removing the probe, the cryoinjured area was confirmed
by observation of a white disk-shaped region. For mice receiving hydrogels, 25 μL of the
liquid hydrogel precursor solutions (same as section 5.2.4) were applied to the surface of
the injured ventricle through a 27G syringe in the presence of curing lamp exposure. For
mice receiving SDF-1α only, 10 μL of a 10 μg/mL rSDF-1α solution was injected into the
ventricle wall using a 30G syringe. The order of therapeutic intervention was rotated
from animal to animal. Following manipulations to the heart, the intercostal space and
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skin were closed with sutures. Mice received 100% oxygen until responding to
interdigital pinch, after which the endotracheal tube was withdrawn. Mice were kept
warm with a heating blanket during recovery. Meloxicam (5 mg/kg) was administered
via intraperitoneal injection 1 hr after surgery and once a day for 1 week following
surgery to minimize pain.

5.2.6 In vivo BMC Homing
After a recovery period of 3 hrs following MI induction, mice were anesthetized with 20
mg/kg ketamine and 5 mg/kg xylazine. Freshly isolated BMCs from a donor mouse were
fluorescently tagged with PKH linker kit, counted on a Vi-CELL (Beckman Coulter, CA),
and 9x106 cells in 300 μL sterile PBS were injected into the femoral vein of the MI
mouse. Blood samples were collected 1 day after BMC injection via retro orbital bleed,
treated for RBC lysis, and analyzed for PKH+ cells using flow cytometry. Briefly, cells
were gated for viability using 4’,6-diamidino-2-phenylindole (DAPI, Invitrogen, CA), size
and granularity using characteristic BMC distributions of forward scatter (FSC) and size
scatter (SSC), respectively, and fluorescent intensity using appropriate controls (Figure
5.1) [34].
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Figure 5.1. PKH- BMC Negative Controls for Flow Cytometry Gating. After gating for viability
with DAPI, BMCs in the blood (A) and the heart (C) were gated based on the typical size of
freshly isolated BMCs (A, inset). The cells within this size range were then analyzed for PKH
fluorescence (C and D). This gating strategy minimized PKH false-positive counts in the blood
6
and heart to less than 1 per 10 events (D). Abbreviations: SSC – side scatter, FSC – forward
scatter.

PKH+ cells in the blood were reported as a percentage of total cells in the blood within
the characteristic BMC size distribution. Mice were anesthetized 7 days after
experimental MI with 100 mg/mL ketamine and xylazine, blood samples were collected
from the abdomen, and hearts were excised and either perfusion digested with
collagenase (150 U/mL type 2 collagenase in Krebs buffer, Worthington, NJ) for PKH+
cell quantification using flow cytometry [34] or flash frozen in embedding medium for
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PKH+ cell visualization using histology. Quantified PKH+ cells in the blood were again
reported as a percentage of total BMCs in the blood, while quantified PKH+ cells in the
heart were reported as a total number of cells/heart. Embedded hearts were sectioned
at a 12 μm thickness and imaged immediately upon thawing at room temperature.

5.2.7 Statistical Analysis
Values are reported as mean ± standard error of the mean. Statistical differences
between groups were determined using ANOVA in conjunction with a student’s twotailed t-test (Microsoft Excel), with P < *0.05, **0.01, and ***0.001 considered as
significant.

5.3 Results: BMC Homing to the Remodeling Heart
In order to quantify BMC homing in vivo, fluorescently tagged BMCs were infused into
the circulation following experimental MI in mice and tracked in the blood and the heart
using flow cytometry (Figure 5.2).

Figure 5.2 In vivo model to quantify BMC homing. HA Gels were applied to the heart
immediately following experimental MI. Freshly isolated BMCs were fluorescently tagged with
PKH linker dyes and infused into the circulation via a femoral vein injection 3 hrs after MI. Blood
samples were collected 1 and 7 days following MI and hearts were digested 7 days following MI
to quantify PKH+ BMCs.

Myocardial delivery of homing factors (HA and rSDF-1α) from hydrogels (formed on
heart using blue light, Figure 5.3) was assessed for the ability to enhance BMC homing
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to the heart and compared to controls of MI-only and MI with intramyocardial injection of
rSDF-1α. Hydrogels were localized to the injury site and adhered to the myocardium for
sustained delivery of homing molecules (Figure 5.3).

Figure 5.3 Hydrogel Placement in situ. A) Hydrogels formed in situ by applying a liquid
precursor solution to the epicardial surface of the ventricle under blue light exposure. B) This
technique allowed the hydrogels to be localized on the injured myocardium for localized molecule
delivery. C) The hydrogels adhered to the myocardium (H&E staining shown).

The circulating PKH+ BMCs were readily quantified in the blood and heart using flow
cytometry (Figure 5.4). The fluorescent intensity of the cells varied over a wide range,
so a PKH+/PKH- threshold was chosen to quantify PKH+ BMCs while minimizing PKHfalse-positive events in the blood and the heart. Using this threshold, we observed a
decrease in fluorescence intensity of the PKH+ BMCs in the blood from day 1 to day 7
(Figure 5.4). Considering that the PKH linker dyes are stable in vivo for weeks [35], the
decrease in fluorescent intensity could be due to cell proliferation, or simply due to
preferential retaining of cell types in the blood that do not uptake PKH dyes as effectively
as others. Interestingly, BMCs quantified in the blood on day 1 were primarily larger
cells around the size and granularity of granulocytes, while the BMCs quantified in the
blood on day 7 were primarily smaller cells around the size and granularity of
lymphocytes (Figure 5.5); however, both size phenotypes show similar ranges of PKH
staining intensity immediately after exposure to the PKH linker dye.
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Figure 5.4 Progenitor Cell Retention in vivo. Representative flow cytometry with constant
threshold to quantify PKH+ BMCs in the blood and heart.

Figure 5.5. Size of PKH+ BMCs in the Blood. Circulating PKH+ BMCs exhibited a larger
diameter characteristic of granulocytes 1 day after infusion (A), while PKH+ BMCs exhibited a
smaller diameter characteristic of lymphocytes/monocytes at 7 days after infusion (B). Both cell
size phenotypes were increased to the same extent in the blood after rSDF-1α delivery to the
heart. Abbreviations: SSC – side scatter, FSC – forward scatter.

Delivery of the HA Gel with encapsulated rSDF-1α and delivery of rSDF-1α as a bolus
injection significantly increased the number of infused BMCs circulating in the blood 1
day after infusion (Figure 5.6A, ***P < 0.001 and *P = 0.01, respectively). Both rSDF-1α
delivery groups more than doubled the number of circulating BMCs on day 1 from 1% to
2% of native BMCs; however, only the HA Gel with encapsulated rSDF-1α increased
circulating BMCs on day 7, although this effect was not statistically significant (Figure
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5.6B). All intervention groups significantly increased the number of BMCs engrafted in
the heart compared to MI-only, and the HA Gel with encapsulated rSDF-1α significantly
increased BMC engraftment compared to rSDF-1α alone and the HA Gel alone (Figure
5.6C, #P = 0.01 and 0.047, respectively), indicating synergy between the released rSDF1α and HA. When normalized to the percentage of BMCs circulating in the blood, the
HA Gel (with and without rSDF-1α) enhanced myocardial engraftment of circulating
BMCs at a significantly improved rate, over 3-fold greater than the bolus rSDF-1α
injection and MI control, which showed the same engraftment rate (Figure 5.6D). While
both the HA Gel/rSDF-1α and bolus rSDF-1α injection groups had the same effect on
circulating BMCs 1 day after infusion (2.2 ± 0.2 and 2.2 ± 0.3% native BMCs,
respectively), they had significantly different effects on enhancing BMC engraftment in
hearts 7 days after infusion, 570 ± 130 and 170 ± 40 BMCs per heart, respectively.
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Figure 5.6. Quantification of BMC Homing with Molecule Delivery to the Heart. A) rSDF-1α
delivery to the heart significantly increased the number of circulating PKH+ BMCs 1 day after
infusion. B) This effect was sustained, although not statistically significant, 7 days after infusion
when rSDF-1α was delivered from the HA Gel. PKH+ BMCs in the blood are reported as a
percentage of total cells in the blood within the BMC size and granularity gating. C)
Intramyocardial injection of rSDF-1α and application of the HA Gel alone following MI significantly
enhanced the number of PKH+ BMCs in the heart compared to MI only 7 days after MI and cell
infusion. Application of the HA Gel with encapsulated rSDF-1α further enhanced PKH+ BMC
engraftment in the heart compared to delivering rSDF-1α or the HA gel individually. D) When
normalized to the percent of PKH+ BMCs in the blood 1 day after infusion (“engraftment
efficiency”), the HA Gel enhances engraftment of circulating PKH+ BMCs. Values reported are
mean ± SEM, n = 7 animals for all groups except for MI-only, n = 6.

Engrafted BMCs localized to the infarct region (IR) and border region (BR) in the heart
following MI (Figure 5.7), while PKH+ BMCs in other regions of the myocardium were
very rare. The infarct region was characterized by dense collagen staining with
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Masson’s Trichrome (Figure 5.7A and 5.7B). This collagen scar tissue autofluoresced,
allowing the infarct region to be easily identified for characterizing engrafted BMC
locations within the heart, and PKH+ BMC fluorescence was bright enough to distinguish
the BMCs against the tissue background as indicated by white arrows (Figure 5.7C).
PKH+ BMCs were identified in the infarct region in all groups, but were rare in the border
region for all groups except for the HA Gel/rSDF-1α group. Border region BMCs in this
group were commonly localized within and around vascular structures (Figure 5.7D).
Some cells also appeared to integrate into the tissue and align with the native tissue
morphology (Figure 5.7E).
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Figure 5.7. Visualization of PKH+ BMCs in the Myocardium 7 Days after Systemic Infusion.
A) The cryoinjury resulted in the formation of a nontransmural collagen rich scar tissue (blue
region) 7 days following MI as visualized with Masson’s Trichrome. An infarct region (IR) and
border region (BR) were defined to assess PKH+ BMC locations within the heart. B) Vasculature
in the IR and BR remained intact following the cryoinjury. C) PKH+ BMCs were identified in the
IR of all groups, while PKH+ BMCs in the BR were rare except in the HA Gel/rSDF-1α group.
PKH+ BMCs were not found in remote regions of the myocardium for all groups. White
arrowheads indicate PKH+ BMCs. D) PKH+ BMCs in the BR were often localized in and around
vascular structures. E) In addition, cells in the BR appeared to align with the myocardial tissue
structure. Scale bars: A-500 μm; B-50 μm; C-100 μm; D and E-50 μm.
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5.4 Discussion
These experiments demonstrate that alterations in the myocardial chemokine milieu can
enhance progenitor cell engraftment. Specifically, the combination of SDF-1a extended
release and hyaluronic acid degradable polymer synergistically augments myocardial
homing and engraftment of infused labeled BMCs. Furthermore, differences between
short and long-term chemokine delivery are exposed as direct myocardial injection of
SDF-1a had no effect on myocardial engraftment at Day 7 but did reduce clearance of
infused BMCs from the circulation at Day 1; whereas the same mass of SDF-1a, when
contained in the heart and released over time, enhanced engraftment.

Interestingly, the HA gel sans SDF-1a caused some increase in BMC engraftment at
Day 7. As unfractionated BMCs may contain progenitor and inflammatory cells [36], it is
difficult to determine what portion, if any, of the enhanced engraftment represents a
foreign body immune response rather than pure progenitor cell recruitment. Prior work
on this material shows that both MSCs (presumably non-immunoresponsive) and BMCs
migrate towards the hyaluronic acid component of this hydrogel in vitro [30]. However,
phenotyping of engrafted cells will be required to fully understand the nature of this
recruitment. In either case, some participation by the inflammatory response may be
beneficial as blockade of inflammation after infarction has mixed results—both a
beneficial reduction in apoptosis [37-40] and a deleterious delay of scarification resulting
in increased infarct size [41-47].

The use of fresh unfractionated BMCs for these studies directly suggests a potential
method for increasing the effectiveness of delivered BMCs (proven myocardial repair
agents, but hindered in effectiveness by low retention rates) [1, 48] while avoiding
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culturing techniques that can alter cell chemokine responsiveness [49, 50]. Additionally,
the labeled BMCs may serve as tracers for natural circulating progenitors, which could
also be drawn to the heart via hydrogel but could not be detected in these studies. The
extent to which endogenous circulating cells (which are derived from but may not
respond similarly to BMCs) can be recruited via SDF-eluting HA hydrogels remains to be
determined but could theoretically provide a substantial repair mechanism. Speculation
aside, the present in work conducted in vivo using a model of myocardial infarction
presents compelling evidence for the therapeutic potential of SDF-eluting HA hydrogels
specifically and myocardial chemokine milieu modification in general.
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CHAPTER 6
6. Adjuvant Therapy for Artificial Enhancement of Progenitor Cell Engraftment
6.1 Introduction
Delivery of bone marrow cell-derived progenitor cells to infarcted myocardium appears to
improve outcomes [1]. Additionally, a subset of preclinical and clinical studies
comparing various dosages (number of therapeutic cells delivered) found that higher
dosages are generally more reparative than lower cell dosages [2]. Indeed, one in vivo
rodent study showed that engraftment success was a prognostic indicator of cardiac
function preservation after AMI [3].

Under the hypothesis that increased stem cell presence improves repair, several
strategies have been employed to increase the effective dosage of delivered stem cells.
Attempts to prevent stem cell apoptosis or increase stem cell proliferation once
engrafted have shown some positive results in rodents [4, 5]. However, the vast majority
of delivered progenitor cells fails to engraft to the injured myocardium and are
immediately swept into the systemic circulation [6-8], where proliferation and improved
survival have no benefit. Accordingly, attempts to modify the delivered cells prior to
infusion using chemokine stimulation, genetic overexpression of adhesion molecules,
and hypoxic environments have been tested [9-12]. While these strategies
demonstrated incremental benefit, evidence that activated endothelium following
ischemia-reperfusion injury rapidly inactivates (within one hour of injury) may limit the
potential of any delivered-cell modification to improve engraftment [13].

As achieving stem cell delivery within the brief window of endothelial cell activation is
logistically difficult, applying adjuvant stimulants to pre-condition and re-activate the
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endothelium immediately prior to stem cell infusion could be used to enhance stem cell
engraftment and thus endothelial repair even after the endothelium has inactivated.

Various methods of stimulating endothelium are known from early studies (circa 1990s)
of inflammation. A wide range of chemokine stimulants are known to enact both shortterm activation as well as long term pro-inflammatory alterations to endothelial cell
transcription. One source postulates the use of some of these chemokines or related
polypeptides (specifically SDF1, IL-6, CCL2, SelE, ICAM-1, VCAM-1, Fibronectin,
Laminin, or Tenascin C) as a stem cell therapeutic adjuvant [14]. However, proinflammatory chemokines may carry unwanted side effects due to long persistence times
in the circulation, unwanted potency at low concentrations, and their function to initiate
long-term endothelial changes in transcription.

Alternatively, short term endothelial activation may provide the benefits of enhanced
stem cell engraftment without substantial systemic effects or long-term local
inflammation. Endothelial application of small molecules such as histamine have been
shown to temporarily (5-30 min post-application) increase the adhesion of mature
neutrophils to HUVECs [15], but have not previously been described as stem cell
adjuvants. Reactive oxygen species (ROS) such as superoxide anions, hydroxyl
radicals, and hydrogen peroxide also induce rapid endothelial activation [16, 17]. These
chemicals, at low concentrations, are used as endogenous messengers for endothelial
injury [18] and are thus natural adjuvant candidates. Though toxic at high
concentrations, modest concentrations are well-tolerated [19, 20]. Furthermore, these
molecules operate in narrow concentration windows [21] and thus, if delivered at
optimum concentrations, will be rapidly neutralized below effective dosage, limiting off120

target reactions [22]. ROS have not been previously proposed as adjuvants for stem cell
therapies.

The purpose of this work is to demonstrate a proof of concept that ROS can be used as
adjuvants to stem cell therapy via endothelial stimulation. Peroxide (H2O2) is a ROS with
several known effects such as vasodilation [23], endothelial cell proliferation [24], and
induced endothelial secretion of VEGF [20]—all of which may be beneficial to the
infarcted heart. Additionally, peroxide is particularly well-suited to such proof concept
experimentation due to its quick (15 min) and long-lasting (45 min) activation [25], which
reduces assay dependence on delivery timing (however, alternative ROS adjuvants with
shorter effect duration may ultimately prove more clinically-desirable to prevent
endogenous inflammatory recruitment).

6.2 Methods
6.2.1 Isolation of Mouse BMCs
Adult Balb/C mice (20–24 g, 10–12 weeks old) were anesthetized with 100mg/kg
ketamine and xylazine, 1000 units/kg of heparin was administered IP, and hearts were
immediately excised as described below. Bone marrow was then obtained by removing
the femurs, and flushing them with sterile PBS over a 40 μm filter. The cells were
pelleted by centrifugation and resuspended in lysis buffer (BD Biosciences, NJ) for 1 min
to lyse red blood cells. Cells were again pelleted and resuspended in 1 mL PBS to
remove remaining lysis buffer. Cells were then stained with the fluorescent general
membrane labeling dye PKH26GL (Sigma Aldrich, MO). Stained cells in suspension
were counted and analyzed using a Vicell XR 2.03 automated cell counter (Beckman
Coulter, CA) for concentration and viability (trypan blue exclusion, automated). Viable
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concentrations were used to ensure accurate delivery of the correct number of BMCs for
each experimental protocol.

6.2.2 Isolated Perfused Mouse Heart (IPMH) for Ischemia–Reperfusion Studies
Adult Balb/C mice (20–24 g, 10–12 weeks old) were anesthetized with 100mg/kg
ketamine and xylazine, and 1000 units/kg of heparin was administered IP. Following
anesthesia and heparization, the heart was rapidly excised, the ascending aorta was
cannulated and perfusion was initiated with a modified Krebs bicarbonate buffer, as
previously described [26]. Perfusion was restored within 1 min of excision and
maintained at 37 °C and 2 mL/min. The perfusion solution was aerated with 95% O2,
5% CO2 in order to maintain a pH of 7.4. A side arm in the perfusion line proximal to the
heart inflow cannula allowed for entrainment of labeled autologous BMCs (isolation,
performed simultaneously with heart IPMH procedure, described above) along with the
oxygenated perfusate.

In all experiments, the perfused hearts underwent 10 min of equilibration time at a flow
rate of 2 mL/min at 37 °C. After equilibration, the trial cohort underwent no-flow
ischemia for 15 min (i.e. buffer pump flow was entirely halted), whereas a control group
(sham ischemia) received normal flow of buffer for 15 min. For all experiments, the
ischemia or sham ischemia was followed by reperfusion of plain buffer for 45 min.
Effects of this injury model (among others) are reviewed by Murphy and Steenbergen
[27]. In some sham ischemia experiments, the initial 10 min of reperfusion included 1
mM, 3 mM, or 10 mM hydrogen peroxide (CVS Pharmacy, RI). After this reperfusion
with plain buffer, 15 min of reperfusion with freshly-harvested, autologous PKH26GL122

labeled (Sigma Aldrich, MO) BMCs occurred. At the completion of cell infusion, plain
buffer was administered for 15 min to clear the circulation of non-engrafted BMCs.
Hearts were then perfusion digested with collagenase (180 unit/mL for 15 min) followed
by filtration (40 µm nylon filer, Becton Dickenson, NJ) for flow cytometry.

6.2.3 Flow Cytometry for Total BMC Retention Rate in Ischemia–Reperfusion Studies
The heart digest was pelleted by centrifugation and resuspended in 0.5 mL PBS and
stained with the viability dye DAPI (4′,6-diamidino-2-phenylindole dihydrochloride,
Invitrogen, CA) at 1.6 µg/mL and immediately analyzed via flow cytometry (BD
Biosciences LSR, NJ).

After excluding dead cells (DAPI+) along with cell fragments and aggregates (gated
based on forward scatter and side scatter to metrics consistent with BMCs, see Figure
6.1), gating based on PKH26GL fluorescence was employed to identify the infused
BMCs. The entire heart was scanned to determine the number of recovered BMCs.

Figure 6.1. Flow Cytometry Gating Strategy for Heart Digest. IPMHs infused with PKH26GLlabeled BMCs were digested with collagenase and stained with DAPI, a DNA-binding fluorescent
molecule that cannot permeate the membrane of intact (viable) cells. DAPI negative events (as
determined by FMO), were then gated for forward scatter (FSC) and side scatter (SSC), which
represent cell size and granularity respectively. The FSC/SSC gatings were chosen to match the
metrics of the infused BMCs (not shown, see Fig 6.2). DAPI-/FSC-SSC-gated events were
evaluated for PKH26GL fluorescence via the FMO technique; the absolute number of PKH26GL
events was recorded and either reported in absolute form or divided by the number of infused
labeled BMCs to determine a recovery rate.
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6.2.4 Flow cytometry for Analysis of Biomarkers in IPMH Ischemia–Reperfusion Studies
Aliquots of PKH26GL-labeled and unlabeled BMCs were reserved for analysis via flow
cytometry. One aliquot was used to determine the prevalence of c-kit+ and CD45+
BMCs in the perfusate; this aliquot received staining with an anti-CD117 (c-kit) antibody
conjugated to AF-488 (Biolegend, CA) and an anti-CD45 antibody conjugated to PETexas Red (Abcam, MA). Additional aliquots were stained with only one fluorochrome
(either c-kit antibody, CD45 antibody, PKH26GL-labeling, or DAPI) to serve as
compensation tubes for the automated flow cytometer algorithm for spectral overlap
compensation.

Similarly, the heart digest was pelleted by centrifugation and resuspended in 0.8 mL
PBS. The heart was divided into 4 aliquots of 0.2 mL each. A primary aliquot received
staining with an anti-CD117 (c-kit) antibody conjugated to AF-488 (Biolegend, CA) and
an anti-CD45 antibody conjugated to PE-Texas Red (Abcam, MA), while one control
aliquot received only the c-kit antibody, one control aliquot received only the CD45
antibody, and one control aliquot received no antibodies—these controls, all of which
received DAPI, are used for comparison to determine the effect of fluorescent
interference when these antibodies are applied to heart digest.

In the fully stained perfusate and heart aliquots, after excluding dead cells (DAPI+) along
with cell fragments and aggregates, forward scatter (a measure of cell size) and side
scatter (a measure of intracellular complexity) gating was performed to exclude cell
fragments and aggregates (Figure 6.2). Then, DAPI-, size/granularity-gated cells from
both the perfusate aliquot and heart digests were evaluated for c-kit and CD45
expression. Demarcation intensities for each fluorochrome were determined using the
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Fluorescence Minus One (FMO) technique (Fig 6.3). For each immunophenotypic
subtype, the percent representation in the retained cells was divided by original percent
representation in the perfusate aliquot to determine a ‘selectivity ratio’ of engraftment: a
ratio of 1 reflects non-selective engraftment while a ratio significantly greater than 1
indicates preferential engraftment.

Figure 6.2. Flow Cytometry Gating Strategy for Biomarker Evaluation. A representative
experiment is shown (15 min sham ischemia, 45 min reperfusion with 3 mM peroxide for the initial
10 min) with flow cytometric serial gating analysis of the perfusate aliquot (A-C) and heart digest
(D-F). DAPI negative events (not shown, see Fig 6.1), were then gated for forward scatter (FSC)
and side scatter (SSC), which represent cell size and granularity respectively (A&D). The
FSC/SSC gatings were chosen to match the metrics of the infused BMCs. DAPI-/FSC&SSCgated events were evaluated for PKH26GL fluorescence via the FMO technique (B&E). Serially
gated PKH26GL+ events were evaluated for c-kit and CD45 fluorescent intensity via FMO
technique (see Fig 6.3). Selectivity ratios were determined for the 4 possible combinations of ckit and CD45 staining, where a selectivity ratio is equal to the percentage representation of that
phenotype in the heart digest divided by the representation in the perfusate.
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Figure 6.3. c-kit FMO on Filtered, RBC-Depleted Bone Marrow Cells. The fluorescence
intensity cutoff between negative and positive cells is determined by comparison of fully-stained
sample to a sample missing only 1 fluorophore. A) BMCs stained with all fluorophores except
AF-488 c-kit, the chosen delineation intensity is the intensity at which false positives are 0.05%,
which is in good agreement with visual assessment. B) The fully stained BMC sample with the
gate from FMO c-kit sample drawn. This cutoff point is used for all samples (perfusate and heart
digest) to which the AF-488 c-kit antibody has been applied.

6.2.5 Statistical Analysis
The primary comparison criteria for these experiments was the heteroscedastic t-Test
(rationale provided by Ruxton [28]). An Absolute Recovery Rate (ARR) was determined
for each experiment by dividing the number of BMCs recovered from the heart divided
by the number of BMCs infused into the heart. Heteroscedastic t-Tests assuming
unequal variance were used to compare ARRs between experimental protocols (n=4).
Viability measurements of native heart cells in heart digests for each experiment were
also compared between protocols by heteroscedastic t-Tests (n=4). Phenotypic
distributions for each sample (heart and BMC perfusate) were recorded and also
compared between protocols (for heart digests) or between type (for heart digest of each
protocol compared to BMC perfusate) via heteroscedastic t-Tests (n=4).
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To compute phenotypic ARRs within a protocol, the absolute counts for total BMC
retention (performed without biomarker staining) were weighted by phenotypic
distributions of heart digest and perfusate aliquot for that protocol (obtained in separate
experiments using antibody marker staining), as specified in the following formula:
. Fractional standard error in the ARR
measurements was calculated as the sum of the fractional errors of the two component
random variables: (1) Selectivity Ratio

and (2) Absolute Recovery Level

. Heteroscedastic t-Tests were used to determine significance protocols
for phenotype ARR (n=4).

6.3 Results
6.3.1 Validation of BMC Recruitment Assay
The following experiments use flow cytometry to quantify the absolute number of cells
retained in the ischemia-reperfused heart. To demonstrate the repeatability and
sensitivity of this assay, IPMHs were produced, underwent 15 min of ischemia followed
by 45 min of reperfusion, and were then perfused with buffer supplemented with 0, 1, 3,
or 9 million viable, PKH26GL-labeled BMCs. After 15 min buffer-only rinse and
collagenase digestion, the number of recovered BMCs for each trial was plotted (Figure
6.4, n=4). As expected, a roughly linear relationship between recovered BMCs and
number of infused BMCs is obtained. The invulnerability of the assay to PKH26GL false
positives (which could stem from the abundance of native heart cells) is demonstrated,
as IPMHs infused with zero PKH26GL-labeled BMCs are almost entirely devoid of
PKH26GL+ events.
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Figure 6.4. IPMH/Flow Cytometry Assay is Sensitive and Linear. IPMHs underwent no-flow
ischemia for 15 min followed by 30 min reperfusion. After reperfusion, either 0, 1, 3, or 9 million
viable, PKH26GL-labeled BMCs were infused. After rinse and collagenase digestion, the
absolute number of DAPI-, forward scatter/side scatter-gated (size and granularity respecitively),
PKH26GL+ events was recorded from the heart digest via flow cytometry. Cell recovery counts
were largely linearly related with infused cell number. Infusion of 3 million versus 1 million BMCs
resulted in greater cell recovery (p<0.05, n=4), however the difference between 3 million and 9
million BMC infusion was not statistically significant at 4 replicates. Importantly, when 0 labeled
BMCs were infused, the number of recovered PKH26GL+ events (false positives) was 19±3
events amongst 1.6±4 million total heart events, suggesting an extremely low false positive rate
stemming from native heart cells. Some evidence of saturation or may be seen in the deviation
from linearity; best fit linear regression lines (green=intercept nonspecified, red = intercept set to
0) are shown for illustration.

6.3.2 Peroxide Increases Engraftment of Bone Marrow Cells
IPMHs were produced undergoing either sham ischemia or no-flow ischemia for 15 min
followed by 45 min reperfusion and infusion with 1 million PKH26GL-labeled viable
(trypan exclusion, automated cell counter) BMCs. After 15 min buffer-only rinse and
collagenase digestion, retained BMCs were quantified by flow cytometry. In a subset of
experiments, the initial 10 min of reperfusion ischemia (following sham ischemia) was
supplemented with 1 mM, 3 mM, or 10 mM hydrogen peroxide (H2O2). The number of
recovered BMCs for each protocol, shown as a percentage retention (recovered BMCs
divided by the 1 million infused BMCs) are plotted in Fig 6.5. Ischemic IPMHs tended to
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retain slightly more BMCs than sham ischemic IPMHs, but this difference could not be
detected to statistical significance with this assay after 4 replicates (1.1%±0.1%
ischemic, 1.3±0.4% sham ischemic). Similarly, IPMH exposed to 1 mM peroxide yielded
1.4%±0.4% retention. However, exposure to 3 mM peroxide yielded 3.6%±0.3%
retention, which was significantly higher than all lower dosages of peroxide and the
sham and ischemic protocols (p<0.01). Exposure to 10 mM peroxide resulted in highly
variable engraftment, with both the lowest and highest retained values occurring for this
protocol, and also caused noticeable blanching of the IPMH preparation; the average
retention rate for this protocol was 3%±1%.

Figure 6.5. BMC Retention Rates are Enhanced by 3 mM Peroxide Exposure. IPMHs
underwent either sham ischemia or no-flow ischemia for 15 min followed by 45 min reperfusion.
In some trials, the initial 10 min of reperfusion were supplemented with 1, 3, or 10 mM peroxide.
After reperfusion, 1 million viable, PKH26GL-labeled BMCs were infused. After rinse and
collagenase digestion, BMC retention rates (#BMCs Recovered/1 Million BMCs infused) were
recorded. Engraftment following 10 mM peroxide exposure was highly variable. 3 mM peroxide
exhibited enhanced engraftment (n=4, p<0.01) over all lower dosages.
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6.3.3 Viability of Heart Cells Post-Exposure to Peroxide
The relative toxicity of various peroxide dosages was estimated by examining the degree
of DAPI (non-viability) staining on native heart (PKH26GL negative) events. After gating
for size and granularity (forward scatter and side scatter, respectively), the percentage of
DAPI+ events was recorded and plotted (Figure 6.6). While 10 mM peroxide was found
to have significantly more native heart DAPI staining than all other protocols (p<0.05), 3
mM peroxide (which achieved the highest improvement in retention) did not result in
increased native heart DAPI staining.

Figure 6.6. Native Heart Non-Viability is Unaffected by Peroxide Dosages Up to 3 mM.
IPMHs underwent either sham ischemia or no-flow ischemia for 15 min followed by 45 min
reperfusion. In some trials, the initial 10 min of reperfusion were supplemented with 1, 3, or 10
mM peroxide. After reperfusion, 1 million viable, PKH26GL-labeled BMCs were infused. After
rinse and collagenase digestion, native heart events (gated on size/granularity, by forward scatter
and side scatter respectively, and for PKH26GL negativity) were evaluated for DAPI (nonviability) staining. Sham ischemia, stop-flow ischemia, and sham ischemia followed by 1 or 3 mM
peroxide showed no difference in native heart non-viability, while 10 mM peroxide resulted in
significantly lower viability (n=4, p<0.05).
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6.3.4 Retention Selectivity Favors c-kit+ BMCs
IPMHs underwent either 15 min of sham ischemia or stop-flow ischemia followed by 45
min of reperfusion. In a subset of the sham ischemic hearts, the first 10 min of
reperfusion was supplemented with 3 mM peroxide. In all trials, 3 million viable,
PKH26GL-labeled BMCs were infused after reperfusion. After BMC infusion, IPMHs
underwent 15 min buffer only rinse followed by collagenase digestion. Perfusate
aliquots and heart digests were incubated with fluorescent antibodies for c-kit and CD45
and stained with the viability dye DAPI. For each experiment, a selectivity ratio for each
of the 4 possible phenotypes (c-kit+/CD45+, c-kit+/CD45-, c-kit-/CD45+, c-kit-/CD45-)
was computed. A representative phenotypic analysis of each protocol (sham ischemia,
no flow ischemia, and sham ischemia + 3 mM peroxide) is shown in Figure 6.7. For
each phenotype, if the percent representation of retained (PKH26GL+) BMCs in the
heart is substantially greater than the representation of the same phenotype in the BMC
perfusate, then BMCs of that phenotype are considered to engraft preferentially under
the given protocol conditions. For example, though c-kit+/CD45+ BMCs comprise
approximately 2% of the perfusate BMCs in all shown representative trials (Fig 6.7), in
the sham ischemia example, c-kit+/CD45+ BMCs comprise 3.87% of the retained BMCs
compared to 27.70% in the ischemic heart and 17.86% in the sham ischemic heart
receiving 3 mM peroxide during reperfusion.
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Figure 6.7. Representative Biomarker Staining for BMC Perfusate and BMCs Retained in
Heart for Various Protocols. Representative experiments for each of 3 protocols are shown.
IPMHs underwent either sham ischemia (A&B), no-flow ischemia (C&D), or sham ischemia in
which the initial 10 min of reperfusion was supplemented with 3 mM peroxide (E&F). After 45 min
reperfusion, 3 million viable PKH26GL-labeled BMCs were infused. Perfusate aliquots and heart
digests were stained with fluorescent antibodies for c-kit and CD45 and gated as described in
Figure 6.2 to identify PKH26GL+ BMCs (in heart digests, these represent cells retained from the
perfusate). BMCs retained in sham ischemic hearts are roughly equal in phenotypic distribution
to perfusate aliquots, while ischemic hearts and sham ischemic hearts receiving peroxide (to a
lesser degree) preferentially retain c-kit+/CD45+ BMCs.

After a series of 4 replicates for each protocol, compiled summary statistics were
computed (Figure 6.8). Figure 6.8 confirms that c-kit+/CD45+ BMCs are preferentially
retained in ischemic and sham ischemic protocols when peroxide is used as an
adjuvant, compared with sham ischemic hearts without peroxide treatment.
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Figure 6.8. Cell Subtype Distribution in Bone Marrow, Sham-ischemic Hearts, Ischemic
Hearts, and Sham-ischemic Hearts Receiving 3 mM Peroxide during the First 10 min of
Reperfusion. For each cell subtype, the percent composition of viable, infused cells
(DAPI−,FSC&SSC-gated, PKH26GL+) isolated from bone marrow, sham-ischemic hearts,
ischemic hearts, and sham ischemic hearts receiving 3 mM peroxide during the first 10 min of
reperfusion are displayed as histograms. The c-kit+/CD45+ subpopulation is more strongly
represented in ischemic and, to a lesser degree, sham ischemic+peroxide heart than in bone
marrow and are considered to be preferentially recruited.

Combining the results of Figure 6.5 regarding absolute BMC recovery rates and the
results of Fig 6.8 regarding ratiometric phenotypic distributions, recovery rates for each
phenotype under each protocol were computed. Thus, the Absolute Recovery Rates
(ARR), defined as
for each phenotype as shown in Table 6.1, n=4.
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Table 6.1: Absolute Recovery Rates for Various Phenotypes
Protocol
c-kit+/CD45+ c-kit+/CD45- * c-kit-/CD45+ c-kit-/CD45Sham Ischemia
3% ± 2%
6% ± 5%
1.2% ± 0.5% 3% ± 2%
No-Flow Ischemia

23% ± 6%

11% ± 6%

1.2% ± 0.4%

0.8% ± 0.2%

Sham Ischemia + 3
27% ± 7%
28% ± 18%
2.8% ± 0.4% 10% ± 5%
mM Peroxide
*This population is rare in the bone marrow (0.3%±0.1%) and difficult to quantify
consistently.
Table 6.1 displays that antecedent no-flow ischemia increases the ARR of c-kit+/CD45+
BMCs relative to sham ischemic protocols (p<0.05), but has no detectable effect on
other phenotypes. Alternatively, sham ischemia followed by 3 mM peroxide also
increases the ARR for c-kit+/CD45+ BMCs compared to sham ischemia alone (p<0.05)
and the ARR of c-kit-/CD45+ BMCs. The effect on c-kit-/CD45+ BMCs, though small,
has a large effect on total number of retained BMCs due to the high prevalence of this
phenotype in BMC perfusate) with p<0.05 when compared to sham ischemia and noflow ischemia.

6.4 Discussion
Previous work in Chapter 4 demonstrated that the IPMH model, combined with flow
cytometry, provides a sensitive assay to evaluate comparative engraftment rates of
various cells in a heterogeneous mixture [29]. However, evaluation of myocardial
interventions requires the ability to compare retention rates between IPMH preparations
rather than merely within a single preparation as there is no internal control or
normalization mechanism for these conditions. Chapter 6 now shows that the IPMH/flow
cytometry assay is sufficiently sensitive and repeatable to detect differences in absolute
(i.e. not merely relative) retention rates for various BMC phenotypes.
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This assay is then used to demonstrate that adjuvant delivery, hydrogen peroxide
specifically, can be used to enhance progenitor cell engraftment in an intact organ. Brief
stimulation with low-dose hydrogen peroxide could potentially be used to stimulate
endothelium immediately prior to progenitor cell infusion. As the engraftment
enhancement achieved by low-dose peroxide stimulation occurred in sham ischemia
hearts, which are considered to exhibit non-stimulated endothelium [30, 31], low-dose
peroxide could be used as an adjuvant for stem cell delivery long after initial ischemiadependent endothelial activation (from myocardial infarction) has subsided. Because
endothelial activation following reperfusion injury has been shown to diminish in under 1
hour in vivo [32], low-dose peroxide therapy could achieve the engraftment yield
associated with quick delivery but may be more feasible clinically. While peroxide is
toxic at high dosages, lower dosages are well tolerated and serve as natural endothelial
mediators; indeed our preliminary exploration of toxicity suggest that 3 mM peroxide
exposure for 10 min is both a safe and effective stimulant. While many studies have
explored the effect of peroxide on signaling in endothelial monolayers (usually 100 µM –
1 mM) [33, 34], apparently higher dosages are needed to achieve stimulation in an intact
organ which may have additional catalases and dismutases that reduce the effective
peroxide dose. Still higher dosages may be required in vivo, depending on the
concentration of reducing agents in the blood [35].

While peroxide may have potential as a therapeutic stem cell adjuvant, it also serves as
proof of concept for additional stimulatory mechanisms such as alternative reactive
oxygen species (superoxide radicals, hydroxyl anions, and others), inhibitors of
catalases and dismutases that destroy naturally or artificially produced ROS, and
proteins or chemokines associated with inflammation. Similarly, these adjuvants could
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be used in combination with each other or in conjugation with additional compounds.
For example, adjuvant and stem cell delivery could be chased with anti-inflammatory
molecules to reduce unwanted lingering inflammatory effects. Additionally, the stem
cells could be modified (either by co-culturing with chemical stimulants or altered genetic
expression) to be more responsive to activated endothelium; such modifications could
aim to increase relevant adhesion molecules such as PSGL1, CD24, or VCAM, among
many others.

Individually or in combination, these therapies could be used to augment progenitor cell
engraftment in a wide range of diseases where cell depletion has occurred. Because
stem cell therapy, with unfractionated BMCs and also with specific subtypes of bone
marrow-derived cells, has proven effective even with very low retention rates (and in a
dose-dependent manner in some analyses [36]), the 3-fold improvement shown here
with peroxide can be expected to provide additional benefit. The increase is especially
encouraging with regards to the much stronger (15-fold) impact on c-kit+ BMCs, which
are known to have superior ability to stimulate new cardiomyocyte formation post-injury
in vivo [37].
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CHAPTER 7
7. Summary, Conclusions, and Future Work
7.1 Summary
Ideally, the heart would regenerate healthy myocardium to replace cells and restore
normal tissue architecture and function following an injury such as acute myocardial
infarction (AMI). Prior dogma asserted that the human heart is a terminally differentiated
organ with no capacity for generating new cardiomyocytes (CMs); however, recent
evidence indicates that CM formation occurs throughout life, though the magnitude is
disputed, and increases briefly post-injury. Controversy over the exact degree of CM
formation rates is especially discordant for older patients, the primary demographic for
AMI.

In Chapter 3, we scrutinized two prominent studies of CM turnover in aging human
hearts. Both the study by Bergmann et al, which favored low age-decreasing turnover
(1% declining to 0.5% with advancing age), and the study by Kajstura et al, which
favored high, age-increasing turnover (4% increasing to 20%), were highly dependent on
complex mathematical models. Both papers were found to be exquisitely sensitive to
variance in primary measured parameters despite limited ability to assess the precision
of these measurements. In particular, the Kajstura study was supra-linearly sensitive to
a parameter describing the number of divisions undergone by cardiac stem cells prior to
senescence, while the Bergmann paper was especially sensitive to assumptions about
the corporeal incorporation of atmospheric C14 levels. Furthermore, the candidate
turnover scenarios tested by Bergmann did not include an option for time-varying
turnover where the attrition rates of CMs could be a function of the patient-age at which
they were formed. In fact, a scenario of age-increasing turnover with new CMs
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experiencing higher rates of attrition than predecessors fit the Bergmann data far better
than all models favored by Bergmann. Interestingly, this solution largely agreed with the
conclusions drawn by Kajstura.

This age-increasing solution, in addition to achieving superior fit, also explains a
discrepancy in the Bergmann turnover conclusions between subjects born prior versus
after the initiation of atomic weapons testing. The relatively insubstantial amount of C14
incorporated by subjects born prior to the atmospheric C14 spike is not consistent with
the higher levels of C14 that would have been incorporated by these older subjects
assuming that, in youth, they experienced cycling rates similar to those of the dataset’s
younger subjects. We observe that, for these pre-spike subjects, two numeric solutions
are possible to compute a turnover level from observed ΔC14 measurements. Pre-spike
subjects can gain C14 content either by slow, steady accumulation or alternatively by
rapid CM formation during the highest levels of atmospheric C14 followed by rapid
replacement of those newly-formed CMs with successor CMs formed at time of
diminished atmospheric C14—thus creating two numerical solutions. Selection of the
low solution, as favored by Bergmann, yields an unreasonable discontinuity in turnover
estimates at the onset of atomic weapons testing, whereas the high solution readily
explains the discontinuity.

All things considered, a scenario of roughly 4% turnover in youth increasing to 15-22% in
old age seems compatible with all known data. This finding implies that the baseline
level of turnover is much higher than is previously thought and that the rates of new CM
formation may be frequent in victims of AMI (who are generally elderly). Such findings
suggest that that the persistent scarring following myocardial infarction may not be due
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to inadequate myogenic capacity, but rather to high rates of new CM destruction and/or
a loss of normal tissue architecture that compromises the ultimate efficacy of native
myogenic processes.

In an attempt to augment endogenous cardiac repair post-AMI, cardiologists have tested
delivery of various bone marrow-derived cells to the injured heart. While the culmination
of a large number of randomized, placebo-controlled clinical trials have demonstrated a
modest improvement in cardiac performance metrics associated with these therapies,
the overall magnitude is too limited to cause an improvement in patient outcomes.

In studies that have measured the degree of cardiac retention of infused cells after
delivery, most find that nearly all of the infused cells are lost to the systemic circulation
within an hour. Given that several studies now implicate paracrine signaling as the
primary mechanism by which cell therapy stimulates cardiac repair, and also that cell
therapy benefits appear to be dose-dependent, improvement of cell engraftment
efficiency would be expected to augment the repair effect of cell therapy.

In Chapter 4, we identified engraftment mechanisms used by bone marrow-derived
progenitor cells with the anticipation that knowledge of these mechanisms would yield an
actionable strategy to improve engraftment in cell therapy. To achieve this end, we
recognized that, within a heterogenous bone marrow source, some phenotypic cell
subsets are likely to have superior engraftment capability relative to others. We
identified strongly-engrafting subsets by comparing the phenotypic composition bone
marrow cells (BMCs) prior to infusion into injured mouse hearts with the composition of
labeled BMCs retained within the heart. We found that, after antecedent ischemia142

reperfusion injury, c-kit+/CD45+ bone marrow cells were preferentially retained in the
heart by approximately 15-fold (relative to non-selective retention), but that this effect
does not fully occur until 30 min post-injury. Subsequent studies using P-selectin
neutralization techniques, parallel plate flow chamber dynamics, and PSGL1/c-kit coexpression assays indicated that interaction with endothelial P-selectin is required to
achieve engraftment by c-kit+ BMCs.

After studying the natural phenomena of cardiac regeneration and stem cell engraftment,
we attempted to manipulate engraftment via two distinct approaches. In Chapter 5, we
manipulated the local concentration of chemotactic factors at the site of cardiac injury.
The chemokine Stromal Derived Factor 1α (SDF), encapsulated in a hydrogel comprised
of polymerized hyaluronic acid (HA), was deployed on the epicardial surface of a
cryoinjury in an in vivo mouse model. We observed that labeled BMCs, infused into the
femoral vein after injury, were more prevalent in the blood at day 1 post-injury and nearly
8-fold more likely to home to the heart when the SDF-containing HA-hydrogel was
applied. Interestingly, we also observed effects in some of the control cohorts;
intramyocardial injection of soluble SDF resulted in higher relative abundance of labeled
cells in the blood at 1 day post injury (though no impact on cardiac retention at day 7
was observed) whereas the addition of the carrier hydrogel alone (sans SDF) had no
effect on day 1 blood but increased retention in the heart at day 7. As BMCs respond to
SDF gradients, it is likely that altering the SDF balance prevented homing of the labeled
cells to natural BMC repositories (such as the bone marrow) and allowed continued
BMC presence in the blood. Hyaluronic acid is also a chemotactic factor, thus
explaining the increased cardiac homing when it was applied. The strongest
engraftment was seen for the SDF-impregnated hyaluronic acid hydrogel suggesting that
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this method is a viable strategy for increasing stem cell homing by retrieving infused
cells lost to the circulation.

Building on results from Chapter 4 and the recognition that endothelial P-selectin
activation may be short-lived, we attempted to artificially induce endothelial activation
prior to BMC infusion in a model of quiescent endothelium. Though several molecules
are capable of inducing endothelial activation via injury, we selected Reactive Oxygen
Species (ROS) as a prime agent due to its ability to stimulate short-term inflammation
and its brief half-life in circulation (both reducing likelihood of off-target effects and
toxicity). In particular, we selected peroxide which, though toxic at high doses, is a
natural paracrine signaling molecule and well tolerated at low dosages. Using prestimulation with 3 mM peroxide, we achieved a 3-fold increase in total BMC engraftment.
Importantly, engraftment rates c-kit+/CD45+ BMCs were 10-fold higher than in untreated
hearts, similar to the engraftment rates seen for this subtype after ischemia-reperfusion
injury. As infused c-kit+ BMCs are known to be a particularly potent stimulant of new
CM formation, the impact of enhancing engraftment of these specific BMCs may be
particularly beneficial. Though higher dosage (10 mM) peroxide caused hyper-variable
overall retention and high toxicity, preliminary tests using DAPI as a viability dye for
native heart showed no overt toxicity at 3 mM. As peroxide is a vasodilator, a stimulator
of endothelial VEGF release, and a stimulator of endothelial proliferation, additional
benefits may result from use of this adjuvant in addition to a boost in engraftment
efficiency.

Thus the attempts to manipulate engraftment have yielded two complementary
strategies for enhanced cell therapy that could be used separately or in tandem. Pre144

stimulation with an endothelial activator, such as peroxide, could be used to increase the
first-pass retention of infused progenitor cells while the application of a chemokineeluting hydrogel patch could encourage homing of both endogenous and delivered cells
from the systemic circulation back to the site of cardiac injury.

7.2 Limitations
While many conclusions can be drawn from the presented studies, a few limitations
deserve mention. For example, in Chapter 3, an analysis is performed using the two
most prominent manuscripts investigating turnover in healthy human hearts. While
these papers are particularly targeted to the scientific question, other studies involving
animals or other patient populations (particularly those with relevant morbidities) exist
but were excluded from the current analysis due to possible confounding variables.
While many statements regarding proper mathematical modeling in biomedical studies
will transcend the underlying manuscripts, the specific turnover conclusions are
beholden to the quality and completeness of the input data. The analysis discovered
turnover ranges compatible with both datasets but does not formally exclude all other
possible turnover scenarios, for which future data will be required. Additionally, the
effect of pathological conditions on these turnover levels is not investigated in Chapter 3.

In Chapter 4, we explored aspects of BMC engraftment using an in-tact organ model;
however as with all experiments, the model system was chosen to achieve balance
between physiological relevance (to human stem cell trials) and controllability, which
generally requires more reductionist methods. For example, we directly infused filtered,
labeled bone marrow constituents into the Isolated Perfused Mouse Heart (IPMH) while
the in vivo setting involves an indirect interaction in which marrow-derived cells are
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released into the circulation and the circulation, in turn, perfuses the myocardium. While
our procedure may have allowed some marrow-derived populations greater access of to
the heart than occurs in vivo, this realization does not diminish the validity of injurytriggered engraftment cues and preferential engraftment dynamics revealed by these
studies.

Similarly, though the IPMH model has been shown to exhibit contractile impairment
following ischemia-reperfusion injury (and also similar Reactive Oxygen Species
release) that is similar to the injury’s effect in vivo, the IPMH undergoes a traumatic
injury, separation from the nervous system, and a transition from blood to crystalloid
buffer. Given that the observed P-selectin-mediated selective engraftment parallels
results from systemic circulation and the fact that this selectivity was not seen in control
IPMHs, the results are likely representative of true physiology.

The utility of the IPMH model is likely greatest for studying early engraftment dynamics
before deterioration of contractile performance and edema of the IPMH reduce its
reproducibility and relevance to in vivo dynamics. Additionally, this model is critically
dependent on rapid cannulation of the mouse heart since delay will induce ischemic
insults that would confound the interpretation of protocol-driven ischemia–reperfusion
stress. To address this concern, we routinely aborted experiments if the heart
cannulation and initiation of perfusion takes more than two minutes.

In Chapter 5, we utilized a rodent model to test a chemokine-eluting hydrogel patch.
Application to a rodent heart required topical delivery to the epicardial surface.
However, as human AMI patients are generally catheterized, a more translatable
146

delivery method may involve infusing the SDF-laced hydrogel as a solution via catheter
and then using chemical initiators, rather than photo-initiation, to form the hydrogel.
While other work using intravascular polymerization of hydrogels has shown a strong
safety record, concentrations and cross-linking density will have to be optimized to
ensure that no obstruction of blood flow occurs in this process. Furthermore, our
presented experiments show an increase in homing for peripherally-infused BMCs (i.e.
BMCs delivered as an intervention), however the hydrogel formulation may also
encourage homing of native BMCs cells to the heart, which is a much more abundant
cell source. While such stimulation of endogenous BMCs is an attractive possibility, our
experiments were not designed to evaluate this potential effect.

In Chapter 6, we return to the IPMH model to study direct engraftment of BMCs flowing
over the coronary endothelium. The peroxide results show that it is possible to increase
engraftment of infused BMCs, particularly for c-kit+/CD45+ BMCs. The optimum dosage
was 3 mM peroxide infused for 10 min for these experiments. However, in vitro cell
culture experiments show endothelial effects occurring at lower dosages (under 1 mM)
with toxicity beyond these levels. Differences in optimum and toxic dosages could result
from the model system used, where the differential concentration of reducing agents
may alter the effective ROS dose. Similarly, the optimum dose for use in patients, where
blood is present rather than crystalloid buffer, may also be different and require reoptimization. While preliminary viability dye staining of native heart cells indicated a
narrow therapeutic range around 3 mM peroxide that is both safe and effective, full
toxicology studies assessing the long-term effects of peroxide dosing have not been
performed. Follow-up therapy with anti-inflammatory agents or possibly substitution of
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peroxide for less toxic molecules in the ROS family may reduce adverse reactions to the
therapy.

7.3 Future Work
The results of these experiments suggest many avenues for new explorations and
continued translation to the clinic. The computer model (full code provided in the
Appendix) is intended to accommodate future fate-mapping and cell dynamics studies
for both physiological and pathophysiological subject sets. Regarding the specific
question of endogenous CM turnover in healthy human hearts, definitive testing of the
emergent theory (from the two studied papers) of age-increasing turnover with
progressively inferior CMs should be performed. Debate over the causes for
discrepancy between subjects born prior to and after the onset of atomic weapons
testing could be clarified by repeating the Bergmann studies using subject hearts
obtained from autopsies over the next few decades (such that subjects of longer
lifespans will contribute to the set of individuals born after the atmospheric C14 spike).
The use of multiple pulse-chase markers in addition to or instead of C14 may be needed
to definitively demonstrate the proposed inferiority of CMs made late in life, and in vitro
testing of biopsied samples or evaluation of CM characteristics dated by surrogate age
markers (such as telomere length) may support more conclusive experiments.

Myocardial ischemia–reperfusion stress is here shown to provoke time-dependent and
highly selective engraftment of c-kit+ cells included in the perfusate via a P-selectindependent mechanism. In this context, additional applications of this model might
include more extensive examinations how the type of ischemia (demand vs. supply),
duration of ischemia or alternative local cytokine manipulations might alter engraftment
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dynamics. More detailed profiling of selectively retained cells via further
immunophenotyping, sorting with gene expression studies, and/or characterization of the
IPMH effluent should provide additional insights into the precise sequence of events
responsible for the highly selective engraftment dynamics we observed. Refined
mechanistic hypotheses raised by such studies could be tested by gain- and loss-offunction studies enabled by altering the myocardial cytokine milieu, exploiting
genetically-manipulated mouse models and/or the varying the composition of the infused
cells. For example, manipulations of the infused cell populations via sorting
and/recombination could permit unique opportunities to examine whether there are
cooperative or inhibitory interactions among infused cells that affect overall engraftment
dynamics.

Two therapeutic strategies— (1) SDF-eluting hydrogels and (2) peroxide adjuvants-have been proposed in this work to enhance the effectiveness of cell therapies for AMI
patients. The specific cell types recruited by the two therapies may offer more benefit to
regeneration than would be expected by simply evaluating the increase in overall BMC
presence. For example, the SDF-hydrogel may preferentially attract Mesenchymal Stem
Cells (MSCs), which are known to release pro-angiogenic chemokines when deployed to
the heart and are strongly attracted to SDF-gradients. Because MSCs may represent a
disproportionate fraction of the cells homing to the heart in response to our hydrogel
therapy, phenotyping the recruited cells would be of great value to these studies.
Regarding the peroxide therapy, c-kit+ BMCs are known to be especially effective at
increasing the formation of new CM when infused into the injured heart; however the
true impact of increasing c-kit- BMCs will require additional studies using measures of
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regional myocardial function, infarct size, and labeling techniques that can define the
ultimate fates of engrafted cells.

The mouse models used provided an expedient method to demonstrate proof of concept
for these candidate procedures. However, these approaches operate under the
assumption that increased BMC retention will ultimately improve repair and patient
outcomes. This assumption is supported by dose-dependent cardiac performance
benefit observed in some cell infusion studies. However, studies of cardiac performance
metrics in vivo would greatly promote translation of both strategies, particularly in larger
animals where more physiologically-relevant injuries can be reliably produced. In each
of these studies, therapeutic agent concentrations and timing deliveries will likely have to
be re-optimized to maximize benefit and minimize adverse reactions.

Though these proof-of-concept studies evaluate the proposed therapies in isolation, they
could also be combined with other therapeutics (including each other). For example, the
peroxide therapy may be combined with anti-inflammatories to avoid exacerbating
damage to the heart after cell infusion is complete. While a multi-faceted approach may
ultimately yield the best results, the complexity of proving additive or synergistic effects
suggests that the direct benefits of therapies suggested by this work are most likely to
have near-term impact.

150

APPENDIX - Hybrid Model JAVA Code
package turnovermodel;
import java.io.BufferedReader;
import java.io.BufferedWriter;
import java.io.FileNotFoundException;
import java.io.FileReader;
import java.io.FileWriter;
import java.io.IOException;
import java.util.StringTokenizer;
import java.util.logging.Level;
import java.util.logging.Logger;
import org.jdesktop.application.Application;
import org.jdesktop.application.SingleFrameApplication;

public class TurnoverModelApp extends SingleFrameApplication {
/*Read Me
Thank You for Studying Our Paper!
The complete code to run our model heart and regenerate our results is divided into two Java classes
(TurnoverModelView and TurnoverModel)
TurnoverModel contains methods for basic tasks such as loading datapoints from databases, also contains global
variables
TurnoverModelView contains a list of high-level methods (top of the class) that produce excel files (.csv) for output
data/figures
TurnoverModelView contains lower level methods (middle of class) that perform basic model tasks that feed into the
upper level methods
TurnoverModelView contains data retrieval methods (end of class) that return age and gender dependent parameters
from published data
This program has no graphical user interface and is intended to be run from within an IDE such as Netbeans
This program requires 2 folders to exist in the working directory, so please create them manually when you
download the program: IndividC14, RawDatabase
The RawDatabase folder requires the 9 .txt data files found in the supplement
If this setup has not been performed, the program will not run and you will not receive an error message
A method will fail to run if the .csv file it is intended to write to is open by the user. You will not receive an error
message. Close the .csv file and re-run.
When the program has completed all scheduled runtime tasks, a generic window will popup. If this window does not
pop up, the program is either still running or an error has occurred
Be aware of the output format of the .csv files. Data matrix structure is annotated in the individual methods that
create the .csv of interest. Charts are not automatically generated from these .csv files.
We would like to acknowledge 3 primary sources of data for this program.
Kajstura J, Gurusamy N, Ogorek B, Goichberg P, Clavo-Rondon C, Hosoda T, D'Amario D, Bardelli S, Beltrami
AP, Cesselli D, Bussani R, del Monte F, Quaini F, Rota M, Beltrami CA, Buchholz BA, Leri A, Anvera P, "Myocyte
Turnover in the Aging Human Heart," Circ Res 2010, 107:1374-1386
Bergmann O, Bhardwaj RD, Bernard S, Zdunek S, Barnabe-Heider F, Walsh S, Zupicich J, Alkass K, Buchholz BA,
Druid H, Jovinge S, Frisen J, "Evidence for Cardiomyocyte Renewal in Humans, Science 2009, 324,5923:98-102
Atmospheric Carbon14 over Time: CALIbomb web site (http://calib.qub.ac.uk/CALIBomb/frameset.html)
*/
@Override protected void startup() {try {
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show(new TurnoverModelView(this));
} catch (IOException ex) {
Logger.getLogger(TurnoverModelApp.class.getName()).log(Level.SEVERE, null, ex);
}
}
@Override protected void configureWindow(java.awt.Window root) { }
public static TurnoverModelApp getApplication() { return Application.getInstance(TurnoverModelApp.class); }
public static void main(String[] args) {
launch(TurnoverModelApp.class, args);
}
public static String workingfold = "C:/Documents and Settings/jelser/Desktop/";
public static double cyclelengthhours = 26; //26 in paper
public static double cyclelengthhoursStdErr = 4;
public static double num20yroldMaleCM = 6*Math.pow(10,9);
public static double num20yroldFemaleCM=4*Math.pow(10,9);
public static double num20yroldMaleCM10g = 500*Math.pow(10,6);
public static double num20yroldFemaleCM10g = 500*Math.pow(10,6);
public static int numC14points=0;
public static double[][] C14points;
public static double scaleinterceptC14=1.0;
public static double scalemultiplierC14=1000;
public static double maxC14raw=1.92035;
public static int numBergmann=12;
public static double[][] Bergmann;
public static double delay=0;
public static int startage=19;
public static int Agerepetitions = 82;
public static double apopdurationhours = 4;//4 in paper
public static double CMvolume = 40000; //cubic microns, Not found in Kajstura. 20x20x100
public static double gramsperheart = 300;
public static double male5percAge = 0;
public static double female5percAge = 0;
public static double[][] holddata = new double[1][1];
public static int holdnumrows = 0;
public static int holdnumcol = 0;
public static double[][] holddata2=new double[1][1];
public static int holdnumrows2=0;
public static int holdnumcol2=0;
public static double[][] holddata3 = new double[1][1];
public static int holdnumrows3=0;
public static int holdnumcol3=0;
public static double[][] KajsturaFig7Histos;
public static int numKajsturaFig7;
public static int[] optimumMaleHistogramAges = {40,55,70};
public static int[] optimumFemaleHistogramAges = {49,69,85};
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public static double initguess=0.001;//0.001 finds lowest for pre-bomb, 0.6 finds highest (For Scenario A, around
150%)
public static int counter =0; public static boolean applysubtract = true; public static double partialploidy=1.0;public
static double addtoC14=0;
public static double modelerror=0;public static double[] modelparams;
public static double holddouble=0;public static double holddouble2=-1;public static double holddouble3=-1;
public static String curmethod = "None";
public static double[][] convertHistotoRiemannSum(double[][] data, int numyears){
//Assumes #CM of Age 0 = EndCount
double endcount = 0;
//Assumes Increment of 1 Year Between Rows
//Need numyears rows of data[i][0]=ageofCM and data[i][3] = %
double[][] riemannsum = new double[numyears+1][2]; //CM age and Riemann Sum %
for (int i=0;i<numyears-1;i++){
riemannsum[i][0]=data[i][0];
riemannsum[i][1]=(data[i][3]+data[i+1][3])/(2*1);
}
riemannsum[numyears-1][0]=1;
riemannsum[numyears-1][1]=(data[numyears-1][3]+endcount)/(2*1);
double cellcount=0;
for (int j=0;j<=numyears;j++){cellcount=cellcount+riemannsum[j][1];}
for (int j=0;j<=numyears;j++){riemannsum[j][1]=100*riemannsum[j][1]/cellcount;}
return riemannsum;
}
public static void fileWriter(double[][] data,int rows,int col, String dataname) throws IOException{
BufferedWriter OUT = new BufferedWriter(new
FileWriter(TurnoverModelApp.workingfold+"/ApopModel/"+dataname+".csv"));
for (int i=0;i<rows;i++){
for (int j=0;j<col;j++){
OUT.write(data[i][j]+",");
}
OUT.write('\r');
}
OUT.close();
}

public static FileReader getfile(String unique) throws FileNotFoundException{
String filetype = ".txt";String preface = workingfold+"/ApopModel/";
FileReader r =new FileReader(preface+unique+filetype);
return r;
}
public static void BuildC14bybirthyear() throws IOException{
TurnoverModelApp.numC14points=914;
TurnoverModelApp.C14points=new double[TurnoverModelApp.numC14points][2];
BufferedReader compIN = null;
try{ compIN = new BufferedReader(TurnoverModelApp.getfile("/RawDatabase/RawBombYears"));}
catch(FileNotFoundException a){System.out.println("RawBombYears Not Found");}
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String bombline = compIN.readLine();
for (int q=0;q<TurnoverModelApp.numC14points;q++){
StringTokenizer bombtok = new StringTokenizer(bombline," ");
TurnoverModelApp.C14points[q][0]=Double.parseDouble(bombtok.nextToken());
bombline = compIN.readLine();
}
compIN.close();
try{ compIN = new BufferedReader(TurnoverModelApp.getfile("/RawDatabase/RawBombC14"));}
catch(FileNotFoundException a){}
bombline = compIN.readLine();
for (int q=0;q<TurnoverModelApp.numC14points;q++){
StringTokenizer bombtok = new StringTokenizer(bombline," ");
TurnoverModelApp.C14points[q][1]=Double.parseDouble(bombtok.nextToken());
bombline = compIN.readLine();
}
//scale to Bergmann
for (int i=0;i<TurnoverModelApp.numC14points;i++){
TurnoverModelApp.C14points[i][1]=TurnoverModelApp.C14points[i][1]TurnoverModelApp.scaleinterceptC14;
TurnoverModelApp.C14points[i][1]=TurnoverModelApp.C14points[i][1]*TurnoverModelApp.scalemultiplierC14/(Tu
rnoverModelApp.maxC14raw-TurnoverModelApp.scaleinterceptC14);
}
compIN.close();
//Add In Pre-1959 data
double[][] holdC14points = new double[TurnoverModelApp.numC14points+(1959-1930)][2];
for (int i=0;i<1959-1930;i++){
holdC14points[i][0]=1930+i;
if (1930+i<1955){holdC14points[i][1]=-2;}
if(1930+i==1955){holdC14points[i][1]=0;}if(1930+i==1956){holdC14points[i][1]=25;}if(1930+i==1957){holdC14po
ints[i][1]=80;}
if(1930+i==1958){holdC14points[i][1]=100;}
}
for (int i=0;i<TurnoverModelApp.numC14points;i++){
holdC14points[i+1959-1930][0]=TurnoverModelApp.C14points[i][0];
holdC14points[i+1959-1930][1]=TurnoverModelApp.C14points[i][1];
}
TurnoverModelApp.C14points=holdC14points;TurnoverModelApp.numC14points=TurnoverModelApp.numC14point
s+1959-1930;
}
public static double getinitialbergmannpatientC14level(int id){
double init=0;
if(TurnoverModelApp.delay==0){
//Standard Bomb Curve Response
// if (id==0){init=-2;}else if (id==1){init=-2;}else if (id==2){init=-2;}else if (id==3){init=-2;}else if
(id==4){init=25;}else if (id==5){init=847;}
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// else if (id==6){init=689;}else if (id==7){init=667;}else if (id==8){init=426;}else if (id==9){init=248;}else if
(id==10){init=239;}else if (id==11){init=184;}
//Adjusted
if (id==0){init=-2;}else if (id==1){init=-2;}else if (id==2){init=-2;}else if (id==3){init=-2;}else if (id==4){init=2;}else if (id==5){init=835;}
else if (id==6){init=647;}else if (id==7){init=653;}else if (id==8){init=417;}else if (id==9){init=238;}else if
(id==10){init=236;}else if (id==11){init=178;}
}
/* else if (TurnoverModelApp.delay==2){
if (id==0){init=-2;}else if (id==1){init=-2;}else if (id==2){init=-2;}else if (id==3){init=-2;}else if (id==4){init=2;}else if (id==5){init=313;}
else if (id==6){init=884;}else if (id==7){init=792;}else if (id==8){init=570;}else if (id==9){init=300;}else if
(id==10){init=270;}else if (id==11){init=217;}
}*/
//To use lowest C14 values in same year
//if (id==0){init=-2;}else if (id==1){init=-2;}else if (id==2){init=-2;}else if (id==3){init=-2;}else if
(id==4){init=0;}else if (id==5){init=809;}
//else if (id==6){init=639;}else if (id==7){init=639;}else if (id==8){init=402;}else if (id==9){init=230;}else if
(id==10){init=230;}else if (id==11){init=211;}
//To use highest C14 values in same year
//if (id==0){init=-2;}else if (id==1){init=-2;}else if (id==2){init=-2;}else if (id==3){init=-2;}else if
(id==4){init=25;}else if (id==5){init=1000;}
//else if (id==6){init=701;}else if (id==7){init=701;}else if (id==8){init=485;}else if (id==9){init=268;}else if
(id==10){init=272;}else if (id==11){init=176;}
return init;
}

public static void ProduceBergmannData(){
//Use Figure 3d in Bergmann. Best Fit for Scenario A. Continuous Ploidy for Both Delta C14 (Fig 3d) and
Turnover (Supp Tab 1)
double[][] bergmann = new double[12][10];
//0=ID, 1=gender(1=male,0=female), 2=birthyear, 3=ageatdeath, 4=Post-ploidcorrect dC14 (final, measured) from
Bergmann Fig 3d,
//5=AveTurnover%PerYear pre-ploidy correction, AveTurnover(ContinuousPloidization)%PerYear, [7]=PrePloidyCorrected dC14 (Fig 3d, Table S1),
//8=k(DNA synthesis), 9=Pre-ploidcorrect dC14 (final, measured) from Bergmann Fig 3a/3b
bergmann[0][0]=1;bergmann[0][1]=1;bergmann[0][2]=1933.7;bergmann[0][3]=73.25;bergmann[0][4]=21.3;bergmann[
0][5]=0.095;bergmann[0][6]=0.095;bergmann[0][7]=21.3-getinitialbergmannpatientC14level(0);
bergmann[0][8]=79.5;bergmann[0][9]=21.3;
bergmann[1][0]=2;bergmann[1][1]=1;bergmann[1][2]=1939.6;bergmann[1][3]=67.58;bergmann[1][4]=18.84;bergman
n[1][5]=0.085;bergmann[1][6]=0.085;bergmann[1][7]=18.84-getinitialbergmannpatientC14level(1);
bergmann[1][8]=58.7;bergmann[1][9]=18.84;
bergmann[2][0]=3;bergmann[2][1]=1;bergmann[2][2]=1944.6;bergmann[2][3]=62.67;bergmann[2][4]=3.65;bergmann[
2][5]=0.0049;bergmann[2][6]=0.0049;bergmann[2][7]=3.65-getinitialbergmannpatientC14level(2);
bergmann[2][8]=72.2;bergmann[2][9]=3.65;
bergmann[3][0]=4;bergmann[3][1]=1;bergmann[3][2]=1948.6;bergmann[3][3]=58.42;bergmann[3][4]=60;bergmann[3
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][5]=0.54;bergmann[3][6]=0.42;bergmann[3][7]=69.45-getinitialbergmannpatientC14level(3);
bergmann[3][8]=101.5;bergmann[3][9]=80;
bergmann[4][0]=5;bergmann[4][1]=1;bergmann[4][2]=1955.9;bergmann[4][3]=50.83;bergmann[4][4]=40;bergmann[4
][5]=0.79;bergmann[4][6]=0.40;bergmann[4][7]=194.6-getinitialbergmannpatientC14level(4);
bergmann[4][8]=57.4;bergmann[4][9]=185;
bergmann[5][0]=6;bergmann[5][1]=1;bergmann[5][2]=1964.1;bergmann[5][3]=42.75;bergmann[5][4]=515;bergmann[
5][5]=1.58;bergmann[5][6]=1.53;bergmann[5][7]=443.24-getinitialbergmannpatientC14level(5);
bergmann[5][8]=74.0;bergmann[5][9]=455;
bergmann[6][0]=7;bergmann[6][1]=1;bergmann[6][2]=1967.4;bergmann[6][3]=39.83;bergmann[6][4]=455;bergmann[
6][5]=1.36;bergmann[6][6]=1.14;bergmann[6][7]=403.08-getinitialbergmannpatientC14level(6);
bergmann[6][8]=52.7;bergmann[6][9]=405;
bergmann[7][0]=8;bergmann[7][1]=0;bergmann[7][2]=1967.7;bergmann[7][3]=39.00;bergmann[7][4]=405;bergmann[
7][5]=1.65;bergmann[7][6]=1.63;bergmann[7][7]=355.7-getinitialbergmannpatientC14level(7);
bergmann[7][8]=83.1;bergmann[7][9]=360;
bergmann[8][0]=9;bergmann[8][1]=1;bergmann[8][2]=1973.5;bergmann[8][3]=33.75;bergmann[8][4]=330;bergmann[
8][5]=1.48;bergmann[8][6]=1.36;bergmann[8][7]=279.94-getinitialbergmannpatientC14level(8);
bergmann[8][8]=64.5;bergmann[8][9]=280;
bergmann[9][0]=10;bergmann[9][1]=1;bergmann[9][2]=1983.5;bergmann[9][3]=23.75;bergmann[9][4]=200;bergmann
[9][5]=0.90;bergmann[9][6]=0.93;bergmann[9][7]=178.4-getinitialbergmannpatientC14level(9);
bergmann[9][8]=74.5;bergmann[9][9]=180;
bergmann[10][0]=11;bergmann[10][1]=0;bergmann[10][2]=1983.8;bergmann[10][3]=23.00;bergmann[10][4]=195;ber
gmann[10][5]=1.51;bergmann[10][6]=1.48;bergmann[10][7]=167.38getinitialbergmannpatientC14level(10);bergmann[10][8]=68.5;bergmann[10][9]=170;
bergmann[11][0]=12;bergmann[11][1]=0;bergmann[11][2]=1987.2;bergmann[11][3]=20;bergmann[11][4]=155;bergm
ann[11][5]=1.86;bergmann[11][6]=1.87;bergmann[11][7]=141.2getinitialbergmannpatientC14level(11);bergmann[11][8]=67.8;bergmann[11][9]=140;
TurnoverModelApp.Bergmann=bergmann; TurnoverModelApp.numBergmann=12;
}

public static void LoadFig7Histograms() throws IOException{
int maxAnversaAge = 20;
double[][] Histos = new double[maxAnversaAge][7];//0=AgeofCM, 1=M-Yng(%),2=M-Mid(%),3=MOld(%),4=F-Yng(%),5=F-Mid(%),6=F-Old(%)
BufferedReader compIN = null;
try{ compIN = new
BufferedReader(TurnoverModelApp.getfile("/RawDatabase/RawFig7Years"));}catch(FileNotFoundException a){}
for (int q=0;q<maxAnversaAge;q++){Histos[q][0]=Double.parseDouble(compIN.readLine());}
try{ compIN = new
BufferedReader(TurnoverModelApp.getfile("/RawDatabase/RawMYoungFig7"));}catch(FileNotFoundException a){}
for (int q=0;q<maxAnversaAge;q++){Histos[q][1]=Double.parseDouble(compIN.readLine());}
try{ compIN = new
BufferedReader(TurnoverModelApp.getfile("/RawDatabase/RawMMiddleFig7"));}catch(FileNotFoundException a){}
for (int q=0;q<maxAnversaAge;q++){Histos[q][2]=Double.parseDouble(compIN.readLine());}
try{ compIN = new
BufferedReader(TurnoverModelApp.getfile("/RawDatabase/RawMOldFig7"));}catch(FileNotFoundException a){}
for (int q=0;q<maxAnversaAge;q++){Histos[q][3]=Double.parseDouble(compIN.readLine());}
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try{ compIN = new
BufferedReader(TurnoverModelApp.getfile("/RawDatabase/RawFYoungFig7"));}catch(FileNotFoundException a){}
for (int q=0;q<maxAnversaAge;q++){Histos[q][4]=Double.parseDouble(compIN.readLine());}
try{ compIN = new
BufferedReader(TurnoverModelApp.getfile("/RawDatabase/RawFMiddleFig7"));}catch(FileNotFoundException a){}
for (int q=0;q<maxAnversaAge;q++){Histos[q][5]=Double.parseDouble(compIN.readLine());}
try{ compIN = new
BufferedReader(TurnoverModelApp.getfile("/RawDatabase/RawFOldFig7"));}catch(FileNotFoundException a){}
for (int q=0;q<maxAnversaAge;q++){Histos[q][6]=Double.parseDouble(compIN.readLine());}
compIN.close();
TurnoverModelApp.KajsturaFig7Histos=Histos;
TurnoverModelApp.numKajsturaFig7=maxAnversaAge;
}
public static void printpercDC14attributedtoploidybybergmann(){
for (int i=0;i<TurnoverModelApp.numBergmann;i++){
double p = 1-TurnoverModelApp.Bergmann[i][4]/TurnoverModelApp.Bergmann[i][7];
System.out.println(p);
}
}
public static int findpatientindex(int lifespan){
int index=-1;
for (int i=0;i<TurnoverModelApp.numBergmann;i++){
if (lifespan==(int)TurnoverModelApp.Bergmann[i][3]){
index=i;
}
}
return index;
}
public static double getTakamatsuPloidy(int age){
double fa =0;
if (age<22){ //all patient deaths are over age 9
fa=113.6+((135.4-113.6)/(22-9))*(age-9);
}
else if (age>22){
fa=135.4+((148.8-135.4)/(75-22))*(age-22);
}
return fa;
}
}
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package turnovermodel;
import java.io.IOException;
import org.jdesktop.application.Action;
import org.jdesktop.application.ResourceMap;
import org.jdesktop.application.SingleFrameApplication;
import org.jdesktop.application.FrameView;
import org.jdesktop.application.TaskMonitor;
import java.awt.event.ActionEvent;
import java.awt.event.ActionListener;
import java.io.BufferedReader;
import java.io.FileNotFoundException;
import java.util.NoSuchElementException;
import java.util.StringTokenizer;
import javax.swing.Timer;
import javax.swing.Icon;
import javax.swing.JDialog;
import javax.swing.JFrame;
public class TurnoverModelView extends FrameView {
public TurnoverModelView(SingleFrameApplication app) throws IOException {
super(app);
//Do Not Comment-Out the Following Block of Programs, They are Required to Run the Program
initComponents();
TurnoverModelApp.ProduceBergmannData();
TurnoverModelApp.BuildC14bybirthyear();
TurnoverModelApp.LoadFig7Histograms();
//You May Comment-Out These Programs or Erase Comments to Activate the Script for Runtime
//Reproduction of Kajstura Results Using Automaton Model
//ProduceFig1Ecmdepletion(); //Demonstrates Model Apoptosis Module Ability to Reproduce Kajstura
Publication Figure1E (Also Prints Year of 95% Reduction of CM for Comparison to Kajstura)
//HierarchModel10gCompareOnlyApop(); //Shows Apoptosis Module Agreement with Kajstura Publication for
Both Male and Female
//HierarchModel10gCompareOnlyBirthRateFig6b(); //Shows Myocyte Formation with Age for Both Genders
(Compare to Kajstura Figure6b)
//ProduceAnnTurnoverFig6c(); //Shows Turnover (Derived from Myocyte Formation) with Age for Both Genders
(Compare to Kajstura Figure6c)
//GetKajsturaTurnoverDenominatorinHeart();
//ProduceKajsturaModelCMoverTime();
//Vary Kajstura Parameters and View Effect on Kajstura Outputs
//VaryBirthCycleDuration(); //Creates Myocyte Formation Over Patient Age for Both Genders for Various Stem
Cell Progenitor Turnover Levels
// KajsturaModelTurnover(); //Creates Turnover Rates Over Patient Age for Both Genders with Total CM Count
Allowed to Vary (Compares to Reported (Fixed CM) Kajstura Results)
//VaryApopRateforHistograms(); //Creates Myocyte-Age Histograms at Time of Death for Young, Middle-Aged,
and Old Patients (Both Genders) for Various Apoptosis Rates
//VaryHalfLifeforHistograms(); //Creates Myocyte-Age Histograms at Time of Death for Young, Middle-Aged,
and Old Patients (Both Genders) for Various Half-Life Parameters
//VaryExpansionExponentforTurnover(); //Creates Myocyte Formation Over Patient Age for Both Genders for
Various Stem Cell Progenitor Turnover Levels Varying Gt Exponent
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//Reproduce Bergmann Results
//PrintBombFunction(); //Displays Atmospheric C14 Data, CALIbomb website accessed 3/28/2011
(http://calib.qub.ac.uk/CALIBomb/frameset.html). 1-Year Smoothing of Levin Dataset.
//TestHybridModelforBergmann();
//TestScenarioA(); //Converts Published DeltaC14 Values for 12 Patients to Published Scenario A Turnover Rates
//IdentifyBifurcation();
//Evaluate Bergmann
//BergmannSensitivityToTrueTurnover();
//TestPloidy(); //Tests effect of Ploidization Variation
//GlobalFit();
GetC14forScenarioE2();
//GetCMAgeHistogramwithGlobal(); //Manually set turnover parameters of interest

//Combine Bergmann and Kajstura Model Results
//AnversaAgeHistogramforBergmannPatients(); //Generates an Age Histogram for Each of the 12 Bergmann
Patients Based on Their Lifespans
//CompareAversaBergmannPercent(); //Generates a Comparison of Bergmann Ploidy-Corrected Turnover Rates
for the 12 Bergmann Patients and Compares to Modeled (Kajstura Parameterized) Hearts of Same Simulated Birthdates
and Lifespans
//VaryHalfLifeforC14andPerc(); //Computes Annual Turnover Rates for the 12 Bergmann Patients, Modeled by
Automaton with Kajstura Parameters for Various Halflife Parameter Values

// status bar initialization - message timeout, idle icon and busy animation, etc
ResourceMap resourceMap = getResourceMap();
int messageTimeout = resourceMap.getInteger("StatusBar.messageTimeout");
messageTimer = new Timer(messageTimeout, new ActionListener() {
public void actionPerformed(ActionEvent e) {
statusMessageLabel.setText("");
}
});
messageTimer.setRepeats(false);
int busyAnimationRate = resourceMap.getInteger("StatusBar.busyAnimationRate");
for (int i = 0; i < busyIcons.length; i++) {
busyIcons[i] = resourceMap.getIcon("StatusBar.busyIcons[" + i + "]");
}
busyIconTimer = new Timer(busyAnimationRate, new ActionListener() {
public void actionPerformed(ActionEvent e) {
busyIconIndex = (busyIconIndex + 1) % busyIcons.length;
statusAnimationLabel.setIcon(busyIcons[busyIconIndex]);
}
});
idleIcon = resourceMap.getIcon("StatusBar.idleIcon");
statusAnimationLabel.setIcon(idleIcon);
progressBar.setVisible(false);
// connecting action tasks to status bar via TaskMonitor
TaskMonitor taskMonitor = new TaskMonitor(getApplication().getContext());
taskMonitor.addPropertyChangeListener(new java.beans.PropertyChangeListener() {
public void propertyChange(java.beans.PropertyChangeEvent evt) {
String propertyName = evt.getPropertyName();
if ("started".equals(propertyName)) {
if (!busyIconTimer.isRunning()) {
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statusAnimationLabel.setIcon(busyIcons[0]);
busyIconIndex = 0;
busyIconTimer.start();
}
//progressBar.setVisible(true);
progressBar.setIndeterminate(true);
} else if ("done".equals(propertyName)) {
busyIconTimer.stop();
statusAnimationLabel.setIcon(idleIcon);
progressBar.setVisible(false);
progressBar.setValue(0);
} else if ("message".equals(propertyName)) {
String text = (String)(evt.getNewValue());
statusMessageLabel.setText((text == null) ? "" : text);
messageTimer.restart();
} else if ("progress".equals(propertyName)) {
int value = (Integer)(evt.getNewValue());
// progressBar.setVisible(true);
progressBar.setIndeterminate(false);
progressBar.setValue(value);
}
}
});
}
public void ProduceFig1Ecmdepletion() throws IOException{
int agerep = TurnoverModelApp.Agerepetitions;
int startage = TurnoverModelApp.startage+1;
boolean hasbeenfoundmale=false;boolean hasbeenfoundfemale=false;
double[][] maleCMaliveMillion = new double[agerep][2];
maleCMaliveMillion[0][0]=startage;
maleCMaliveMillion[0][1]=TurnoverModelApp.num20yroldMaleCM;
int age=startage;int repetitions = agerep;
for (int i=1;i<repetitions;i++){
maleCMaliveMillion[i][0]=age+1;
double startyearCM = maleCMaliveMillion[i-1][1];
int numAnnualCycles = (int) Math.rint(365*24/TurnoverModelApp.apopdurationhours);
for (int j=0;j<numAnnualCycles;j++){
double apopLost = ApopCMperMillionCM("Male",age)*(startyearCM/Math.pow(10,6));
startyearCM=startyearCM-apopLost;
}
maleCMaliveMillion[i][1]=startyearCM;
if (hasbeenfoundmale==false&&maleCMaliveMillion[i][1]<TurnoverModelApp.num20yroldMaleCM*0.05){
hasbeenfoundmale=true;TurnoverModelApp.male5percAge=maleCMaliveMillion[i][0];
}
age++;
}
double[][] femaleCMaliveMillion = new double[agerep][2];
femaleCMaliveMillion[0][0]=startage;
femaleCMaliveMillion[0][1]=TurnoverModelApp.num20yroldFemaleCM;
age=startage; repetitions = agerep;
for (int i=1;i<repetitions;i++){
femaleCMaliveMillion[i][0]=age+1;
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double startyearCM = femaleCMaliveMillion[i-1][1];
int numAnnualCycles = (int) Math.rint(365*24/TurnoverModelApp.apopdurationhours);
for (int j=0;j<numAnnualCycles;j++){
double apopLost = ApopCMperMillionCM("Female",age)*(startyearCM/Math.pow(10,6));
startyearCM=startyearCM-apopLost;
}
femaleCMaliveMillion[i][1]=startyearCM;
if
(hasbeenfoundfemale==false&&femaleCMaliveMillion[i][1]<TurnoverModelApp.num20yroldFemaleCM*0.05){
hasbeenfoundfemale=true;TurnoverModelApp.female5percAge=femaleCMaliveMillion[i][0];
}
age++;
}
System.out.println("Age of 95% Reduction in CM: "+TurnoverModelApp.male5percAge+"-Male,
"+TurnoverModelApp.female5percAge+"-Female");
double[][] combined = new double[repetitions][3];
for (int k=0;k<repetitions;k++){
combined[k][0]=maleCMaliveMillion[k][0];combined[k][1]=maleCMaliveMillion[k][1];combined[k][2]=femaleCMali
veMillion[k][1];
}
TurnoverModelApp.holddata=combined;
TurnoverModelApp.fileWriter(combined,repetitions , 3, "ApoptosisFig1E");
}
public void AnversaAgeHistogramforBergmannPatients() throws IOException{
double gtmult=1;
int numtoshow = 25;
double[][] data = new double[numtoshow][TurnoverModelApp.numBergmann+1]; //columns are age histograms
(to 25 years) for each patient
for (int i=0;i<numtoshow;i++){data[i][0]=numtoshow-i;}
for (int g=0;g<TurnoverModelApp.numBergmann;g++){
int[] ages =
{(int)TurnoverModelApp.Bergmann[g][3],(int)TurnoverModelApp.Bergmann[g][3],(int)TurnoverModelApp.Bergman
n[g][3]}; //Dummy ages[] to satisfy CompareHistograms
String gender = "Male"; if (TurnoverModelApp.Bergmann[g][1]==0){gender = "Female";}
CompareHistogramsforVariousPatientAges(gender,ages,1.0,gtmult);
for (int i=0;i<numtoshow;i++){
data[i][g+1]=
TurnoverModelApp.holddata2[i+TurnoverModelApp.Agerepetitions+TurnoverModelApp.startage-numtoshow][1];
}
}
TurnoverModelApp.fileWriter(data,numtoshow,TurnoverModelApp.numBergmann+1,"BergmannAgeHistosbyAnvers
a");
}
public double ComputeDeltaC14forConstantTurnover(int patient, double turn, boolean ploidyindependent) throws
IOException{
turn = turn + 0.0; //must be a decimal (int value will cause error)
int birthyear = (int)TurnoverModelApp.Bergmann[patient][2]; int deathyear =
(int)(TurnoverModelApp.Bergmann[patient][2]+(int)TurnoverModelApp.Bergmann[patient][3]);
int lifespan= (int)TurnoverModelApp.Bergmann[patient][3];
double[][] agedist = new double[lifespan][4]; //0=CMage, 3=CMcount at Age
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for (int j=0;j<lifespan;j++){
agedist[j][0]=lifespan-j; //CM Age
if (j>0){agedist[j][3]=turn*Math.pow((1-turn),lifespan-j);}
else if (j==0){agedist[j][3]=Math.pow((1-turn),lifespan);}
}
double[][] riemanndata = TurnoverModelApp.convertHistotoRiemannSum(agedist, deathyear-birthyear);
//riemanndata = agedist;
double[][] data = new double[deathyear-birthyear][3]; //0=AgeofCM, 1=#CMProducedofAge,
2=C14atDateofProduction
for (int i=0;i<deathyear-birthyear;i++){
data[i][0]=riemanndata[i][0];
data[i][1]=riemanndata[i][1];
data[i][2]=GetC14atyear(birthyear+i);
}
double[] aveC14postploidy=new double[lifespan];for (int
w=0;w<lifespan;w++){aveC14postploidy[w]=data[w][2];}
if (ploidyindependent==false){ //remove ploidy
for (int p=0;p<lifespan;p++){ //each cell-age cohort contributes a certain amount of C14. p = year of pt life
double aveC14foragegroup = data[p][2];
for (int q=p;q<lifespan;q++){ //q = years after cell born in patient life p
double percadded = computepersonalizedpolyploidyc14rate(patient, q,1);
aveC14foragegroup = (aveC14foragegroup + percadded*data[q][2])/(1+percadded);
}
data[p][2]=aveC14foragegroup;
}
}

double CMcount=0; double C14count=0;
for (int i=0;i<deathyear-birthyear;i++){
CMcount=CMcount+data[i][1];C14count=C14count+data[i][1]*data[i][2];
}
double aveC14 = C14count/CMcount;
//Normalize for PrintOut
double c1 = 0;double[][] normdata = data;
for (int i=0;i<deathyear-birthyear;i++){c1=c1+normdata[i][1];}
for (int i=0;i<deathyear-birthyear;i++){normdata[i][1]=100*normdata[i][1]/c1;}
TurnoverModelApp.fileWriter(normdata,deathyear-birthyear,3,"/IndividC14/C14"+birthyear+deathyear);
System.out.println(patient+" AveC14 "+aveC14+", DeltaC14 "+(aveC14TurnoverModelApp.getinitialbergmannpatientC14level(patient)));
return aveC14-TurnoverModelApp.getinitialbergmannpatientC14level(patient);
//return (aveC14-GetC14atyear((double)(birthyear)));
}

public void VaryBirthCycleDuration() throws IOException{
double holdbirthcycle = TurnoverModelApp.cyclelengthhours;
//Datafile = A=Age, B=CM(CycLengthFactor=1/2), B=CM(CycLengthFactor=1), C=CM(CycLengthFactor=3/2)
double[][] data = new double[TurnoverModelApp.Agerepetitions][4];
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for (int p=1;p<=3;p++){
TurnoverModelApp.cyclelengthhours=holdbirthcycle*(0.5*p);
HierarchicalModel10g("Male",false,true,false,1,1,1);
for (int i=1;i<TurnoverModelApp.Agerepetitions;i++){
data[i][p]=TurnoverModelApp.holddata[i][7];
if(p==1){data[i][0]=TurnoverModelApp.holddata[i][0];}
}
}
TurnoverModelApp.fileWriter(data, TurnoverModelApp.Agerepetitions, 4, "VaryBirthRate-M");
TurnoverModelApp.cyclelengthhours=holdbirthcycle;
data = new double[TurnoverModelApp.Agerepetitions][4];
for (int p=1;p<=3;p++){
TurnoverModelApp.cyclelengthhours=holdbirthcycle*(0.5*p);
HierarchicalModel10g("Female",false,true,false,1,1,1);
for (int i=1;i<TurnoverModelApp.Agerepetitions;i++){
data[i][p]=TurnoverModelApp.holddata[i][7];
if(p==1){data[i][0]=TurnoverModelApp.holddata[i][0];}
}
}
TurnoverModelApp.fileWriter(data, TurnoverModelApp.Agerepetitions, 4, "VaryBirthRate-F");
TurnoverModelApp.cyclelengthhours=holdbirthcycle;
}

public void ProduceAnnTurnoverFig6c() throws IOException{
//Comparing Kajstura Fig 6
boolean allowapop=false;
TurnoverModelApp.curmethod="AllowNumCellstoFluctuate";allowapop=true; //Comment out if testing Kajstura
turnover as done in paper (turnover=new cells/constant old cells), allow if testing turnover = new cells/fluctuating old
cells
//Hierchical Model Params: String gender,boolean includeapop,boolean includebirth, boolean
includeCMsen,double gtmult, double apopfractmult,double apopdurationmult
//Datafile = A=Age, B=M-KajsturaAnnCMTurnover%,C=M-MyModelAnnCMTurnover%,D=FKajsturaAnnCMTurnover%,E=F-MyModelAnnCMTurnover%
int rep=TurnoverModelApp.Agerepetitions;double[][] data = new double[rep][5];
//Test My Model
HierarchicalModel10g("Male",allowapop,true,false,.8,1,1); //GT, Apop Fract, ApopDur
data[0][0]=TurnoverModelApp.holddata[0][0];data[0][2]=TurnoverModelApp.holddata[0][6];
for (int
i=1;i<rep;i++){data[i][0]=TurnoverModelApp.holddata[i][0];data[i][2]=TurnoverModelApp.holddata[i][6];}
HierarchicalModel10g("Female",allowapop,true,false,.8,1,1);
data[0][4]=TurnoverModelApp.holddata[0][6];
for (int i=1;i<rep;i++){data[i][4]=TurnoverModelApp.holddata[i][6];}
//Test Kajstura Model
for (int i=0;i<rep;i++){
data[i][1]=AnnTurnoverCombinedModel("Male",data[i][0]);
data[i][3]=AnnTurnoverCombinedModel("Female",data[i][0]);
}
TurnoverModelApp.fileWriter(data, rep, 5, "Figure6C");
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}
public void ProduceKajsturaModelCMoverTime() throws IOException{
//Compare Effect of Apoptosis, Senescence, and Birth
//Datafile = A=Age, B=CM(OnlyApop), C=CM(Apop,Birth), D=CM(Apop,Birth,Senescence)
int rep=TurnoverModelApp.Agerepetitions;double[][] data = new double[rep][5];
HierarchicalModel10g("Male",true,false,false,1,1,1);
data[0][0]=TurnoverModelApp.holddata[0][0];data[0][1]=TurnoverModelApp.num20yroldMaleCM10g;
for (int
i=1;i<rep;i++){data[i][0]=TurnoverModelApp.holddata[i][0]+1;data[i][1]=TurnoverModelApp.holddata[i][5];}
HierarchicalModel10g("Male",true,true,false,1,1,1);
data[0][0]=TurnoverModelApp.holddata[0][0];data[0][2]=TurnoverModelApp.num20yroldMaleCM10g;
for (int i=1;i<rep;i++){data[i][2]=TurnoverModelApp.holddata[i][5];}
HierarchicalModel10g("Male",true,true,true,1,1,1);
data[0][0]=TurnoverModelApp.holddata[0][0];data[0][3]=TurnoverModelApp.num20yroldMaleCM10g;
for (int i=1;i<rep;i++){data[i][3]=TurnoverModelApp.holddata[i][5];}
TurnoverModelApp.fileWriter(data, rep, 4, "KajsturaModel-M");
HierarchicalModel10g("Female",true,false,false,1,1,1);
data[0][0]=TurnoverModelApp.holddata[0][0];data[0][1]=TurnoverModelApp.num20yroldFemaleCM10g;
for (int
i=1;i<rep;i++){data[i][0]=TurnoverModelApp.holddata[i][0];data[i][1]=TurnoverModelApp.holddata[i][5];}
HierarchicalModel10g("Female",true,true,false,1,1,1);
data[0][0]=TurnoverModelApp.holddata[0][0];data[0][2]=TurnoverModelApp.num20yroldFemaleCM10g;
for (int i=1;i<rep;i++){data[i][2]=TurnoverModelApp.holddata[i][5];}
HierarchicalModel10g("Female",true,true,true,1,1,1);
data[0][0]=TurnoverModelApp.holddata[0][0];data[0][3]=TurnoverModelApp.num20yroldFemaleCM10g;
for (int i=1;i<rep;i++){data[i][3]=TurnoverModelApp.holddata[i][5];}
TurnoverModelApp.fileWriter(data, rep, 4, "KajsturaModel-F");
}
public void HierarchModel10gCompareOnlyApop() throws IOException{
//Comparing Kajstura Fig 1
//Datafile = A=Age, B=M-KajsturaApopScaled10g,C=M-MyModelApop10g,D=F-KajsturaApopScaled10g,E=FMyModelApop10g
int rep=TurnoverModelApp.Agerepetitions;double[][] data = new double[rep][5];
double holdnum20yearoldMaleCM=TurnoverModelApp.num20yroldMaleCM;
double holdnum20yearoldFemaleCM=TurnoverModelApp.num20yroldFemaleCM;
//Test Kajstura Models Scaled to 10g
TurnoverModelApp.num20yroldMaleCM=TurnoverModelApp.num20yroldMaleCM10g;
TurnoverModelApp.num20yroldFemaleCM=TurnoverModelApp.num20yroldFemaleCM10g;
ProduceFig1Ecmdepletion();//Holdata COL0=age,COL1=maleWholeHeart,COL2=femaleWholeHeart
boolean malefound=false; boolean femalefound=false;double
malestartCM=TurnoverModelApp.holddata[0][1];double femalestartCM=TurnoverModelApp.holddata[0][2];
for (int i=0;i<rep;i++){
data[i][0]=TurnoverModelApp.holddata[i][0];data[i][1]=TurnoverModelApp.holddata[i][1];data[i][3]=TurnoverModel
App.holddata[i][2];
if
(TurnoverModelApp.holddata[i][1]<0.05*malestartCM&&!malefound){malefound=true;System.out.println("Kajstura
Model Male 5% Year = "+data[i][0]);}
if
(TurnoverModelApp.holddata[i][2]<0.05*femalestartCM&&!femalefound){femalefound=true;System.out.println("Kaj
stura Model Female 5% Year = "+data[i][0]);}
}
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HierarchicalModel10g("Male",true,false,false,1,1,1);
boolean found = false;double startCM = TurnoverModelApp.holddata[0][4];
for (int i=0;i<rep;i++){data[i][2]=TurnoverModelApp.holddata[i][4];
if (TurnoverModelApp.holddata[i][4]<0.05*startCM&&!found){found=true;System.out.println("My Model
Male 5% Year = "+data[i][0]);}
}
HierarchicalModel10g("Female",true,false,false,1,1,1);
found = false; startCM = TurnoverModelApp.holddata[0][4];
for (int i=0;i<rep;i++){data[i][4]=TurnoverModelApp.holddata[i][4];
if (TurnoverModelApp.holddata[i][4]<0.05*startCM&&!found){found=true;System.out.println("My Model
Female 5% Year = "+data[i][0]);}
}
TurnoverModelApp.fileWriter(data, rep, 5, "CompareModelsofApopAlone");
TurnoverModelApp.num20yroldMaleCM=holdnum20yearoldMaleCM;
TurnoverModelApp.num20yroldFemaleCM=holdnum20yearoldFemaleCM;
}
public void HierarchModel10gCompareOnlyBirthRateFig6b() throws IOException{
//Comparing Kajstura Fig 6
//Datafile = A=Age, B=M-KajsturaAnnCMform10g/Million,C=M-MyModelAnnCMform10g/Million,D=FKajsturaAnnCMform10g/Million,E=F-MyModelAnnCMform10g/Million
int rep=TurnoverModelApp.Agerepetitions;double[][] data = new double[rep][5];
//Test My Model
HierarchicalModel10g("Male",false,true,false,1,1,1);
double startCM = TurnoverModelApp.holddata[0][4];
data[0][0]=TurnoverModelApp.holddata[0][0];data[0][2]=TurnoverModelApp.holddata[0][4]-startCM;
for (int
i=1;i<rep;i++){data[i][0]=TurnoverModelApp.holddata[i][0];data[i][2]=(TurnoverModelApp.holddata[i][3]TurnoverModelApp.holddata[i-1][3])/Math.pow(10,6);}
HierarchicalModel10g("Female",false,true,false,1,1,1);
startCM = TurnoverModelApp.holddata[0][4];
data[0][4]=TurnoverModelApp.holddata[0][4]-startCM;
for (int i=1;i<rep;i++){data[i][4]=(TurnoverModelApp.holddata[i][3]-TurnoverModelApp.holddata[i1][3])/Math.pow(10,6);}
//Test Kajstura Model
for (int i=0;i<rep;i++){
data[i][1]=MillionsMyocyteFormationCombinedModelPer10gPerYear("Male",data[i][0]);
data[i][3]=MillionsMyocyteFormationCombinedModelPer10gPerYear("Female",data[i][0]);
}
TurnoverModelApp.fileWriter(data, rep, 5, "CompareModelsofBirthAlone");
}
public void KajsturaModelTurnover() throws IOException{
int rep=TurnoverModelApp.Agerepetitions;double[][] data = new double[rep][7];
//Datefile = A=age,B=PublishedTurnover,C=BirthRate/MyModelCellsinHeart
String gender = "Male";
HierarchicalModel10g(gender,true,true,true,1,1,1);
for (int i=0;i<rep;i++){
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data[i][0]=TurnoverModelApp.holddata[i][0];
data[i][1]=AnnTurnoverCombinedModel(gender,data[i][0]);
data[i][2]=100*TurnoverModelApp.holddata[i][7]/TurnoverModelApp.holddata[i][2];
}
gender = "Female";
HierarchicalModel10g(gender,true,true,true,1,1,1);
for (int i=0;i<rep;i++){
data[i][4]=TurnoverModelApp.holddata[i][0];
data[i][5]=AnnTurnoverCombinedModel(gender,data[i][0]);
data[i][6]=100*TurnoverModelApp.holddata[i][7]/TurnoverModelApp.holddata[i][2];
}
TurnoverModelApp.fileWriter(data,rep,7,"TurnoverComparison");
}
public void VaryApopRateforHistograms() throws IOException{
double gtmult=1;
int numtoshow = 25;double[][] data = new double[numtoshow][10]; //0=Age(25->1),1=Y-80%,2=Y-100%,3=Y120%,4=M-80%,5=M-100%,6=M-120%,7=O-80%,8=O-100%,9=O-120%
double holdapop = TurnoverModelApp.apopdurationhours;
for (int i=0;i<numtoshow;i++){data[i][0]=numtoshow-i;}
String gender = "Male"; int[] ages = new int[3]; ages[0]=49;ages[1]=69;ages[2]=74;
TurnoverModelApp.apopdurationhours=holdapop*0.8;
CompareHistogramsforVariousPatientAges(gender,ages,1,gtmult);
for (int i=0;i<numtoshow;i++){
data[i][1]= TurnoverModelApp.holddata2[i+TurnoverModelApp.Agerepetitions+TurnoverModelApp.startagenumtoshow][1];
data[i][4]= TurnoverModelApp.holddata2[i+TurnoverModelApp.Agerepetitions+TurnoverModelApp.startagenumtoshow][2];
data[i][7]= TurnoverModelApp.holddata2[i+TurnoverModelApp.Agerepetitions+TurnoverModelApp.startagenumtoshow][3];
}
TurnoverModelApp.apopdurationhours=holdapop*1.0;
CompareHistogramsforVariousPatientAges(gender,ages,1,gtmult);
for (int i=0;i<numtoshow;i++){
data[i][2]= TurnoverModelApp.holddata2[i+TurnoverModelApp.Agerepetitions+TurnoverModelApp.startagenumtoshow][1];
data[i][5]= TurnoverModelApp.holddata2[i+TurnoverModelApp.Agerepetitions+TurnoverModelApp.startagenumtoshow][2];
data[i][8]= TurnoverModelApp.holddata2[i+TurnoverModelApp.Agerepetitions+TurnoverModelApp.startagenumtoshow][3];
}
TurnoverModelApp.apopdurationhours=holdapop*1.2;
CompareHistogramsforVariousPatientAges(gender,ages,1,gtmult);
for (int i=0;i<numtoshow;i++){
data[i][3]= TurnoverModelApp.holddata2[i+TurnoverModelApp.Agerepetitions+TurnoverModelApp.startagenumtoshow][1];
data[i][6]= TurnoverModelApp.holddata2[i+TurnoverModelApp.Agerepetitions+TurnoverModelApp.startagenumtoshow][2];
data[i][9]= TurnoverModelApp.holddata2[i+TurnoverModelApp.Agerepetitions+TurnoverModelApp.startagenumtoshow][3];
}
TurnoverModelApp.fileWriter(data,numtoshow,10,"VaryApopHistogram-M");
gender = "Female"; ages = new int[3]; ages[0]=49;ages[1]=69;ages[2]=80;
TurnoverModelApp.apopdurationhours=holdapop*0.8;
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CompareHistogramsforVariousPatientAges(gender,ages,1,gtmult);
for (int i=0;i<numtoshow;i++){
data[i][1]= TurnoverModelApp.holddata2[i+TurnoverModelApp.Agerepetitions+TurnoverModelApp.startagenumtoshow][1];
data[i][4]= TurnoverModelApp.holddata2[i+TurnoverModelApp.Agerepetitions+TurnoverModelApp.startagenumtoshow][2];
data[i][7]= TurnoverModelApp.holddata2[i+TurnoverModelApp.Agerepetitions+TurnoverModelApp.startagenumtoshow][3];
}
TurnoverModelApp.apopdurationhours=holdapop*1.0;
CompareHistogramsforVariousPatientAges(gender,ages,1,gtmult);
for (int i=0;i<numtoshow;i++){
data[i][2]= TurnoverModelApp.holddata2[i+TurnoverModelApp.Agerepetitions+TurnoverModelApp.startagenumtoshow][1];
data[i][5]= TurnoverModelApp.holddata2[i+TurnoverModelApp.Agerepetitions+TurnoverModelApp.startagenumtoshow][2];
data[i][8]= TurnoverModelApp.holddata2[i+TurnoverModelApp.Agerepetitions+TurnoverModelApp.startagenumtoshow][3];
}
TurnoverModelApp.apopdurationhours=holdapop*1.2;
CompareHistogramsforVariousPatientAges(gender,ages,1,gtmult);
for (int i=0;i<numtoshow;i++){
data[i][3]= TurnoverModelApp.holddata2[i+TurnoverModelApp.Agerepetitions+TurnoverModelApp.startagenumtoshow][1];
data[i][6]= TurnoverModelApp.holddata2[i+TurnoverModelApp.Agerepetitions+TurnoverModelApp.startagenumtoshow][2];
data[i][9]= TurnoverModelApp.holddata2[i+TurnoverModelApp.Agerepetitions+TurnoverModelApp.startagenumtoshow][3];
}
TurnoverModelApp.fileWriter(data,numtoshow,10,"VaryApopHistogram-F");
TurnoverModelApp.apopdurationhours=holdapop*1.0;
}
public void VaryHalfLifeforHistograms() throws IOException{
double gtmult=1;
int numtoshow = 25;double[][] data = new double[numtoshow][10]; //0=Age(25->1),1=Y-80%,2=Y-100%,3=Y120%,4=M-80%,5=M-100%,6=M-120%,7=O-80%,8=O-100%,9=O-120%
for (int i=0;i<numtoshow;i++){data[i][0]=numtoshow-i;}
String gender = "Male"; int[] ages = new int[3]; ages[0]=49;ages[1]=69;ages[2]=74;
CompareHistogramsforVariousPatientAges(gender,ages,0.8,gtmult);
for (int i=0;i<numtoshow;i++){
data[i][1]= TurnoverModelApp.holddata2[i+TurnoverModelApp.Agerepetitions+TurnoverModelApp.startagenumtoshow][1];
data[i][4]= TurnoverModelApp.holddata2[i+TurnoverModelApp.Agerepetitions+TurnoverModelApp.startagenumtoshow][2];
data[i][7]= TurnoverModelApp.holddata2[i+TurnoverModelApp.Agerepetitions+TurnoverModelApp.startagenumtoshow][3];
}
CompareHistogramsforVariousPatientAges(gender,ages,1.0,gtmult);
for (int i=0;i<numtoshow;i++){
data[i][2]= TurnoverModelApp.holddata2[i+TurnoverModelApp.Agerepetitions+TurnoverModelApp.startagenumtoshow][1];
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data[i][5]= TurnoverModelApp.holddata2[i+TurnoverModelApp.Agerepetitions+TurnoverModelApp.startagenumtoshow][2];
data[i][8]= TurnoverModelApp.holddata2[i+TurnoverModelApp.Agerepetitions+TurnoverModelApp.startagenumtoshow][3];
}
CompareHistogramsforVariousPatientAges(gender,ages,1.2,gtmult);
for (int i=0;i<numtoshow;i++){
data[i][3]= TurnoverModelApp.holddata2[i+TurnoverModelApp.Agerepetitions+TurnoverModelApp.startagenumtoshow][1];
data[i][6]= TurnoverModelApp.holddata2[i+TurnoverModelApp.Agerepetitions+TurnoverModelApp.startagenumtoshow][2];
data[i][9]= TurnoverModelApp.holddata2[i+TurnoverModelApp.Agerepetitions+TurnoverModelApp.startagenumtoshow][3];
}
TurnoverModelApp.fileWriter(data,numtoshow,10,"VaryHLhistogram-M");
gender = "Female"; ages = new int[3]; ages[0]=49;ages[1]=69;ages[2]=80;
CompareHistogramsforVariousPatientAges(gender,ages,0.8,gtmult);
for (int i=0;i<numtoshow;i++){
data[i][1]= TurnoverModelApp.holddata2[i+TurnoverModelApp.Agerepetitions+TurnoverModelApp.startagenumtoshow][1];
data[i][4]= TurnoverModelApp.holddata2[i+TurnoverModelApp.Agerepetitions+TurnoverModelApp.startagenumtoshow][2];
data[i][7]= TurnoverModelApp.holddata2[i+TurnoverModelApp.Agerepetitions+TurnoverModelApp.startagenumtoshow][3];
}
CompareHistogramsforVariousPatientAges(gender,ages,1.0,gtmult);
for (int i=0;i<numtoshow;i++){
data[i][2]= TurnoverModelApp.holddata2[i+TurnoverModelApp.Agerepetitions+TurnoverModelApp.startagenumtoshow][1];
data[i][5]= TurnoverModelApp.holddata2[i+TurnoverModelApp.Agerepetitions+TurnoverModelApp.startagenumtoshow][2];
data[i][8]= TurnoverModelApp.holddata2[i+TurnoverModelApp.Agerepetitions+TurnoverModelApp.startagenumtoshow][3];
}
CompareHistogramsforVariousPatientAges(gender,ages,1.2,gtmult);
for (int i=0;i<numtoshow;i++){
data[i][3]= TurnoverModelApp.holddata2[i+TurnoverModelApp.Agerepetitions+TurnoverModelApp.startagenumtoshow][1];
data[i][6]= TurnoverModelApp.holddata2[i+TurnoverModelApp.Agerepetitions+TurnoverModelApp.startagenumtoshow][2];
data[i][9]= TurnoverModelApp.holddata2[i+TurnoverModelApp.Agerepetitions+TurnoverModelApp.startagenumtoshow][3];
}
TurnoverModelApp.fileWriter(data,numtoshow,10,"VaryHLhistogram-F");
}
public void VaryHalfLifeforC14andPerc() throws IOException{
double hmult = 1.0;//halflife,
double gtmult=1.0;//expansion exponent
CompareAversaBergmannPercent(hmult,gtmult);//hmult, gtmult
}

168

public void CompareHistogramsforVariousPatientAges(String gender,int[] ages,double halflifemultiplier,double
gtmult) throws IOException{
double[][] data = new double[TurnoverModelApp.Agerepetitions+TurnoverModelApp.startage+50][4];
for (int
i=0;i<TurnoverModelApp.Agerepetitions+TurnoverModelApp.startage;i++){data[i][0]=TurnoverModelApp.Agerepetit
ions+TurnoverModelApp.startage-i;}
//Age Selection is Very Critical to Fit with Anversa Figure 7
int patientage=ages[0];
ComputeAgeHistograms(gender,patientage,halflifemultiplier,gtmult,1,true);
int start=TurnoverModelApp.Agerepetitions+TurnoverModelApp.startage-patientage;
for (int i=start;i<start+patientage;i++){data[i][1]=TurnoverModelApp.holddata[i-start][3];}
patientage=ages[1];
ComputeAgeHistograms(gender,patientage,halflifemultiplier,gtmult,1,true);
start=TurnoverModelApp.Agerepetitions+TurnoverModelApp.startage-patientage;
for (int i=start;i<start+patientage;i++){data[i][2]=TurnoverModelApp.holddata[i-start][3];}
patientage=ages[2];
ComputeAgeHistograms(gender,patientage,halflifemultiplier,gtmult,1,true);
start=TurnoverModelApp.Agerepetitions+TurnoverModelApp.startage-patientage;
for (int i=start;i<start+patientage;i++){data[i][3]=TurnoverModelApp.holddata[i-start][3];}
//Normalize to %
double c1 = 0; double c2=0; double c3=0;
for (int
i=0;i<TurnoverModelApp.Agerepetitions+TurnoverModelApp.startage+50;i++){c1=c1+data[i][1];c2=c2+data[i][2];c3
=c3+data[i][3];}
for (int
i=0;i<TurnoverModelApp.Agerepetitions+TurnoverModelApp.startage+50;i++){data[i][1]=100*data[i][1]/c1;data[i][2
]=100*data[i][2]/c2;data[i][3]=100*data[i][3]/c3;}
TurnoverModelApp.holddata2=data;TurnoverModelApp.holdnumrows2=TurnoverModelApp.Agerepetitions+Turnove
rModelApp.startage;
TurnoverModelApp.fileWriter(data,TurnoverModelApp.Agerepetitions+TurnoverModelApp.startage,4,"HistogrambyP
atientAge");
}
public double ComputeAveC14atDeath(int patient, String gender, int patientbirthyear,int patientdeathyear,double
hmult,double gtmult, double apopmultfract,boolean recompute) throws IOException{
//Turn on for Anversa Histograms and Off for Bergmann
if (recompute){
ComputeAgeHistograms(gender,patientdeathyear-patientbirthyear,hmult,gtmult,apopmultfract,true);
}
double[][] riemanndata = TurnoverModelApp.convertHistotoRiemannSum(TurnoverModelApp.holddata,
patientdeathyear-patientbirthyear);
double[][] data = new double[patientdeathyear-patientbirthyear][3]; //0=AgeofCM, 1=#CMProducedofAge,
2=C14atDateofProduction
for (int i=0;i<patientdeathyear-patientbirthyear;i++){
data[i][0]=riemanndata[i][0];
data[i][1]=riemanndata[i][1];
data[i][2]=GetC14atyear(patientbirthyear+i);
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}
data[0][2]=TurnoverModelApp.getinitialbergmannpatientC14level(patient);
//TurnoverModelApp.fileWriter(data,patientdeathyear-patientbirthyear,3,"C14forPatient");
double CMcount=0; double C14count=0;
for (int i=0;i<patientdeathyear-patientbirthyear;i++){
CMcount=CMcount+data[i][1];C14count=C14count+data[i][1]*data[i][2];
}
double aveC14 = C14count/CMcount;
System.out.println(aveC14);
//System.out.println("Delta C14: "+(aveC14-GetC14atyear((double)(patientbirthyear))));
//Normalize for PrintOut
double c1 = 0;double[][] normdata = data;
for (int i=0;i<patientdeathyear-patientbirthyear;i++){c1=c1+normdata[i][1];}
for (int i=0;i<patientdeathyear-patientbirthyear;i++){normdata[i][1]=100*normdata[i][1]/c1;}
TurnoverModelApp.fileWriter(normdata,patientdeathyearpatientbirthyear,3,"/IndividC14/C14"+patientbirthyear+patientdeathyear);
return aveC14;
}
public void CompareAnversaBergmannC14(double hmult, double gtmult) throws IOException{
//double hmult=1.0;double gtmult=1.0;
double[][] patients = new double[12][3]; //Patient,Bergmann Raw Delta C14,AnversaPredictedDeltaC14
String gender="";
for (int i=0;i<12;i++){
patients[i][0]=TurnoverModelApp.Bergmann[i][0];
patients[i][1]=TurnoverModelApp.Bergmann[i][7];
if (TurnoverModelApp.Bergmann[i][1]==1){gender="Male";}else if
(TurnoverModelApp.Bergmann[i][1]==0){gender="Female";}else{System.out.println("Gender
Error"+TurnoverModelApp.Bergmann[i][2]);}
patients[i][2]=ComputeAveC14atDeath(i,gender,(int)TurnoverModelApp.Bergmann[i][2],(int)(TurnoverModelApp.Be
rgmann[i][2]+TurnoverModelApp.Bergmann[i][3]),hmult,gtmult,1,true);
patients[i][2]=patients[i][2]-TurnoverModelApp.getinitialbergmannpatientC14level(i);
// patients[i][2]=patients[i][2]-GetC14atyear(TurnoverModelApp.Bergmann[i][2]);
}
TurnoverModelApp.fileWriter(patients,12,3,"BergmannAnversaC14");
TurnoverModelApp.holddata=patients;TurnoverModelApp.holdnumrows=12;
}
public void CompareAversaBergmannPercent(double hmult, double gtmult) throws IOException{
CompareAnversaBergmannC14(hmult, gtmult);
double[][] data = new double[12][3]; //patient, Bergmann Reported %, Anversa-Produced Bergmann
double C14multiplier=1.0;
for (int i=0;i<12;i++){
data[i][0]=TurnoverModelApp.Bergmann[i][0];
data[i][1]=TurnoverModelApp.Bergmann[i][6];
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data[i][2]=100*TurnDeltaC14intoScenarioATurnover(i,(int)TurnoverModelApp.Bergmann[i][2],(int)TurnoverModelA
pp.Bergmann[i][3],C14multiplier*TurnoverModelApp.holddata[i][2],TurnoverModelApp.initguess,true,1.0,0);
}
System.out.println("Finished");
TurnoverModelApp.fileWriter(data,12,3,"BergmannAnversaPerc");
}

public void ComputeAgeHistograms(String gender, int patientage,double halflifemultiplier,double gtmult,double
apopfractmult, boolean addploidy) throws IOException{
double BergmannTurnover=0.01;double cellsinheart=500000000;
boolean senescencebool = false; //normally true, try false for trajectories
double[][] CMbyAge = new double[patientage][4];//0=AgeofCM, 1=Number of Age Births,2=N(a) No Apop
Funct, 3=N(a)
//false turns off apoptosis so it can be handled with random kill applied to previous cycles below
HierarchicalModel10g(gender,false,true,senescencebool,gtmult,1,1);
for (int i=0;i<patientage;i++){CMbyAge[i][0]=patientage-i;}
///for (int i=0;i<patientage;i++){CMbyAge[i][1]=TurnoverModelApp.holddata[i][7];} //For Kajstura
//Make constant to match Bergmann (or age declining)
for (int i=0;i<patientage;i++){CMbyAge[i][1]=BergmannTurnover*cellsinheart;} //New CM in Year
for (int i=0;i<patientage;i++){
double n = 500*Math.pow(10,6);
//n = TurnoverModelApp.holddata[i][2]; //Total Myocyte Count Allowed to Vary with Age, Comment Out to
Fix CM count at 500 Million
double a=CMbyAge[i][0]; //a = age of CM at TIME OF DEATH
double h;
h = TimetoSenescence(gender,i)/2; //Variable is required for older patients to have young CM. Reverse if h is
constant
h = h*halflifemultiplier; //usually 1.0
CMbyAge[i][2]=n*Math.exp(-1*((Math.pow(a,2))/(2*Math.pow(h,2))));CMbyAge[i][3]=CMbyAge[i][2];
for (int j=0;j<=i;j++){
double deathcyclesperyear = 365*24/TurnoverModelApp.apopdurationhours;
for (int k=0;k<=deathcyclesperyear;k++){
CMbyAge[i][3] = CMbyAge[i][3](CMbyAge[j][2])*apopfractmult*ApopCMperMillionCM(gender,i)/Math.pow(10,6); //using i instead of j means i
takes all death
}
}
if (CMbyAge[i][3]<0){CMbyAge[i][3]=0;}
}//patientage for loop
if (addploidy){ //Worst Case Scenario For Concordance - Adds All Ploidy to End
double TetraPerc = AnversaPloidyLinear4n(gender,patientage);double
OctaPerc=AnversaPloidyLinear8n(gender,patientage);
CMbyAge[patientage-1][3]=CMbyAge[patientage1][3]+TetraPerc*TurnoverModelApp.holddata[patientage-1][2]+2*OctaPerc*TurnoverModelApp.holddata[patientage1][2];
}
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TurnoverModelApp.holddata=CMbyAge;TurnoverModelApp.holdnumrows=patientage;
TurnoverModelApp.fileWriter(CMbyAge,patientage,4,"AgeHistogram");
}
public void HierarchicalModel10g(String gender,boolean includeapop,boolean includebirth, boolean
includeCMsen,double gtmult, double apopfractmult,double apopdurationmult) throws IOException{
// System.out.println("GTmult"+gtmult);
int Agerepetitions = TurnoverModelApp.Agerepetitions;
int startage = TurnoverModelApp.startage;
double[][] CellTypesByAge = new double[Agerepetitions][8];
//0=Age,1=FunctCompCSCs,2=StartingCM,3=CMafterBirths,4=CMafterapop,5=CMafterCMSenescence(afterApopC
M),6=PercTurnOver,7=NewCMinYear
double cyclemult = 1;
CellTypesByAge[0][0]=startage;
CellTypesByAge[0][1]=CSCper10gram(gender,startage);
if (gender.equals("Male")){CellTypesByAge[0][2] =
TurnoverModelApp.num20yroldMaleCM10g;}else{CellTypesByAge[0][2] =
TurnoverModelApp.num20yroldFemaleCM10g;}
if (gender.equals("Male")){CellTypesByAge[0][3] =
TurnoverModelApp.num20yroldMaleCM10g;}else{CellTypesByAge[0][3] =
TurnoverModelApp.num20yroldFemaleCM10g;}
if (gender.equals("Male")){CellTypesByAge[0][4] =
TurnoverModelApp.num20yroldMaleCM10g;}else{CellTypesByAge[0][4] =
TurnoverModelApp.num20yroldFemaleCM10g;}
if (gender.equals("Male")){CellTypesByAge[0][5] =
TurnoverModelApp.num20yroldMaleCM10g;}else{CellTypesByAge[0][5] =
TurnoverModelApp.num20yroldFemaleCM10g;}
startage++;
double CMbirthsPerCycle=0; double FunctCSCs=0;int deathcyclesperbirthcycle =
(int)Math.rint((cyclemult*TurnoverModelApp.cyclelengthhours)/(apopdurationmult*TurnoverModelApp.apopduration
hours));
int cyclesperyear=(int) Math.rint(365*24/(cyclemult*TurnoverModelApp.cyclelengthhours));
for (int i=1;i<Agerepetitions;i++){
CellTypesByAge[i][7]=0; //NewCMinYear
CellTypesByAge[i][0]=startage;
//Starting CM = Last End (After Birth and Apop Removal but BEFORE Senescence BC Senescence is
Measured Percent Found So Not Iterative)
CellTypesByAge[i][2]=CellTypesByAge[i-1][4];
//Prior to Birth/Death, Initialize to Start
CellTypesByAge[i][3]=CellTypesByAge[i][2];
CellTypesByAge[i][4]=CellTypesByAge[i][3]; //Initialize Prior to Apop
CellTypesByAge[i][5]=CellTypesByAge[i][4]*(1-PercP16ink4aPositiveCM(gender,startage)/100);;
for (int b=0;b<cyclesperyear;b++){ //Assumes CMbirthsPerCycle is constant throughout year
FunctCSCs=FunctCompCSCsper10g(gender,startage);
double LCCs = Math.pow(2,0)*FunctCSCs; //Right Now, No Expansion for LCC. All in Gt
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double PercCycling =
(CSCper10gram(gender,startage)*PercOfCSCcycling(gender,startage)/(FunctCompCSCsper10g(gender,startage)))/100
;
//Don't divide by cycle length since per cycle
double gt = GTbyAge(gender,startage)*gtmult;
CMbirthsPerCycle =PercCycling*LCCs*Math.pow(2,gt);
//System.out.println(gt+" "+CMbirthsPerCycle);
//CMafterBirths
if (includebirth==true){
CellTypesByAge[i][3]=CellTypesByAge[i][3]+CMbirthsPerCycle;
CellTypesByAge[i][4]=CellTypesByAge[i][4]+CMbirthsPerCycle;
CellTypesByAge[i][5]=CellTypesByAge[i][5]+CMbirthsPerCycle;
CellTypesByAge[i][7]=CellTypesByAge[i][7]+CMbirthsPerCycle;//NewCMinYear Explicitly
}
//Subtract Apoptosis (Assumes apop cycle < prolif cycle)
//Assumes only CM apoptose
//Assumes Birth Occurs Before Apoptosis Starts & Newly Born CM Can't be Killed Right Away
if (includeapop==true){
for (int p=0;p<deathcyclesperbirthcycle;p++){
CellTypesByAge[i][4]=CellTypesByAge[i][4](apopfractmult*ApopCMperMillionCM(gender,startage)*(CellTypesByAge[i][4]/Math.pow(10,6)));
}
}
//Scale for Senescence of MYOCYTES after Birth and Apoptosis
if (includeCMsen==true){
CellTypesByAge[i][5]=CellTypesByAge[i][4]*(1-PercP16ink4aPositiveCM(gender,startage)/100);
}
}
//Compute Turnover
double CMper10g=0;
//If Assumption of Constant Denominator (500 Million CM per 10g)
if
(gender.equals("Male")){CMper10g=TurnoverModelApp.num20yroldMaleCM10g;}else{CMper10g=TurnoverModel
App.num20yroldFemaleCM10g;}
if (TurnoverModelApp.curmethod.equals("AllowNumCellstoFluctuate")){
CMper10g =CellTypesByAge[i][2];System.out.println(i+" "+CellTypesByAge[i][7]+"
"+CellTypesByAge[i][2]+" "+Math.round(100*CellTypesByAge[i][7]/CellTypesByAge[i][2]));
}
CellTypesByAge[i][6]=100*CellTypesByAge[i][7]/CMper10g;
startage++;
}
TurnoverModelApp.holddata=CellTypesByAge;TurnoverModelApp.holdnumrows=Agerepetitions;TurnoverModelAp
p.holdnumcol=8;
}
//Compiled Data Extraction
public double PercP16ink4aPositiveCM(String gender,double ageyears){
//From Kajstura Fig 1. Intercepts Estimated
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double perc=0;
if (gender.equals("Female")){perc = 0.68*ageyears+0;}
else if (gender.equals("Male")){perc = 0.89*ageyears+5;}
return perc;
}
public double ApopCMperMillionCM(String gender,double ageyears){
//From Kajstura Fig 1. Intercepts Estimated
double apop=0;
if (gender.equals("Female")){apop = 1.23*ageyears-18;}
else if (gender.equals("Male")){apop = 1.31*ageyears+7;}
return apop;
//From Mallet
/* double apop=0;
if (gender.equals("Female")){apop = 42;}
else if (gender.equals("Male")){apop = 133;}
return apop;*/
}
public double CSCper10gram(String gender,double ageyears){
//From Kajstura Fig 2. Intercepts Estimated
double CSCs=0;
if (gender.equals("Female")){CSCs = 2.344*ageyears - 26;}//CSCs = 2.344*ageyears - 37;
else if (gender.equals("Male")){CSCs = 1.44*ageyears - 10;}
CSCs = CSCs*1000;
return CSCs;
}
public double PercOfCSCcycling(String gender,double ageyears){
//From Kajstura Fig 2. Intercepts Estimated
double perc=0;
if (gender.equals("Female")){perc = 0.0514*ageyears + 4.5;}//0.0514*ageyears + 4.1;
else if (gender.equals("Male")){perc = 0.0193*ageyears+5;}
return perc;
}
public double PercOfCSCsenescent(String gender,double ageyears){
//From Kajstura Fig 3. Intercepts Estimated
double perc=0;
if (gender.equals("Female")){perc = 0.59*ageyears - 3.6;}
else if (gender.equals("Male")){perc = 0.73*ageyears + 3.6;}
return perc;
}
public double FunctCompCSCsper10g(String gender,double ageyears){
//From Kajstura Fig 3. Intercepts Estimated
double CSCs=0;
if (gender.equals("Female")){CSCs = 918*ageyears + 0;}
else if (gender.equals("Male")){CSCs = 295*ageyears + 20000;}
return CSCs;
}
public double GTbyAge(String gender,double ageyears){
//From Kajstura Fig 3. Intercepts Estimated
double GT=0;
if (gender.equals("Female")){GT = -0.0091*ageyears + 5.8;}//-0.0086*ageyears + 6;
else if (gender.equals("Male")){GT = -0.0036*ageyears + 5.4;}
return GT;
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}
public void GetKajsturaTurnoverDenominatorinHeart(){
double ave = 0; double numpoints = 0; double thisyear=0;
for (int i=20;i<100;i++){
thisyear=1000000*MillionsMyocyteFormationCombinedModelPer10gPerYear("Female",i)/AnnTurnoverCombinedMo
del("Female",i);
System.out.println(thisyear);
ave=ave+thisyear;numpoints++;
}
ave=ave/numpoints;
System.out.println("Ave: "+ave);
}
public double MillionsMyocyteFormationCombinedModelPer10gPerYear(String gender,double ageyears){
//From Kajstura Fig 6. Intercepts Estimated
double MillionsNewCMPerYear=0;
if (gender.equals("Female")){MillionsNewCMPerYear = 2.5*ageyears - 34;}
else if (gender.equals("Male")){MillionsNewCMPerYear = 1.0*ageyears + 0;}
return MillionsNewCMPerYear;
}
public double AnnTurnoverCombinedModel(String gender,double ageyears){
//From Kajstura Fig 6. Intercepts Estimated
double AnnPerc=0;
if (gender.equals("Female")){AnnPerc = 0.434*ageyears - 4;}
if(AnnPerc<0){AnnPerc=0;}
else if (gender.equals("Male")){AnnPerc = 0.2*ageyears + 0;}
return AnnPerc;
}
public double AnversaPloidyLinear4n(String gender, double ageyears){
//From Kajstura Fig 5. Points Estimated
double perc=0;
if (gender.equals("Female")){perc = 0.000259*ageyears + 0.001457;}
else if (gender.equals("Male")){perc = 0.000176*ageyears + 0.003647;}
return perc;
}
public double AnversaPloidyLinear8n(String gender, double ageyears){
//From Kajstura Fig 5. Points Estimated
double perc=0;
if (gender.equals("Female")){perc = 0.000063*ageyears + 0.002799;}
else if (gender.equals("Male")){perc = 0.000057*ageyears + 0.002910;}
return perc;
}
public double TimetoSenescence(String gender, double ageyears){
//From Kajstura Supp. Fig XIV. Intercepts Estimated
double tts=0;
if (gender.equals("Female")){tts = -0.16*ageyears + 17.4;}
else if (gender.equals("Male")){tts = -0.19*ageyears + 17.4;}
if (tts<0){tts=0;}
return tts;
}
public double PercPostMitNonSenCM(String gender, double ageyears){
//From Kajstura Fig 4. Intercepts Estimated
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double tts=0;
if (gender.equals("Female")){tts = -0.69*ageyears + 100;}
else if (gender.equals("Male")){tts = -0.89*ageyears + 94;}
if (tts<0){tts=0;}
return tts;
}
public static double GetC14atyear(double year){
//Returns first datapoint of that exceeds year (Consider for Rounding)
double C14=-100; boolean found=false;
for (int i=0;i<TurnoverModelApp.numC14points;i++){
if (!found&&TurnoverModelApp.C14points[i][0]>=year){
//Average Over Year
int thisyear = (int)TurnoverModelApp.C14points[i][0];
int count=0;double c14=0;
for (int j=0;j<TurnoverModelApp.numC14points;j++){
if ((int)TurnoverModelApp.C14points[j][0]==thisyear){
c14=c14+TurnoverModelApp.C14points[j][1];count++;
}
}
C14=c14/count;
//Does Not Average Over Year
C14=TurnoverModelApp.C14points[i][1];
found=true;
return C14;
}
}
if (C14==-100){C14=TurnoverModelApp.C14points[TurnoverModelApp.numC14points-1][1];}
return C14;
}
public static void TestPloidy() throws IOException{
int numtotest=20;
double[][] data = new double[TurnoverModelApp.numBergmann][numtotest+1]; //each row is a patient, each
column is i/10% of Bergmann ploidy applied
double perc=0;
for (int j=0;j<=numtotest;j++){
for (int i=0;i<TurnoverModelApp.numBergmann;i++){
data[i][j]=100*TurnDeltaC14intoScenarioATurnover(i,(int)TurnoverModelApp.Bergmann[i][2],
(int)TurnoverModelApp.Bergmann[i][3],TurnoverModelApp.Bergmann[i][7],TurnoverModelApp.initguess,true,.1*j,0)
;
}
}
TurnoverModelApp.fileWriter(data, TurnoverModelApp.numBergmann, numtotest+1, "TestPloidy");
}
public static void TestScenarioA() throws IOException{
double[][] data = new
double[TurnoverModelApp.numBergmann][3];//Patient,BergmannReported,BergmannScenA
double scale=1;double delay=TurnoverModelApp.delay;//Scale controls polyploidy magnitude, delay controls
delay from C14 atmosphere to body
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for (int i=0;i<TurnoverModelApp.numBergmann;i++){
double initguess=TurnoverModelApp.initguess;
//Use scale*TurnoverModelApp.Bergmann[i][7] for no ploidy correction, [i][4] for correction
data[i][2]=100*TurnDeltaC14intoScenarioATurnover(i,(int)TurnoverModelApp.Bergmann[i][2],
(int)TurnoverModelApp.Bergmann[i][3],TurnoverModelApp.Bergmann[i][7],initguess,true,scale,0);
data[i][0]=i;data[i][1]=TurnoverModelApp.Bergmann[i][6];
}
TurnoverModelApp.holddata3=data;TurnoverModelApp.holdnumrows3=TurnoverModelApp.numBergmann;
TurnoverModelApp.holdnumcol3=3;
TurnoverModelApp.fileWriter(data, TurnoverModelApp.numBergmann, 3, "ScenarioA");
}
public static void GlobalFit() throws IOException{
String scenario = "E2";
//global mode
GlobalFitRange(scenario,0,TurnoverModelApp.numBergmann);
//individual patient list mode
//for (int i=0;i<TurnoverModelApp.numBergmann;i++){GlobalFitRange(scenario,i,i+1); }
//single patient model
//GlobalFitRange(scenario,6,7);
//GetCMAgeHistogramwithGlobal();
}
public static void GlobalFitRange(String scenario,int spatient, int endpatient) throws IOException{
double lowesterr=999999999; double holdbesterr=0;
if (scenario.equals("A")){
double Aparam = 0; TurnoverModelApp.modelparams = new double[1];
for (int k=0;k<10000;k++){
TurnoverModelApp.modelerror=0;
for (int i=spatient;i<endpatient;i++){
TurnDeltaC14intoScenarioTurnover(i,(int)TurnoverModelApp.Bergmann[i][2],(int)TurnoverModelApp.Bergmann[i][3
],Aparam,Aparam);
}
//System.out.println("B: "+Math.round(10000*Aparam)*0.01+"%, D: "+Math.round(10000*Aparam)*0.01+"%,
E: "+TurnoverModelApp.modelerror);
if
(TurnoverModelApp.modelerror<lowesterr){lowesterr=TurnoverModelApp.modelerror;TurnoverModelApp.modelpar
ams[0]=Aparam;}
Aparam=Aparam+0.0001;
}
System.out.println("BF Turnover: "+100*TurnoverModelApp.modelparams[0]+"%, SSE="+lowesterr);
}
if (scenario.equals("B")){
double Bbirth = 0; double Bdeath=0; TurnoverModelApp.modelparams = new double[2];
for (int k=0;k<100;k++){
Bdeath=0;
for (int d=0;d<10;d++){
TurnoverModelApp.modelerror=0;
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for (int i=spatient;i<endpatient;i++){
TurnDeltaC14intoScenarioTurnover(i,(int)TurnoverModelApp.Bergmann[i][2],(int)TurnoverModelApp.Bergmann[i][3
],Bdeath,Bbirth);
}
if
(TurnoverModelApp.modelerror<lowesterr){lowesterr=TurnoverModelApp.modelerror;TurnoverModelApp.modelpar
ams[0]=Bbirth;TurnoverModelApp.modelparams[1]=Bdeath; }
//System.out.println("B: "+Math.round(10000*Bbirth)*0.01+"%, D: "+Math.round(10000*Bdeath)*0.01+"%,
E: "+TurnoverModelApp.modelerror);
Bdeath=Bdeath+0.001;
}
Bbirth=Bbirth+0.001;
}
System.out.println("BF Turnover: B="+100*TurnoverModelApp.modelparams[0]+"%,
D="+100*TurnoverModelApp.modelparams[1]+"%, SSE="+lowesterr);
}
if(scenario.equals("E2")){
TurnoverModelApp.modelparams = new double[2];
double gamma0low = 0; double gamma0high = .5;double gamma0increment = 0.01;
double gamma1low = 0.0; double gamma1high = 2;double gamma1increment = 0.05;
int gamma0reps = (int) Math.rint((gamma0high - gamma0low)/gamma0increment);
int gamma1reps = (int) Math.rint((gamma1high - gamma1low)/gamma1increment);
if (gamma0reps==0){gamma0reps=1;}if (gamma1reps==0){gamma1reps=1;}
double gamma0=gamma0low;double gamma1=gamma1low;
for (int k=0;k<gamma0reps;k++){ //controls gamma0
gamma1=gamma1low;
for (int d=0;d<gamma1reps;d++){//controls gamma1
TurnoverModelApp.modelerror=0;
for (int i=spatient;i<endpatient;i++){
TurnDeltaC14intoScenarioE2Turnover(i,(int)TurnoverModelApp.Bergmann[i][2],(int)TurnoverModelApp.Bergmann[i
][3],gamma0,gamma1);
}
if
(TurnoverModelApp.modelerror<lowesterr){lowesterr=TurnoverModelApp.modelerror;TurnoverModelApp.modelpar
ams[0]=gamma0;TurnoverModelApp.modelparams[1]=gamma1; holdbesterr= TurnoverModelApp.modelerror; }
//System.out.println("G0: "+gamma0+", G1: "+gamma1+", E: "+TurnoverModelApp.modelerror);
gamma1=gamma1+gamma1increment;
}
gamma0=gamma0+gamma0increment;
}
System.out.println("BEST: Gamma0: "+TurnoverModelApp.modelparams[0]+", Gamma1:
"+TurnoverModelApp.modelparams[1]+", E: "+holdbesterr);
}
if (scenario.equals("TVB-TVDR")){ //Birth increases with patient age, Annual Death rate of CM increases with
patient age
double desiredDINTrange = 0.1; //0.05 = 0->5%
int numrepsDINT = 10;
double desiredBINTrange=0.1; //0.05 = 0->10%
int numrepsBINT = 10;
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double desiredDSLOPErange=0.01; //0.005 = -0.005 -> 0.005, in per year
int numrepsDSLOPE = 20;
double desiredBSLOPErnage=0.01;//0.005 = -0.005 -> 0.005, in per year
int numrepsBSLOPE = 20;
double bslope = -1*desiredBSLOPErnage; double bint=0; double dslope=-1*desiredDSLOPErange; double dint=0;
TurnoverModelApp.modelparams = new double[4];
for (int b0=0;b0<numrepsBSLOPE;b0++){ //controls bslope
System.out.println("Progress:"+ (int)(100*b0/numrepsBSLOPE)+"%");
bint=0;
for (int b1=0;b1<numrepsBINT;b1++){ //controls bint
dslope=-1*desiredDSLOPErange;
for(int d0=0;d0<numrepsDSLOPE;d0++){ //controls slope
dint=0;
for (int d1=0;d1<numrepsDINT;d1++){ //controls dint
TurnoverModelApp.modelerror=0;
for (int i=spatient;i<endpatient;i++){
GfitCustomScenVaryDeath(i,(int)TurnoverModelApp.Bergmann[i][2],(int)TurnoverModelApp.Bergmann[i][3],bslope,
bint,dslope,dint);
}
if (TurnoverModelApp.modelerror<lowesterr){
lowesterr=TurnoverModelApp.modelerror;TurnoverModelApp.modelparams[0]=bslope;TurnoverModelApp.modelpar
ams[1]=bint;TurnoverModelApp.modelparams[2]=dslope;TurnoverModelApp.modelparams[3]=dint;
TurnoverModelApp.holddouble2=lowesterr;TurnoverModelApp.holddouble3=TurnoverModelApp.holddouble;//Test
Scenario A
}
dint=dint+desiredDINTrange/numrepsDINT;
TurnoverModelApp.holddouble=TurnoverModelApp.holddouble+0.0001;//Test Scenario A
}
dslope=dslope+2*desiredDSLOPErange/numrepsDSLOPE;
}
bint=bint+desiredBINTrange/numrepsBINT;
}
bslope=bslope+2*desiredBSLOPErnage/numrepsBSLOPE;
}
System.out.println("BF Turnover: Bs="+TurnoverModelApp.modelparams[0]+", Bi=
"+TurnoverModelApp.modelparams[1]+", Ds: "+TurnoverModelApp.modelparams[2]+", Di:
"+TurnoverModelApp.modelparams[3]+", SSE= "+lowesterr);
}
//System.out.println("FINISH A "+TurnoverModelApp.holddouble2+" "+TurnoverModelApp.holddouble3); //Test
Scenario A
}//end global method
public static void GetC14forScenarioE2() throws IOException{
double gamma0=0.123;double gamma1=1.42;
for (int i=0;i<TurnoverModelApp.numBergmann;i++){
TurnDeltaC14intoScenarioE2Turnover(i,(int)TurnoverModelApp.Bergmann[i][2],(int)TurnoverModelApp.Bergmann[i
][3],gamma0,gamma1);
}
}
public static void GetCMAgeHistogramwithGlobal() throws IOException{
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double bslope=0.001;double bint=0.03;double dslope = 0.004; double dint=0.02; //bestfit
//double bslope=0.0;double bint=0.03;double dslope = 0.004; double dint=0.025; //secondbestfit
//double bslope=-0.0004;double bint=0.03;double dslope = 0.002; double dint=0.035; //thirdbestfit
//double bslope=0;double bint=0.01;double dslope = 0; double dint=.01; //constant

double[] endC14= new double[TurnoverModelApp.numBergmann];
for(int i=0;i<TurnoverModelApp.numBergmann;i++){
endC14[i]=GfitCustomScenVaryDeath(i,(int)TurnoverModelApp.Bergmann[i][2],(int)TurnoverModelApp.Bergmann[i
][3],bslope,bint,dslope,dint);
System.out.println(endC14[i]);
}
}
public static double GfitCustomScenVaryDeath(int patient,int birthyear, int lifespan,double birthslope,double
birthintercept,double deathslope,double deathintercept) throws IOException{
double[][] agedist = new double[lifespan+1][3]; //age, %CMatAge, C14atyear
//assume totally random turnover but variable death rate
agedist = new double[lifespan+1][3];
for (int j=0;j<=lifespan;j++){
agedist[j][0]=lifespan-j; //CM Age
//Allow Constant Birth and Constant Death Rate
double deathrate = deathintercept+deathslope*j;
//deathrate = TurnoverModelApp.holddouble; //Test Scenario A
if (j==0){agedist[j][1]=Math.pow((1-deathrate),lifespan);}
double birthrate = birthintercept+birthslope*j;
//birthrate = deathrate;//Test Scenario A
if (j>0){agedist[j][1]=birthrate*Math.pow((1-deathrate),lifespan-j);}
agedist[j][2]=GetC14atyear(birthyear+j);
}
//agedist[0][2]=TurnoverModelApp.getinitialbergmannpatientC14level(patient);
//Normalize to cell count
double tot=0;
for (int j=0;j<=lifespan;j++){tot=tot+agedist[j][1];}
for (int j=0;j<=lifespan;j++){agedist[j][1]=agedist[j][1]/tot;}
double[] aveC14postploidy=new double[lifespan+1];for (int
w=0;w<lifespan+1;w++){aveC14postploidy[w]=agedist[w][2];}
for (int p=0;p<lifespan;p++){ //each cell-age cohort contributes a certain amount of C14. p = year of pt life
double aveC14foragegroup = agedist[p][2];
for (int q=p;q<lifespan;q++){ //q = years after cell born in patient life p
double percadded = computepersonalizedpolyploidyc14rate(patient, q, 1);
aveC14foragegroup = (aveC14foragegroup + percadded*agedist[q][2])/(1+percadded);
}
aveC14postploidy[p]=aveC14foragegroup;
}
double newaveC14=0;for (int k=0;k<=lifespan;k++){newaveC14 =
newaveC14+agedist[k][1]*aveC14postploidy[k];}
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double modeldC14 = newaveC14-GetC14atyear(birthyear);
TurnoverModelApp.modelerror=TurnoverModelApp.modelerror+Math.pow(modeldC14TurnoverModelApp.Bergmann[patient][7],2); //SSE
//System.out.println("TOT: " + tot);
TurnoverModelApp.fileWriter(agedist,lifespan+1,3,"/Individual/"+patient);
return newaveC14;
}

public static void TurnDeltaC14intoScenarioTurnover(int patient,int birthyear, int lifespan,double deathrate,double
birthrate) throws IOException{
double[][] agedist = new double[lifespan+1][3]; //age, %CMatAge, C14atyear
//assume totally random turnover but variable death rate
agedist = new double[lifespan+1][3];
for (int j=0;j<=lifespan;j++){
agedist[j][0]=lifespan-j; //CM Age
//Allow Constant Birth and Constant Death Rate
if (j==0){agedist[j][1]=Math.pow((1-deathrate),lifespan);}
if (j>0){agedist[j][1]=birthrate*Math.pow((1-deathrate),lifespan-j);}
agedist[j][2]=GetC14atyear(birthyear+j);
}
//Normalize to cell count
double tot=0;
for (int j=0;j<=lifespan;j++){tot=tot+agedist[j][1];}
for (int j=0;j<=lifespan;j++){agedist[j][1]=agedist[j][1]/tot;}
double[] aveC14postploidy=new double[lifespan+1];for (int
w=0;w<lifespan+1;w++){aveC14postploidy[w]=agedist[w][2];}
for (int p=0;p<lifespan;p++){ //each cell-age cohort contributes a certain amount of C14. p = year of pt life
double aveC14foragegroup = agedist[p][2];
for (int q=p;q<lifespan;q++){ //q = years after cell born in patient life p
double percadded = computepersonalizedpolyploidyc14rate(patient, q, 1);
aveC14foragegroup = (aveC14foragegroup + percadded*agedist[q][2])/(1+percadded);
}
aveC14postploidy[p]=aveC14foragegroup;
}
double newaveC14=0;for (int k=0;k<=lifespan;k++){newaveC14 =
newaveC14+agedist[k][1]*aveC14postploidy[k];}
double modeldC14 = newaveC14-GetC14atyear(birthyear);
//double modeldC14 = newaveC14-TurnoverModelApp.getinitialbergmannpatientC14level(patient);
TurnoverModelApp.modelerror=TurnoverModelApp.modelerror+Math.pow(modeldC14TurnoverModelApp.Bergmann[patient][7],2); //SSE
}
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public static void TurnDeltaC14intoScenarioE2Turnover(int patient,int birthyear, int lifespan,double
gamma0,double gamma1) throws IOException{
double[][] celldist = new double[lifespan+1][3]; //0=CM age at death, 1=%survive till death, 2=%formation
//compute death
for(int a=0;a<=lifespan;a++){
celldist[a][0]=a;
double deathrate = gamma0*gamma1/(gamma1+a);
double liverate = 1-deathrate;
for (int j=0;j<a;j++){
liverate=liverate*(1-gamma0*gamma1/(gamma1+j));
}
celldist[a][1]=liverate;
//System.out.println(liverate);
}
//compute formation
double[] holdformed = new double[lifespan];
for(int k=0;k<lifespan;k++){
double formed=0;
if(k>0){
for (int j=0;j<k;j++){
int a = j+k;
double newdeath = gamma0*gamma1/(gamma1+a);
formed = formed+holdformed[j]*newdeath;
}
}
else{formed=1;}
holdformed[k]=formed;
//System.out.println(k+" "+holdformed[k]);
celldist[lifespan-k-1][2]=formed;
}
//System.out.println(" A
Live to End Formed%");
for(int i=0;i<lifespan-1;i++){
//System.out.println(celldist[i][0]+" "+celldist[i][1]+" "+celldist[i][2]);
}
double[][] agedist = new double[lifespan+1][3];
for (int j=0;j<=lifespan;j++){
agedist[j][0]=lifespan-j; //CM Age
agedist[j][1]=celldist[lifespan-j][1]*celldist[lifespan-j][2];
agedist[j][2]=GetC14atyear(birthyear+j);
if(j==1){agedist[j][2]=TurnoverModelApp.getinitialbergmannpatientC14level(patient);}
}
for(int i=0;i<=lifespan;i++){
//System.out.println(agedist[i][0]+" "+agedist[i][1]+" "+agedist[i][2]);
}
//Normalize to cell count
double tot=0;
for (int j=0;j<=lifespan;j++){tot=tot+agedist[j][1];}
//System.out.println("TOT: "+tot);
for (int j=0;j<=lifespan;j++){agedist[j][1]=agedist[j][1]/tot;}
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double[] aveC14postploidy=new double[lifespan+1];for (int
w=0;w<lifespan+1;w++){aveC14postploidy[w]=agedist[w][2];}
for (int p=0;p<lifespan;p++){ //each cell-age cohort contributes a certain amount of C14. p = year of pt life
double aveC14foragegroup = agedist[p][2];
for (int q=p;q<lifespan;q++){ //q = years after cell born in patient life p
double percadded = computepersonalizedpolyploidyc14rate(patient, q, 1);
aveC14foragegroup = (aveC14foragegroup + percadded*agedist[q][2])/(1+percadded);
}
aveC14postploidy[p]=aveC14foragegroup;
}
double newaveC14=0;for (int k=0;k<=lifespan;k++){newaveC14 =
newaveC14+agedist[k][1]*aveC14postploidy[k];}
double modeldC14 = newaveC14-GetC14atyear(birthyear);
System.out.println(newaveC14);
//double modeldC14 = newaveC14-TurnoverModelApp.getinitialbergmannpatientC14level(patient);
TurnoverModelApp.modelerror=TurnoverModelApp.modelerror+Math.pow(modeldC14TurnoverModelApp.Bergmann[patient][7],2); //SSE
}
public void TestHybridModelforBergmann() throws IOException{
double[][] data = new double[TurnoverModelApp.numBergmann][3];
//int i=4;
for (int i=0;i<TurnoverModelApp.numBergmann;i++){
data[i][0]=i;
data[i][1]=TurnoverModelApp.Bergmann[i][4]-TurnoverModelApp.Bergmann[i][9]; //How much Bergmann
Corrected for Ploidy
data[i][2]=ComputeDeltaC14forConstantTurnover(i,TurnoverModelApp.Bergmann[i][6]/100, true)ComputeDeltaC14forConstantTurnover(i, TurnoverModelApp.Bergmann[i][6]/100, false);
//System.out.println("A "+i+" "+ data[i][1]+" "+data[i][2]);
TurnoverModelApp.holddata3=data;TurnoverModelApp.holdnumrows3=TurnoverModelApp.numBergmann;
TurnoverModelApp.holdnumcol3=3;
TurnoverModelApp.fileWriter(data, TurnoverModelApp.numBergmann, 3, "HybridModelPloidyCompProof");
}
}
public static double computepersonalizedpolyploidyc14rate(int patientID, int a, double ploidyscale){
//smooth - break into 10 parts and compute a CAGR
double d0 = 110.5; double theta = 7; double n=5.4;
double k=76;k=TurnoverModelApp.Bergmann[patientID][8];
double c14percrate=0;
//compute f(a)
double FofA=0;
if (a==0){FofA=d0;}
if (a>0){FofA=d0+k/(1+Math.pow((a/theta),-1*n));}
//compute f(a-1)
double FofAminus1=0;
if (a>1){FofAminus1=d0+k/(1+Math.pow(((a-1)/theta),-1*n));}
if(a==1){FofAminus1=d0;}
if(a==0){FofAminus1=d0;}
c14percrate = ((FofA-FofAminus1)/(FofAminus1));
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c14percrate = c14percrate*ploidyscale;
//System.out.println(patientID+" "+a+" "+c14percrate);
return c14percrate;
}
public static double TurnDeltaC14intoScenarioATurnover(int patientid, int birthyear, int lifespan, double
BergmanndeltaC14,double initguess, boolean subtract,double ploidyscale,double delay) throws IOException{
double guessturn = initguess; int numtries = 400;
double[][] agedist = new double[lifespan+1][3]; //age, %CMatAge, C14atyear
//assume totally random turnover
double error=0; double lastC14=0;
for (int i=0;i<numtries;i++){
//System.out.println("Guess "+guessturn);
agedist = new double[lifespan+1][3];
for (int j=0;j<=lifespan;j++){
agedist[j][0]=lifespan-j; //CM Age
if (j>0){agedist[j][1]=guessturn*Math.pow((1-guessturn),lifespan-j);}
else if (j==0){agedist[j][1]=Math.pow((1-guessturn),lifespan);}
agedist[j][2]=GetC14atyear(birthyear+j);
//System.out.println("R " + agedist[j][0]+" "+100*agedist[j][1]+" "+agedist[j][2]);
}
double[] aveC14postploidy=new double[lifespan+1];for (int
w=0;w<lifespan+1;w++){aveC14postploidy[w]=agedist[w][2];}
if (subtract==true){ //remove ploidy
for (int p=0;p<lifespan;p++){ //each cell-age cohort contributes a certain amount of C14. p = year of pt life
double aveC14foragegroup = agedist[p][2];
for (int q=p;q<lifespan;q++){ //q = years after cell born in patient life p
double percadded = computepersonalizedpolyploidyc14rate(patientid, q, ploidyscale);
aveC14foragegroup = (aveC14foragegroup + percadded*agedist[q][2])/(1+percadded);
}
aveC14postploidy[p]=aveC14foragegroup;
}
}
double newaveC14=0;for (int k=0;k<=lifespan;k++){newaveC14 =
newaveC14+agedist[k][1]*aveC14postploidy[k];}
double modeldeltaC14 = newaveC14-GetC14atyear(birthyear);double
desireddeltaC14=TurnoverModelApp.Bergmann[patientid][7];
lastC14=newaveC14;
//System.out.println(patientid +", % "+guessturn+", New C14 "+ newaveC14+", ModelDc14
"+modeldeltaC14+ ", DesiredDC14 "+desireddeltaC14);
error = modeldeltaC14-BergmanndeltaC14;
TurnoverModelApp.modelerror=TurnoverModelApp.modelerror+Math.pow(error,2); //SSE
//System.out.println(guessturn+" "+error+" "+BergmanndeltaC14+ " "+modeldeltaC14);
double trylower =
CheckDeltaC14intoScenarioATurnover(patientid,birthyear,lifespan,BergmanndeltaC14,guessturn*.98,subtract,ploidysc
ale,delay); //returns new modeldeltaC14
double tryhigher =
CheckDeltaC14intoScenarioATurnover(patientid,birthyear,lifespan,BergmanndeltaC14,guessturn*1.02,subtract,ploidys
cale,delay);
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if (Math.abs(BergmanndeltaC14-trylower)<Math.abs(BergmanndeltaC14tryhigher)){guessturn=guessturn*0.98;}
else if(Math.abs(BergmanndeltaC14 - trylower)>Math.abs(BergmanndeltaC14 - tryhigher)){guessturn =
guessturn * 1.02;}
}
//System.out.println(lastC14);
return guessturn;
}
public static double CheckDeltaC14intoScenarioATurnover(int patientid,int birthyear, int lifespan, double
BergmanndeltaC14,double initguess,boolean subtract,double ploidyscale,double delay) throws IOException{
double guessturn = initguess;
double[][] agedist = new double[lifespan+1][3]; //age, %CMatAge, C14atyear
agedist = new double[lifespan+1][3];
for (int j=0;j<=lifespan;j++){
agedist[j][0]=lifespan-j; //CM Age
//For Scenario A
if (j>0){agedist[j][1]=guessturn*Math.pow((1-guessturn),lifespan-j);}
else if (j==0){agedist[j][1]=Math.pow((1-guessturn),lifespan);}
//For Scenario B
// if (j>0){agedist[j][1]=guessturn*Math.pow((1-TurnoverModelApp.deathrate),lifespan-j);}
// else if (j==0){agedist[j][1]=Math.pow((1-TurnoverModelApp.deathrate),lifespan);}
agedist[j][2]=GetC14atyear(birthyear+j-delay);
}
double[] aveC14postploidy=new double[lifespan+1];for (int
w=0;w<lifespan+1;w++){aveC14postploidy[w]=agedist[w][2];}
if (subtract==true){ //remove ploidy
for (int p=0;p<lifespan;p++){ //each cell-age cohort contributes a certain amount of C14. p = year of pt life
double aveC14foragegroup = agedist[p][2];double massadded=1;
for (int q=p;q<lifespan;q++){ //q = years after cell born in patient life p
double percadded = computepersonalizedpolyploidyc14rate(patientid, q,ploidyscale);
aveC14foragegroup = (aveC14foragegroup + percadded*agedist[q][2])/(1+percadded);
}
aveC14postploidy[p]=aveC14foragegroup;
}
}
double newaveC14=0;for (int k=0;k<=lifespan;k++){newaveC14 =
newaveC14+agedist[k][1]*aveC14postploidy[k];}

double modeldeltaC14 = newaveC14-GetC14atyear(birthyear);
return modeldeltaC14;
}

public static void PrintBombFunction(boolean smoothed) throws IOException{
if (smoothed==false){
TurnoverModelApp.fileWriter(TurnoverModelApp.C14points,TurnoverModelApp.numC14points,2,"/Bomb");
}
else if(smoothed == true)
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{
int range = 2006-1930;
double[][] bomb = new double[range][2];
for (int i=0;i<range;i++){
bomb[i][0]=1930+i;
bomb[i][1]=GetC14atyear(1930+i);
}
TurnoverModelApp.fileWriter(bomb,range,2,"/Bomb");
}
}
public static void VarydC14forBergmannTurnoverAnalysis() throws IOException{
//data is column for each (0.8, 1.0, 1.2); row for each patient
double[][] data = new double[TurnoverModelApp.numBergmann][3];
double initguess=TurnoverModelApp.initguess;
for (int i=0;i<TurnoverModelApp.numBergmann;i++){
data[i][0]=100*TurnDeltaC14intoScenarioATurnover(i,(int)TurnoverModelApp.Bergmann[i][2],
(int)TurnoverModelApp.Bergmann[i][3],0.8*TurnoverModelApp.Bergmann[i][4],initguess,true,1,0);
data[i][1]=100*TurnDeltaC14intoScenarioATurnover(i,(int)TurnoverModelApp.Bergmann[i][2],
(int)TurnoverModelApp.Bergmann[i][3],1.0*TurnoverModelApp.Bergmann[i][4],initguess,true,1,0);
data[i][2]=100*TurnDeltaC14intoScenarioATurnover(i,(int)TurnoverModelApp.Bergmann[i][2],
(int)TurnoverModelApp.Bergmann[i][3],1.2*TurnoverModelApp.Bergmann[i][4],initguess,true,1,0);
}
TurnoverModelApp.fileWriter(data,TurnoverModelApp.numBergmann,3,"VaryBergmanndC14");
}
public void VaryExpansionExponentforTurnover() throws IOException{
double[][] data = new double[TurnoverModelApp.Agerepetitions-1][7]; //Patient Age, M-Exponent = 80%, FExponent = 100%, F-Exponent = 120%, F-Exponent = 80%, F-Exponent = 100%, F-Exponent = 120%
HierarchicalModel10g("Male",false,true,false,0.8,1,1);
for (int i=0;i<TurnoverModelApp.Agerepetitions1;i++){data[i][0]=TurnoverModelApp.holddata[i+1][0];data[i][1]=TurnoverModelApp.holddata[i+1][6];}
HierarchicalModel10g("Male",false,true,false,1.0,1,1);
for (int i=0;i<TurnoverModelApp.Agerepetitions-1;i++){data[i][2]=TurnoverModelApp.holddata[i+1][6];}
HierarchicalModel10g("Male",false,true,false,1.2,1,1);
for (int i=0;i<TurnoverModelApp.Agerepetitions-1;i++){data[i][3]=TurnoverModelApp.holddata[i+1][6];}
HierarchicalModel10g("Female",false,true,false,0.8,1,1);
for (int i=0;i<TurnoverModelApp.Agerepetitions-1;i++){data[i][4]=TurnoverModelApp.holddata[i+1][6];}
HierarchicalModel10g("Female",false,true,false,1.0,1,1);
for (int i=0;i<TurnoverModelApp.Agerepetitions-1;i++){data[i][5]=TurnoverModelApp.holddata[i+1][6];}
HierarchicalModel10g("Female",false,true,false,1.2,1,1);
for (int i=0;i<TurnoverModelApp.Agerepetitions-1;i++){data[i][6]=TurnoverModelApp.holddata[i+1][6];}
TurnoverModelApp.fileWriter(data,TurnoverModelApp.Agerepetitions-1,7,"VaryExponentforTurnover");
}

public void BergmannSensitivityToTrueTurnover() throws IOException{
//patients: 0=patient,
1=BergOutputifTrueTurn=0.1%,2=BergOutputifTrueTurn=1.0%,3=BergOutputifTrueTurn=10%
//True Turn = Constant Through Life but Includes Cell Inter-Life CM Death
double[] truepercs =
{0.1,0.2,0.4,0.75,1.0,1.5,1.75,2.0,2.5,3.0,4.0,5.0,6.0,7.0,8.0,9.0,10,12.5,15,17.5,20,25,30,35,40};
//double[] truepercs = {0.1,0.2,0.75,1.0,2.0,4.0,7.0,10,15,20,30,40};
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//double[] truepercs = {22};
double[][] patients = new double[truepercs.length][TurnoverModelApp.numBergmann+2];
for (int k=0;k<truepercs.length;k++){patients[k][0]=truepercs[k];patients[k][1]=truepercs[k];}
// int i=0;
for (int i=0;i<TurnoverModelApp.numBergmann;i++){
System.out.println("1 "+i);
for (int k=0;k<truepercs.length;k++){
TurnoverModelApp.counter=i;
patients[k][i+2]=100*TurnDeltaC14intoScenarioATurnover(i,(int)TurnoverModelApp.Bergmann[i][2],(int)TurnoverM
odelApp.Bergmann[i][3],
ComputeDeltaC14forConstantTurnover(i,truepercs[k]/100,true),TurnoverModelApp.initguess,true,1,0);
}
}
TurnoverModelApp.fileWriter(patients,truepercs.length,TurnoverModelApp.numBergmann+2,"BergSensitivity");
}
public void IdentifyBifurcation() throws IOException{
for (int i=0;i<TurnoverModelApp.numBergmann;i++){
double C14 = ComputeDeltaC14forConstantTurnover(i,0.2,true); //must send a DECIMAL (sending 10/100 for
10% will not work!)
System.out.println(C14);
}
}
public static void PrintC14forYearRange(int yearstart,int yearend){
// for (int i=0;i<yearend-yearstart;i++){ System.out.println(GetC14atyear(yearstart+i));}
for (int
i=0;i<TurnoverModelApp.numBergmann;i++){System.out.println(GetC14atyear(TurnoverModelApp.Bergmann[i][2])
);}
}

@SuppressWarnings("unchecked")
// <editor-fold defaultstate="collapsed" desc="Generated Code">
private void initComponents() {
mainPanel = new javax.swing.JPanel();
menuBar = new javax.swing.JMenuBar();
javax.swing.JMenu fileMenu = new javax.swing.JMenu();
javax.swing.JMenuItem exitMenuItem = new javax.swing.JMenuItem();
javax.swing.JMenu helpMenu = new javax.swing.JMenu();
javax.swing.JMenuItem aboutMenuItem = new javax.swing.JMenuItem();
statusPanel = new javax.swing.JPanel();
javax.swing.JSeparator statusPanelSeparator = new javax.swing.JSeparator();
statusMessageLabel = new javax.swing.JLabel();
statusAnimationLabel = new javax.swing.JLabel();
progressBar = new javax.swing.JProgressBar();
mainPanel.setName("mainPanel"); // NOI18N
javax.swing.GroupLayout mainPanelLayout = new javax.swing.GroupLayout(mainPanel);
mainPanel.setLayout(mainPanelLayout);
mainPanelLayout.setHorizontalGroup(
mainPanelLayout.createParallelGroup(javax.swing.GroupLayout.Alignment.LEADING)
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.addGap(0, 400, Short.MAX_VALUE)
);
mainPanelLayout.setVerticalGroup(
mainPanelLayout.createParallelGroup(javax.swing.GroupLayout.Alignment.LEADING)
.addGap(0, 252, Short.MAX_VALUE)
);
menuBar.setName("menuBar"); // NOI18N
org.jdesktop.application.ResourceMap resourceMap =
org.jdesktop.application.Application.getInstance(turnovermodel.TurnoverModelApp.class).getContext().getResourceM
ap(TurnoverModelView.class);
fileMenu.setText(resourceMap.getString("fileMenu.text")); // NOI18N
fileMenu.setName("fileMenu"); // NOI18N
javax.swing.ActionMap actionMap =
org.jdesktop.application.Application.getInstance(turnovermodel.TurnoverModelApp.class).getContext().getActionMap
(TurnoverModelView.class, this);
exitMenuItem.setAction(actionMap.get("quit")); // NOI18N
exitMenuItem.setName("exitMenuItem"); // NOI18N
fileMenu.add(exitMenuItem);
menuBar.add(fileMenu);
helpMenu.setText(resourceMap.getString("helpMenu.text")); // NOI18N
helpMenu.setName("helpMenu"); // NOI18N
aboutMenuItem.setAction(actionMap.get("showAboutBox")); // NOI18N
aboutMenuItem.setName("aboutMenuItem"); // NOI18N
helpMenu.add(aboutMenuItem);
menuBar.add(helpMenu);
statusPanel.setName("statusPanel"); // NOI18N
statusPanelSeparator.setName("statusPanelSeparator"); // NOI18N
statusMessageLabel.setName("statusMessageLabel"); // NOI18N
statusAnimationLabel.setHorizontalAlignment(javax.swing.SwingConstants.LEFT);
statusAnimationLabel.setName("statusAnimationLabel"); // NOI18N
progressBar.setName("progressBar"); // NOI18N
javax.swing.GroupLayout statusPanelLayout = new javax.swing.GroupLayout(statusPanel);
statusPanel.setLayout(statusPanelLayout);
statusPanelLayout.setHorizontalGroup(
statusPanelLayout.createParallelGroup(javax.swing.GroupLayout.Alignment.LEADING)
.addComponent(statusPanelSeparator, javax.swing.GroupLayout.DEFAULT_SIZE, 400, Short.MAX_VALUE)
.addGroup(statusPanelLayout.createSequentialGroup()
.addContainerGap()
.addComponent(statusMessageLabel)
.addPreferredGap(javax.swing.LayoutStyle.ComponentPlacement.RELATED, 226, Short.MAX_VALUE)
.addComponent(progressBar, javax.swing.GroupLayout.PREFERRED_SIZE,
javax.swing.GroupLayout.DEFAULT_SIZE, javax.swing.GroupLayout.PREFERRED_SIZE)
.addPreferredGap(javax.swing.LayoutStyle.ComponentPlacement.RELATED)
.addComponent(statusAnimationLabel)
.addContainerGap())
);
statusPanelLayout.setVerticalGroup(
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statusPanelLayout.createParallelGroup(javax.swing.GroupLayout.Alignment.LEADING)
.addGroup(statusPanelLayout.createSequentialGroup()
.addComponent(statusPanelSeparator, javax.swing.GroupLayout.PREFERRED_SIZE, 2,
javax.swing.GroupLayout.PREFERRED_SIZE)
.addPreferredGap(javax.swing.LayoutStyle.ComponentPlacement.RELATED,
javax.swing.GroupLayout.DEFAULT_SIZE, Short.MAX_VALUE)
.addGroup(statusPanelLayout.createParallelGroup(javax.swing.GroupLayout.Alignment.BASELINE)
.addComponent(statusMessageLabel)
.addComponent(statusAnimationLabel)
.addComponent(progressBar, javax.swing.GroupLayout.PREFERRED_SIZE,
javax.swing.GroupLayout.DEFAULT_SIZE, javax.swing.GroupLayout.PREFERRED_SIZE))
.addGap(3, 3, 3))
);
setComponent(mainPanel);
setMenuBar(menuBar);
setStatusBar(statusPanel);
}// </editor-fold>
// Variables declaration - do not modify
private javax.swing.JPanel mainPanel;
private javax.swing.JMenuBar menuBar;
private javax.swing.JProgressBar progressBar;
private javax.swing.JLabel statusAnimationLabel;
private javax.swing.JLabel statusMessageLabel;
private javax.swing.JPanel statusPanel;
// End of variables declaration
private final Timer messageTimer;
private final Timer busyIconTimer;
private final Icon idleIcon;
private final Icon[] busyIcons = new Icon[15];
private int busyIconIndex = 0;
private JDialog aboutBox;
}
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